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Thesis summary 
 
The classical myeloproliferative disorders (MPD), comprising essential 
thrombocythaemia (ET), polycythaemia vera (PV) and idiopathic myelofibrosis 
(IMF), are clonal premalignant haematopoietic neoplasms associated with 
activating mutations in signalling pathway molecules and a variable tendency to 
develop acute myeloid leukaemia (AML). This thesis examined genotype-
phenotype associations of JAK2 and MPL mutations, the presence of clonal 
diversity in the MPD and the genetic events associated with progressive 
disease.  
 
Mutations in MPL were identified in 4% of ET and 7% of IMF but not in PV. 
Three different acquired MPL mutations were identified, one of which had been 
reported as an inherited allele. Although MPL mutations did not delineate a 
distinct clinical or histopathological subtype of ET, molecular testing provides an 
important new tool in the diagnostic armamentarium. Clones homozygous for 
the JAK2 V617F mutation were identified in female but not male patients with 
ET, suggesting that gender differences may be important in the determination of 
disease phenotype. In patients with two acquired genetic alterations, a signalling 
pathway mutation and a cytogenetic abnormality were usually present within the 
same clone. By contrast, coexistence of two signalling pathway mutations 
indicated the presence of biclonal disease that in two patients had arisen 
independently and not from a shared founder clone.  
 
RAS mutations were identified as potential cooperating events in patients with 
JAK2 or MPL mutant IMF. In patients developing AML following a JAK2 V617F-
positive MPD, those with V617F-positive leukaemia had progressed via an 
accelerated phase of disease and harboured acquired alterations of RUNX1 or 
EVI1. V617F-negative leukaemias tended to follow directly from ET or PV, and 
loss of the JAK2 mutation by reversion to wild-type due to mitotic recombination, 
gene deletion or gene conversion was excluded. The thesis concludes with a 
discussion of how clonal heterogeneity can be integrated into current models of 
MPD disease pathogenesis. 
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Chapter 1 
 
Introduction: The classical myeloproliferative disorders 
 
 
The classical myeloproliferative disorders (MPD), comprising polycythaemia 
vera (PV), essential thrombocythaemia (ET) and idiopathic myelofibrosis (IMF) 
are clonal stem cell disorders associated with overproduction of one or more 
myeloid elements. PV, first described in 18921, is characterised by 
overproduction of erythroid cells, often accompanied by an increase in 
neutrophils and/or platelets. In ET, first described as a distinct syndrome in 
19342, an increased platelet count is seen in the absence of significant 
erythrocytosis. The main clinical complication of ET and PV is thrombosis, both 
arterial and venous3,4, with thrombotic complications resulting in a median 
survival of only 18 months in untreated PV5. A proportion of patients with PV or 
ET develop IMF, which may also present as a de novo disease. First described 
in 18796, IMF is characterised by bone marrow fibrosis leading to extramedullary 
haematopoiesis, splenomegaly and bone marrow failure. All three conditions 
may terminate in acute myeloid leukaemia (AML) which is generally refractory to 
therapy. William Dameshek, writing in 1951, was the first to suggest these three 
conditions may be related7, recognising both the phenotypic overlap and 
tendency for phenotypic shift in the MPD. 
 
1.1  Incidence and aetiology 
 
The annual UK incidence of both PV and ET is in the order of 1 case per 
100,000 population, with IMF being slightly less common8. In PV, men out 
number women, with the reverse seen in ET8. Little is known about the precise 
aetiology of these disorders. An increased incidence of IMF has been reported 
in survivors of the atomic bombs at Hiroshima and Nagasaki9, although the 
incidence of PV appeared unaffected10. Although an increased risk of PV was 
reported in a cohort of nuclear weapons workers11, the numbers affected were 
too small to draw firm conclusions. More recently, a cluster of PV cases was 
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reported around Tamaqua (Pennsylvania, USA) close to the site of a previous 
toxic waste dump. Although the exact nature of the chemical contamination 
could not be determined, the risk of PV among local residents was 4.5 times 
higher compared to adjacent counties12. Data from the comprehensive Swedish 
Cancer Registry has suggested a familial tendency to develop an MPD, with an 
increased risk of both PV and ET noted among first degree relatives of affected 
individuals13,14. Several families have been reported with multiple members 
affected by an MPD, with inheritance patterns suggestive of an autosomal 
dominant trait with incomplete penetrance15-19. X-chromosome inactivation 
studies have demonstrated clonal haematopoiesis in affected family members 
indicative of a genuine MPD. Of note, a proportion of apparently unaffected 
relatives showed erythropoietin-independent erythroid colony growth, 
suggesting an early phase or forme fruste MPD15. Affected families may contain 
individuals with different disease phenotypes, including ET, PV, IMF or chronic 
myeloid leukaemia (CML)16. Clinical phenotype and complication rates are 
reportedly similar in familial and sporadic cases, although some kindreds may 
show evidence of genetic anticipation18. 
 
1.2  Early studies 
 
In 1974, in vitro culture studies demonstrated the ability of erythroid colonies 
from PV patients to grow in the absence of erythropoietin, a phenomenon not 
observed in normal individuals20. This finding of cytokine-independent 
differentiation became one of the hallmark features of the MPD. The clonal 
nature of these disorders was first elucidated in 1976, when studies of 2 female 
PV patients revealed expression of a single isoform of the polymorphic, X-linked 
G6PD gene in erythrocytes, granulocytes and platelets21, a finding that was 
subsequently extended to patients with ET22. Dysregulation of several pathways 
has been identified in MPD patients, including up regulation of NFE223, PRV124, 
BCL-xL25 and the JAK-STAT pathway26, and down regulation of thrombopoietin 
receptor (MPL) expression27. Many of these observations were subsequently 
explained by the identification of an activating mutation in the JAK2 tyrosine 
kinase. 
 
12
1.3  Activating mutations in Janus kinase 2 (JAK2) in the MPD 
 
In 2005, four international groups described the same acquired point mutation in 
the JAK2 gene in most patients with PV and around half those with ET or IMF28-
31. Diverse approaches were used to identify this mutation, comprising 
dissection of signalling pathways in PV28, high throughput sequencing of kinase 
genes29,30 and sequencing of candidate genes within a region of chromosome 9 
known to undergo loss of heterozygosity in PV patients31. JAK2, one of four JAK 
family cytoplasmic tyrosine kinases (comprising JAK1, JAK2, JAK3 and TYK2), 
is essential for signalling by the erythropoietin receptor (EpoR)32 and 
thrombopoietin receptor (MPL)33, and is also involved in signalling through the 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor34 and interferon-γ receptors35. Studies of EpoR indicate that 
ligand binding results in a conformation change in the receptor36, with 
consequent phosphorylation of JAK2 and the receptor itself resulting in 
activation of downstream signalling pathways32. JAK2 also plays a vital role in 
EpoR trafficking, with absence of JAK2 resulting in retention of EpoR within the 
endoplasmic reticulum37. The central role of JAK2 in haematopoiesis is 
highlighted by a JAK2 knock-out mouse, which dies at embryonic day 12.5 due 
to a complete absence of definitive erythropoiesis35.  
 
1.4 The JAK2 V617F mutation: mechanisms of cellular transformation  
 
1.4.1 Increased cellular proliferation 
 
The JAK2 V617F substitution, resulting from a single base change, affects the 
pseudokinase (JH2) domain of the protein. This domain is required for both 
JAK2 activation and inhibition of basal kinase activity38,39. The JAK2 V617F 
mutation results in substitution of a bulky phenylalanine at a highly conserved 
residue, and is thought to impair autoinhibition of JAK2, leading to constitutive 
activation of tyrosine kinase activity28-31. Expression of JAK2 V617F leads to 
cytokine independent growth of various cytokine dependent cell lines, with 
constitutive activation of pathways implicated in the control of proliferation, 
differentiation and cell survival such as STAT5, PI3K/AKT and MAPK28,30,31. 
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Consistent with these findings, cell line studies suggest a role for mutant JAK2 
in promoting G1/S transition40. Mutant JAK2 also appears resistant to 
inactivation by members of the suppressor of cytokine signalling (SOCS) family, 
particularly SOCS341. Taken together, these studies indicate a role for mutant 
JAK2 in driving cellular proliferation by constitutive activation of signalling 
pathways, increased entry into cell cycle and resistance to inhibition by negative 
regulatory proteins.  
 
1.4.2 Inhibition of apoptosis 
 
The anti-apoptotic protein Bcl-xL, a direct transcriptional target of STAT5, 
appears to play a central role in cellular survival in JAK2 V617F associated 
disease. Early studies demonstrated a correlation between increased Bcl-xL 
expression and cytokine independent growth of erythroid cells from PV 
patients25. Subsequently over-expression of either Bcl-xL or a constitutively 
active STAT5 were shown to induce cytokine independent erythroid 
differentiation of normal human progenitors42. The cellular metabolism of Bcl-xL 
is also altered in the presence of mutant JAK2. In normal cells, DNA damage 
induced by irradiation or clastogen exposure leads to deamidation of the Bcl-xL 
protein, reducing its ability to sequester pro-apoptotic proteins with consequent 
cell death by apoptosis43. This pathway is blocked in the presence of mutant 
JAK2 in both cells lines and patient granulocytes. Moreover, this reduction in 
Bcl-xL deamidation can be overcome by chemical inhibition of JAK244. A block in 
the Bcl-xL deamidation pathway was also observed in BCR-ABL1 expressing 
cells44, but does not appear to be a general feature of malignancy as the 
pathway is intact in various cancer cell lines43,45 and primary chronic lymphocytic 
leukaemia cells46.   
 
Mutant JAK2 also confers resistance to FAS-mediated apoptosis. Studies of 
erythroid progenitors from JAK2 V617F-positive PV patients demonstrated 
continued proliferation and differentiation in the presence of a FAS-activating 
antibody. By comparison, normal progenitors failed to proliferate in the presence 
of the antibody, with a significant fraction undergoing apoptosis. Biochemical 
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studies implicated activation of the PI3K/AKT pathway in the resistance to FAS-
induced apoptosis47.  
 
In summary, expression of mutant JAK2 induces resistance to apoptosis via 
several mechanisms. Levels of functional Bcl-xL are increased by both activation 
of JAK-STAT signalling and inhibition of Bcl-xL deamidation. Mutant JAK2 
expression also confers resistance to FAS-mediated apoptosis.
 
1.4.3 Cytokine independent differentiation 
 
Differentiation of haematopoietic cells in the absence of cytokines is one of the 
hallmark features of the MPD20. Coexpression of mutant JAK2 with the 
erythropoietin or thrombopoietin receptor results in cellular transformation in the 
absence of cytokine (erythropoietin or thrombopoietin respectively)48, suggesting 
that mutant JAK2 is able to signal via cytokine receptors in the absence of 
ligand binding. Consistent with this notion, studies of MPD patients 
demonstrated that only progenitors harbouring a JAK2 mutation formed 
erythroid colonies in the absence of erythropoietin29,49. Moreover inhibition of 
JAK2 by small-interfering RNA abrogated erythropoietin independent 
differentiation of progenitors from PV patients28. In vitro culture of patient cells 
suggested that JAK2 V617F-positive progenitors also show an increased 
sensitivity to erythropoietin when compared to wild-type controls49.  
 
1.4.4 Mouse models of JAK2 V617F associated disease 
 
Expression of the mouse equivalent JAK2 V617F in a retroviral murine bone 
marrow transplant system resulted in an oligoclonal MPD-like disease with many 
similarities to the human MPD. Transplanted mice developed marked 
erythrocytosis and leucocytosis followed by progression to bone marrow fibrosis 
and anaemia, a phenotype that was recapitulated in secondarily transplanted 
animals. Thrombocytosis, however, was not commonly observed, being present 
only in mice with low expression of mutant JAK250,51. Other similarities to human 
disease observed in retroviral models include cytokine independent 
differentiation of erythroid and granulocytic precursors and reduced serum 
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erythropoietin levels50-52. Whereas retrovirally-induced JAK2 V617F expression 
was associated with erythrocytosis in the majority of cases, transgenic mouse 
lines expressing JAK2 V617F developed either erythrocytosis or 
thrombocytosis. Of note, thrombocytosis was observed in mice expressing low 
levels of mutant JAK2, whereas erythrocytosis was seen in high-expressing 
animals, suggesting that gene dosage may play a role in the determination of 
disease phenotype53,54.  
 
Independent studies have shown that progenitors from patients with a JAK2 
V617F-positive MPD are able to engraft immunodeficient mice. Progenitors from 
MPD patients appear to be skewed towards myeloid differentiation in this model 
when compared to normal controls (where B-lymphoid differentiation is 
predominant)55-57. In one study, to date published only in abstract form, mice 
engrafted with progenitors from IMF patients developed megakaryocyte 
hyperplasia and bone marrow fibrosis, thus recapitulating features of human 
IMF57.  
 
1.4.5 Mechanisms of cellular transformation: summary 
 
An identical point mutation in JAK2 is present in the majority of MPD patients, 
resulting in constitutive phosphorylation of JAK2 and activation of downstream 
signalling pathways. Expression of mutant JAK2 is associated with increased 
proliferation, impaired apoptosis, cytokine independence and cytokine 
hypersensitivity. Retroviral and transgenic mouse models recapitulate many 
features of the human MPD, including erythrocytosis, thrombocytosis and bone 
marrow fibrosis. These findings suggest that mutant JAK2 is central to the MPD 
phenotype, and taken together imply a role for JAK2 V617F in disease initiation.  
 
1.5  Lineage involvement in JAK2 V617F associated disease 
 
In MPD patients, the JAK2 V617F mutation can be detected in progenitors with 
B-cell, T-cell, NK-cell and myeloid lineage potential, demonstrating that the 
mutation arises in a multipotent haematopoietic stem cell (HSC)58. However the 
mutation is detected only rarely and at low levels in peripheral blood 
16
lymphocytes58. Of relevance to this observation, the transforming effects of 
JAK2 V617F are only manifest in cell lines when mutant JAK2 is co-expressed 
with a type I homodimeric receptor48,59. Type 1 homodimeric receptors, including 
those for erythropoietin, thrombopoietin and G-CSF, are present in myeloid but 
not lymphoid cells, and as such lymphocytes harbouring the JAK2 V617F 
mutation may not have a selective advantage in vivo. In keeping with this 
finding, the JAK2 V617F mutation appears to be exclusive to myeloid 
neoplasms60,61, despite reports of JAK2 overexpression in lymphoid 
malignancies62. Along with its common occurrence in the classical MPD, the 
JAK2 V617F mutation is found rarely in a number of other chronic myeloid 
malignancies including myeloproliferative-myelodysplastic syndromes and 
chronic neutrophilic leukaemia63,64. The JAK2 V617F mutation has also been 
detected in 1-8% of de novo AML, and shows an association with aberrations of 
the core binding factor complex associated with AML1-ETO or CBFB-MYH11 
fusion genes60,61,65,66. 
 
Progenitor compartment studies in PV patients have suggested an increase in 
the number of phenotypic HSC and common myeloid progenitors67. In culture 
experiments, however, the total number of bone marrow derived long-term 
culture initiating cells from PV and ET patients was no different to normal 
controls49. In vitro culture assays of PV HSC have suggested skewing towards 
erythroid differentiation when compared to normal controls, with this effect 
largely abrogated by the application of a chemical inhibitor of JAK267. Moreover, 
culture of bone marrow progenitors in conditions specific for erythroid 
differentiation suggested increased expansion of erythroid cells from JAK2 
V617F-positive PV and ET samples compared to normal controls. Of interest, 
this expansion was associated with an increase in the proportion of cells 
harbouring the JAK2 V617F mutation, suggesting mutant JAK2 drives 
proliferation at the later stages of erythroid differentiation49.  
 
In summary, the JAK2 V617F mutation appears specific to myeloid malignancy. 
Despite its presence in haematopoietic stem cells, mutant JAK2 may not provide 
a proliferative advantage in lymphoid cells due to the absence of a type 1 
homodimeric receptor. Expression of mutant JAK2 in progenitor cells produces 
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a bias towards the erythroid lineage, and leads to expansion of erythroid cells at 
the later stages of differentiation. 
 
1.6 JAK2 V617F: one mutation associated with three apparently distinct 
disease phenotypes 
 
1.6.1 Essential thrombocythaemia and polycythaemia vera 
 
Traditionally, PV and ET have been considered as separate but related disease 
entities7. Using sensitive detection techniques, however, the same JAK2 V617F 
mutation can be found in nearly all PV patients and around half of those with 
ET29, raising questions as to how a single mutation is associated with two 
apparently distinct clinical phenotypes. Initial clues came from analysis of 776 
ET patients enrolled into one of three prospective trials. When compared to ET 
patients without the JAK2 mutation, JAK2 V617F-positive ET patients were 
found to have multiple features resembling PV, including higher haemoglobin 
levels and white cell counts, lower serum erythropoietin levels, increased bone 
marrow erythroid and granulocytic activity and higher rates of venous 
thrombosis. Moreover, all patients who transformed from ET to PV were positive 
for the JAK2 V617F mutation68. These data suggest that ET and PV form part of 
a biological continuum, with ET representing a forme fruste of PV. 
 
Prior to the discovery of the JAK2 V617F mutation, loss of heterozygosity for the 
telomeric end of chromosome 9p had been identified in one third of PV 
patients69. This was subsequently shown to be secondary to mitotic 
recombination, which gives rise to a clone that is homozygous for the JAK2 
V617F mutation with preservation of JAK2 copy number28,29,31. Studies of 
individual progenitor colonies from MPD patients revealed that whereas a JAK2 
V617F-homozygous clone was present in the majority of patients with PV, such 
clones were rare in ET70, suggesting that gene dosage may play a role in 
disease phenotype. Further evidence for this hypothesis came from JAK2 
V617F transgenic mice models, where mice with a low mutant to wild-type JAK2 
expression ratio developed an ET-like phenotype, whereas those with a high 
mutant to wild-type ratio manifested a PV-like disease54. Of note, cell line 
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studies have suggested that co-expression of wild-type JAK2 may inhibit the 
transforming effects of the mutant allele28. Taken together, these studies 
suggest that either loss of the wild-type allele or duplication of the mutant allele 
may be associated with erythrocytosis and thus a PV phenotype. 
 
A potential biological mechanism for this hypothesis was suggested by studies 
of normal human haematopoietic progenitors, wherein over-expression of 
STAT5, an important downstream target of JAK2, was associated with 
preferential erythroid differentiation, whereas inhibition of STAT5 favoured 
megakaryocyte differentiation71. It is possible, therefore, that homozygosity for 
the JAK2 V617F mutation results in stronger activation of STAT5 and a 
consequent bias towards erythroid differentiation.  
 
The size of the chromosome 9p region involved in mitotic recombination is 
variable between patients, suggesting this process is not due a fragile site on 
9p31. Of interest, rates of mitotic recombination are highly variable between 
normal individuals72. Following acquisition of the JAK2 V617F mutation, 
therefore, individuals with higher rates of mitotic recombination may be more 
likely to develop a JAK2 V617F-homozygous clone and consequently a PV 
phenotype. Other host genetic modifiers could also play a role in determining 
disease phenotype, such as inter-individual differences in erythropoietin 
homeostasis or JAK2 signalling. Indeed specific polymorphisms in JAK2 and the 
erythropoietin receptor are over-represented in patients with either ET or PV73. 
 
1.6.2 Idiopathic myelofibrosis 
 
Whereas similarities exist between the phenotype and clinical complications of 
ET and PV, IMF is a more distinct clinical syndrome, showing features such as 
bone marrow fibrosis and extramedullary haematopoiesis which are absent from 
both ET and PV74. Around half of IMF patients, however, harbour the JAK2 
V617F mutation29, and 15-30% of patients with ET or PV eventually develop 
IMF75-77. Acquired cytogenetic abnormalities are present in 10-15% of patients 
with PV or ET and up to 50% in those with IMF78-80, suggesting a greater degree 
of genetic instability within an IMF clone. Consistent with this observation, IMF is 
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associated with features of increasing stem cell dysfunction, such as circulating 
myeloid and erythroid progenitors81, increased levels of lactate dehydrogenase 
indicative of ineffective erythropoiesis82, shortened survival and increased rates 
of progression to acute leukaemia83,84. Taken together, these findings suggest 
that IMF, presenting either de novo or following ET or PV, may represent an 
accelerated phase of disease, most likely due to the acquisition of further 
genetic lesions. 
 
In a murine retroviral transplantation model, an IMF-like phenotype was 
observed in the majority of mice by 2-4 months28, suggesting a direct 
association between the JAK2 V617F mutation and the development of IMF. 
Moreover a higher JAK2 V617F mutant allele burden has been reported in 
patients who develop secondary IMF (following ET or PV) compared to patients 
with ET or PV, suggesting an increase in the size of the mutant clone with 
progressive disease85. Studies have indicated a role for mutant JAK2 in driving 
genetic instability, with increases in homologous recombination, point mutations 
and small deletions observed in cell lines expressing mutant compared to wild-
type JAK2. Moreover foci of nuclear RAD51, a marker of DNA breakage, were 
more frequent in progenitors from PV patients compared to normal controls86. 
Other factors implicated in the development of IMF include reduced GATA-1 
expression87,88, increased thrombopoietin and transforming growth factor β 
signalling89,90 and altered expression of molecules involved in stem cell 
trafficking such as CXCR491. It is unclear, however, whether such changes are 
directly involved in the pathogenesis of IMF, or represent epiphenomena related 
to as yet unknown genetic lesions. As such, the specific genetic events 
underlying the development of IMF are yet to be fully elucidated. 
 
1.6.3 Progression to acute myeloid leukaemia 
 
Progression to AML is seen in 2-5% of patients with ET or PV76,77,92 and 15-30% 
of patients with IMF75,83. Risk factors for progression to AML in patients with ET 
or PV include increasing age92 and prior use of genotoxic agents such as 
radioactive phosphorous, alkylating agents or radiotherapy92-94, particularly 
when used sequentially with hydroxycarbamide92,95,96. The association of single 
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agent hydroxycarbamide with the development of AML remains controversial97. 
Transformation to AML has been reported in a number of MPD patients who 
have never received cytotoxic therapy92,98-100, suggesting that progression to 
acute leukaemia is part of the natural history of these disorders. Additional risk 
factors for AML in IMF patients include karyotypic abnormalities (other than 
del(20q) or del(13q)83,101), higher peripheral blood blast counts84 and prior 
splectomy84. 
 
Independent studies have reported the absence of the JAK2 V617F mutation in 
leukaemic blasts from patients with a preceding V617F-positive MPD102,103. 
Reversion of a JAK2 V617F-heterozygous clone back to wild-type by mitotic 
recombination was excluded in 3 cases examined102,103. X-chromosome 
inactivation patterns were uninformative in a single case, with both the V617F-
positive MPD and the V617F-negative AML expressing the same allele of a 
polymorphic X-linked gene103. As such, the mechanism by which a V617F-
positive MPD transforms to a V617F-negative AML is yet to be elucidated. 
Although additional cytogenetic changes are common at the time of 
transformation to both V617F-positive and V617F-negative AML, these 
generally consist of unbalanced chromosomal gains or deletions102,103. AML 
associated aberrations including FLT-ITD and mutations in NPM have been 
reported in V617F-negative transformations103,104, but there are as yet no 
reports of additional genetic events associated with progression to V617F-
positive AML.  
 
1.6.4 JAK2 V617F: one mutation associated with three apparently distinct 
disease phenotypes: summary 
 
The same JAK2 V617F mutation is found in patients with ET, PV, and IMF, and 
in the leukaemic blasts of a proportion of patients who progress to AML. 
Similarities exist between ET and PV in both disease phenotype and clinical 
complications, suggesting that these conditions may form part of a biological 
continuum. Several lines of evidence suggest that the JAK2 mutant to wild-type 
ratio plays a role in determining the precise phenotype that is manifest, with 
patients harbouring JAK2 V617F-homozygous clones more likely to develop PV, 
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possibly due to increased signalling via STAT5. IMF may be best considered as 
an accelerated phase of disease, associated with increased genetic instability, 
dysregulated stem cell function and higher rates of progression to acute 
leukaemia, although the genetic events leading to disease evolution are 
currently unknown. A proportion of patients develop an acute leukaemia that 
may be negative for the JAK2 V617F mutation. 
 
1.7 Other JAK2 mutations in haematological disease 
 
1.7.1 JAK2 exon 12 mutations in polycythaemia vera 
 
Using sensitive detection techniques, up to 97% of PV patients harbour the 
JAK2 V617F mutation, located in exon 14 of the gene29. Subsequent 
sequencing of JAK2 in V617F-negative PV patients identified a cluster of 
mutations in JAK2 exon 12105. These mutations were associated with a distinct 
variant of PV characterised by higher haemoglobin levels and lower white cell 
and platelet counts compared to JAK2 V617F-positive PV. Expression of JAK2 
exon 12 mutations conferred cytokine independence to cytokine dependent cell 
lines in the presence of a type I homodimeric receptor, associated with a greater 
degree of downstream pathway activation compared to the JAK2 V617F 
mutation. Expression of a JAK2 exon 12 allele (JAK2 L539K) in murine bone 
marrow resulted in marked erythrocytosis in vivo. The JAK2 exon 12 mutations 
are predicted to lie at the interface between the kinase and pseudokinase 
domains, and are likely to perturb the autoinhibitory function of the 
pseudokinase domain. JAK2 exon 12 mutations have not been reported in 
patients with ET or de novo IMF.  
 
1.7.2 JAK2 kinase domain mutation in a leukaemia cell line 
 
High-throughput screening for tyrosine-phosphorylated proteins identified a 
JAK2 T875N mutation in an acute megakaryoblastic leukaemia cell line. This 
mutation results in an amino acid substitution within the kinase domain at the 
predicted interface with the autoinhibitory pseudokinase region. As with the 
JAK2 V617F mutation, expression of JAK2 T875N conferred cytokine 
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independence to cytokine-dependent cells lines only in the presence of a 
homodimeric type I cytokine receptor. Expression in a murine retroviral 
transplant system resulted in an MPD-like phenotype characterised by 
erythrocytosis and variable leucocytosis. Although platelet numbers were not 
increased, mice expressing the JAK2 T875N allele showed megakaryocyte 
proliferation and bone marrow fibrosis106. To date, this mutation has not been 
reported in human disease. 
 
1.7.3 JAK2 mutations in acute lymphoblastic leukaemia 
 
A cluster of mutations centred around JAK2 R683 within the autoinhibitory 
pseudokinase domain have been reported in 18% of Down’s syndrome acute 
lymphoblastic leukaemia (ALL)107,108. Of interest, a mutation was also observed 
in a single case of non-Down’s syndrome ALL in association with 
isochromosome 21q, suggesting cooperation between the JAK2 R683 allele and 
one or more genes on chromosome 21q. Expression of these alleles conferred 
cytokine independence to cytokine-dependent cells lines only in the presence of 
a homodimeric type I cytokine receptor. It is not currently known whether a type 
I receptor is present in the leukaemic blasts of these patients. Expression of the 
JAK2 I682-D686del allele in murine bone marrow resulted in an MPD phenotype 
in vivo with elevation of red cell, white cell and platelet counts108. 
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 Figure 1.1. Oncogenic mutations and rearrangements of JAK2. (A) JAK2
mutations and their associated haematopoietic malignancies. (B)
Chromosomal translocations leading to rearrangement of JAK2. PV:
polycythaemia vera; ET: essential thrombocythaemia; IMF: idiopathic
myelofibrosis; ALL: acute lymphoblastic leukaemia; AML: acute myeloid
leukaemia; Mk: megakaryocytic.  24
1.7.4 JAK2 rearrangements in myeloid and lymphoid neoplasia 
 
Translocations resulting in a fusion gene in which JAK2 is the 3’ partner have 
been reported in myeloid and lymphoid leukaemias (Figure 1.1). In all cases, the 
5’ partner (ETV6109,110, BCR111 or PCM1112) contains a protein-protein 
interaction domain, suggesting that forced dimerisation leads to constitutive 
JAK2 kinase activation. Of note, expression of the ETV6-JAK2 fusion conferred 
cytokine independent growth to a cytokine dependent cell line in the absence of 
a homodimeric type I receptor113. Transplantation of ETV6-JAK2 expressing 
human cord blood progenitors into immunodeficient mice resulted in an IMF-like 
phenotype with anaemia and bone marrow fibrosis114. 
 
Table 1.1. Activating mutations and rearrangements of JAK2 in human 
haematopoietic malignancy.  
 
Mutation Cell line  
transformation 
Mouse bone marrow 
transplantation 
Human disease 
    
JAK2 V617F Only with type I 
homodimeric receptor 
Erythrocytosis 
+/- leucocytosis 
Bone marrow fibrosis 
PV (97%) 
ET (50%) 
IMF (50%) 
AML (1-8%) 
    
JAK2 exon 12 Only with type I 
homodimeric receptor 
Erythrocytosis 
Leucocytosis 
PV (3%) 
    
JAK2 T875N Only with type I 
homodimeric receptor 
Erythrocytosis 
+/- leucocytosis 
Bone marrow fibrosis 
AML cell line 
    
JAK2 R683 Only with type I 
homodimeric receptor 
Erythrocytosis 
Leucocytosis 
Thrombocytosis 
Down’s syndrome 
ALL (18%) 
    
ETV6-JAK2 Without type I 
homodimeric receptor 
Anaemia 
Bone marrow fibrosis 
CML-like 
B-ALL 
T-ALL 
    
BCR-JAK2 Unknown Unknown CML-like 
AML 
    
PCM1-JAK2 Unknown Unknown CML-like 
B-ALL 
T-ALL 
 
PV: polycythaemia vera; ET: essential thrombocythaemia; IMF: idiopathic myelofibrosis; AML: 
acute myeloid leukaemia; ALL: acute lymphoblastic leukaemia; CML: chronic myeloid leukaemia 
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1.7.5 Other JAK2 mutations in haematological disease: summary 
 
Oncogenic alterations in JAK2 are associated with both myeloid and lymphoid 
malignancy (Table 1.1; Figure 1.1). Point mutations are associated with either 
loss of autoinhibitory function or activation of the kinase domain, and these 
alleles are only able to transform cell lines in the presence of a type 1 
homodimeric receptor. By contrast, translocations involving JAK2 appear to 
result in constitutive dimerisation and consequent activation of JAK2 without the 
need for a type 1 receptor. 
 
1.8 Therapeutic considerations in the myeloproliferative disorders 
 
Thrombotic complications are the leading cause of morbidity and mortality in 
patients with ET or PV3,4, and reducing the frequency of thrombosis is the main 
aim of therapy in these patients. Established risk factors for thrombotic events 
include past history of thrombosis76,115-118, age over 60 years76,116-118, 
leucocytosis76,119-121, increased haematocrit (PV patients)122 and presence of a 
JAK2 V617F mutation (ET patients)68,119,123. A clear association between degree 
of thrombocytosis and thrombotic risk in ET or PV has not been 
established115,117,119. Whereas the vast majority of patients with PV will require 
treatment to lower the haematocrit, rates of thrombosis in ET are more variable, 
such that ET patients can be stratified and treated according to thrombotic 
risk115,124-126. In IMF, survival is significantly reduced due to bone marrow failure 
and transformation to acute leukaemia82,127. At present, IMF therapy is largely 
supportive, aimed at ameliorating symptoms due to bone marrow failure and 
extramedullary haematopoiesis. 
 
1.8.1 Anti-platelet therapy 
 
A large, randomised controlled trial in PV demonstrated a reduction in 
thrombotic events in those taking aspirin3. Retrospective studies also suggest 
that aspirin may prevent thrombotic complications in ET patients128,129. An 
association between aspirin use and haemorrhage has been reported, 
particularly in patients with very high platelet counts128, although this remains to 
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be proven in a prospective study. Based on current evidence, aspirin is 
recommended for all ET and PV patients unless otherwise contraindicated. 
Although there is little data concerning the use of newer anti-platelet agents 
such as clopidogrel, their proven track record in the prevention of atherosclerotic 
vascular disease suggests they may be appropriate for patients unable to 
tolerate aspirin.  
 
1.8.2 Venesection 
 
Reduction of the haematocrit to <0.45 has been associated with a decreased 
risk of thrombotic complications in patients with PV122, and is suitable therapy for 
patients with an isolated erythrocytosis. However given the association of 
leucocytosis with thrombotic complications121, many patients will require therapy 
with cytoreductive agents. 
 
1.8.3 Hydroxycarbamide (previously known as hydroxyurea) 
 
Hydroxycarbamide, a ribonucleotide reductase inhibitor, is the only 
cytoreductive agent proven to reduce thrombotic events in a randomised 
controlled trial124. Major complications of this drug include reversible 
myelosuppression and ulceration of the buccal mucosa or lower leg. Although 
hydroxycarbamide appears non-carcinogenic when used to treat sickle cell 
disease, an inherited non-clonal disorder of erythrocyte production130, 
controversy remains concerning leukaemogenicity when used in the MPD97. 
Although several retrospective studies have suggested an increased risk of 
leukaemia in hydroxycarbamide treated patients131-133, others have not observed 
this association96,100,134. Problems with these studies include small patient 
numbers, retrospective data collection and relatively short follow-up. Overall, 
any increased risk of leukaemia is likely to be small, and should be balanced 
against the likely reduction in thrombotic risk. 
 
 
 
 
27
1.8.4 Interferon 
 
Recombinant interferon alpha is effective at controlling blood counts in MPD 
patients, although there is little evidence regarding efficacy in the prevention of 
thrombotic complications135. Treatment is often associated with significant side-
effects, including flu-like symptoms and psychiatric disturbance that may 
mandate cessation of therapy. Of note, interferon therapy in JAK2 V617F-
positive PV patients may lead to a significant reduction in peripheral blood 
mutant allele burden, with occasional patients achieving a molecular 
remission136.  
 
1.8.5 Anagrelide 
 
Anagrelide, a quinazoline derivative, reduces the platelet count by inhibition of 
megakaryocyte differentiation137. Although the white cell count is unaffected, 
anaemia is common and may be delayed in onset and progressive over the first 
years of treatment68,138. Up to a third of patients cannot tolerate anagrelide 
because of side effects, many of which result from its vasodilatory and positive 
inotropic effects, including fluid retention, palpitations and arrhythmias, heart 
failure and headaches4,138. Although anagrelide is not cytotoxic, and therefore 
free from leukaemogenic risk, the PT-1 randomised controlled trial 
demonstrated inferiority to hydroxycarbamide in the prevention of thrombotic 
complications in ET. In this study, anagrelide treated patients experienced 
higher rates of arterial thrombosis, major haemorrhage and progression to 
myelofibrosis, despite equivalent control of the platelet count4. Comparison of 
ET patients in the PT-1 and Italian prospective studies, however, revealed 
actuarial rates of first thrombosis by 2 years of 4% (hydroxycarbamide +/- 
aspirin, both studies), 8% (anagrelide plus aspirin, PT-1 study) and 26% (no 
cytoreductive therapy, Italian study)139, suggesting that anagrelide provides at 
least partial protection from thrombotic complications.  
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1.8.6 Alkylating and radiomimetic agents 
 
Radioactive phosphorous and alkylating agents such as busulphan and 
chlorambucil are effective at controlling blood counts, but are associated with an 
increased risk of acute leukaemia, particularly when used sequentially with 
hydroxycarbamide92,95,96,133. As such, these agents should be reserved for older 
patients unable to tolerate safer therapies. Pipobroman, a piperazine derivative, 
is effective at reducing blood counts in MPD patients, although there is little 
direct evidence for efficacy in thrombosis prevention95,140. Despite structural 
similarities to other alkylating agents, pipobroman does not appear to be 
associated with high rates of leukaemic transformation95,140,141, but should none-
the-less be avoided in the treatment of younger patients. 
 
1.8.7 Therapeutic strategies for IMF 
 
Therapy for IMF, occurring de novo or secondary to ET or PV, is essentially 
supportive, with transfusion of blood products for symptomatic anaemia or 
bleeding providing the mainstay of treatment. Cytoreductive therapy such as 
hydroxycarbamide may be useful in patients with thrombocytosis or progressive 
splenomegaly. Danazol, a synthetic testosterone derivative, alleviates anaemia 
in around one third of patients142. Thalidomide has also been reported to 
improve haemoglobin and occasionally platelet counts143. The mechanism of 
action of thalidomide is not fully understood but probably includes 
immunomodulation, antiangiogenic affects and modulation of cytokines including 
tumour necrosis factor-alpha. Early studies have suggested that thalidomide 
analogues such as lenalidomide may also be useful in reducing splenomegaly 
and alleviating cytopenias144. Splenectomy may be considered for those with 
significant splenic discomfort and may also reduce or obviate the need for red 
cell transfusion145. Splenectomy in patients with IMF carries a significant risk of 
adverse outcome, including bleeding, infection and thrombocytosis leading to 
thrombosis or haemorrhage, and is associated with operative mortality rates of 
5-10%145. Splenic irradiation has occasionally been used for patients with 
symptomatic splenomegaly who are unfit for surgery, although this procedure 
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may be complicated by severe and occasionally prolonged cytopenias146. 
Allogeneic bone marrow transplantation has been used with some success in 
younger patients with IMF, with reduced intensity conditioning extending the age 
range of the procedure147. The clinical course of IMF is highly variable, however, 
with some patients surviving for long periods with stable disease. Bone marrow 
transplantation should therefore be reserved for those with clear evidence of 
progressive disease.  
 
1.8.8 JAK2 inhibitors 
 
Since the identification of the JAK2 V617F mutation, several small molecule 
inhibitors of the JAK2 protein have been tested in animal models or early clinical 
trials. JAK2 inhibitors are able to attenuate the disease phenotype in mouse 
models51,148-150, and in vitro studies of human cells have suggested a selective 
effect of JAK2 inhibitors on JAK2 V617F-positive haematopoiesis151,152. Early 
clinical trials in humans, however, have suggested limited efficacy of JAK2 
inhibitors in IMF patients. As JAK2 is the sole tyrosine kinase associated with 
the erythropoietin and thropmbopoietin receptors, JAK2 inhibition is associated 
with a predicatble, dose dependent anaemia and thrombocytopenia, limiting the 
therapeutic utility of this agent in many patients. Reduction in spleen size 
associated with freedom from blood transfusion has been reported in rare IMF 
patients (although similar responses are also seen in occassional hydroxyurea-
treated patients). A proportion of patients report improvement in constitutional 
symptoms, an effect that may be related to inhibition of JAK1 with consequent 
reduction in cytokine secretion153,154.  
 
1.9  The thrombopoietin receptor, MPL, and the myeloproliferative 
disorders 
 
The thrombopoietin receptor, MPL, was first identified through the study of 
transforming retroviruses in murine bone marrow. Transduction of murine 
haematopoietic progenitors with murine friend virus along with the replication 
incompetent myeloproliferative leukaemia virus (MPLV) was shown to induce 
proliferation and terminal differentiation of granulocyte, erythroid and 
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megakaryocyte lineages in the absence of growth factors155. Subsequent 
cloning of the MPLV virus pin-pointed the v-mpl gene as responsible for this 
activity, and identified a murine homologue, c-mpl, with structural homology to 
previously identified haematopoietic growth factor receptors156. Following 
identification of the human homologue (MPL)157, studies suggested a specific 
role for this receptor in megakaryopoiesis, with transfection of human progenitor 
cells with MPL antisense RNA inhibiting megakaryocyte but not erythroid or 
granulocytic colony formation158. In 1994, the MPL ligand, thrombopoietin (Tpo), 
was identified using diverse approaches: capture and protein sequencing of Tpo 
on immobilised MPL159,160, chemical mutagenesis to produce a thrombopoietin 
secreting cell line161 and conventional protein purification and sequencing162,163. 
Subsequent studies using Tpo-neutralising antibodies confirmed that Tpo/MPL 
signalling is required for terminal megakaryocyte differentiation164.  
  
Studies of MPL knockout mice have suggested a role for Tpo/MPL signalling not 
only in megakaryopoiesis, but also in the maintenance of the HSC 
compartment165. Mice lacking the MPL receptor are born at the expected 
Mendelian ratio with platelet counts around 6% of normal. In vitro progenitor 
assays, however, demonstrated a significant reduction in erythroid and 
granulocyte as well as megakaryocyte colony formation165. Moreover in 
competitive reconstitution assays into normal mice, MPL knockout bone marrow 
showed only 10-15% of normal repopulating activity166, suggesting either a 
numeric or functional HSC defect. MPL expression segregates with stem cell 
activity in both human and murine haematopoietic progenitors167, and Tpo alone 
is able to maintain murine HSC in an undifferentiated state in liquid culture168. 
Recent work has suggested that Tpo/MPL signalling acts to maintain HSC in a 
quiescent state169,170. TPO knockout mice were shown to have normal numbers 
of HSC in the mid-gestation foetal liver, with HSC numbers subsequently falling 
through the life of the animal169. Taken together, these studies indicate a role for 
Tpo/MPL signalling in maintaining the quiescent state of HSC, with loss of this 
pathway leading to stem cell exhaustion. 
 
Loss of function mutations in MPL are the cause of congenital amegakaryocytic 
thrombocytopenia (CAMT) in humans. This autosomal recessive disorder is 
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manifest by severe thrombocytopenia from birth and the development of aplastic 
anaemia between 1-3 years of age. A number of different mutations have been 
reported, with some correlation between genotype and phenotype171. The 
development of aplastic anaemia in these patients is consistent with mouse 
models, with loss of Tpo/MPL signalling leading to a gradual depletion of the 
HSC compartment. 
The first MPL gain of function mutation identified in humans was the MPL 
S505N allele reported in a Japanese pedigree with dominantly inherited familial 
thrombocytosis172. The mutation was shown to segregate with affected family 
members across three generations, and was absent from unaffected relatives. 
Expression of MPL S505N resulted in cytokine independent proliferation of a 
cytokine dependent cell line, associated with constitutive activation of 
downstream targets such as MEK and STAT5. The amino acid change is within 
the transmembrane region of MPL, although the precise mechanisms leading to 
cellular transformation are not known. 
 
Comparison of MPL and EpoR, which share around one third homology at the 
protein level, identified a five amino acid juxtamembrane motif in MPL that was 
absent from EpoR. Deletion or alteration of this motif resulted in constitutive 
activation of the MPL receptor, suggesting an autoinhibitory role for this 
region173. Subsequent analysis of patient samples identified acquired mutations 
at MPL W515, within the juxtamembrane region, in 9% of patients with JAK2 
V617F-negative IMF and 1% of patients with ET174,175. Expression of the MPL 
W515L allele resulted in cytokine-independent growth of several cytokine 
dependent cell lines, associated with constitutive phosphorylation of 
downstream targets including JAK2, STAT3, STAT5, AKT and ERK174. 
Transplantation of mice with bone marrow expressing the MPL W515L allele 
resulted in an MPD-like phenotype characterised by marked thrombocytosis, 
splenomegaly, splenic infarction and reduced life expectancy174. More recently, 
an acquired MPL T487A mutation was reported in a child with acute 
megakaryoblastic leukaemia. Of note, expression of this allele in a mouse model 
resulted in a similar phenotype to expression of the MPL W515L allele.  
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In summary, Tpo/MPL signalling is required for both terminal differentiation of 
megakaryocytes and maintenance of the HSC compartment. Loss of MPL 
function in humans is associated with profound thrombocytopenia and 
progression to aplastic anaemia. A germline gain of function mutation has been 
associated with dominantly inherited familial thrombocytosis. Acquired mutations 
in MPL have been reported in IMF, occasional patients with ET and a single 
case of acute megakaryoblastic leukaemia. 
 
1.10 Genetic complexity in the MPD: are mutations in JAK2 disease 
initiating events? 
 
JAK2 mutations are present in most patients with PV and half of those with ET 
or IMF29,105,176. JAK2 V617F or exon 12 mutations result in dysregulated JAK2 
kinase activity, induce growth factor independence in factor-dependent cell 
lines28,30,31,48,105 and are sufficient to produce an MPD phenotype in retroviral 
transplant models28,105. Taken together these results demonstrate the centrality 
of JAK2 mutations to their associated MPD and imply a role for such mutations 
in disease initiation. However several observations have suggested a degree of 
genetic complexity in the human MPD that may be interpreted as evidence for 
clonal haematopoiesis prior to the acquisition of a JAK2 mutation.  
 
An inherited predisposition to develop an MPD is supported by both kindred 
studies15-19 and registry data14. Affected family members manifest a genuine 
clonal disorder associated with acquired mutations in JAK2 and clinical features 
indistinguishable from sporadic MPD15,16,19. Although the nature of the inherited 
allele is currently unknown, these observations have led to speculation that 
mutations in JAK2 may be insufficient alone to cause a clinical MPD, with an 
additional genetic event being inherited in familial cases and acquired in 
sporadic cases.  
 
Studies have described female MPD patients with a JAK2 V617F-positive MPD 
in whom clonality of peripheral blood granulocytes, as assessed by X-
inactivation patterns, was in excess of JAK2 V617F mutant allele burden177,178, 
leading to the hypothesis that the JAK2 mutation had arisen within a pre-existing 
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clonal expansion. The results of these studies, however, are complicated by the 
phenomenon of age related skewing within the haematopoietic compartment, 
present in up to a half of normal older females179,180. Skewing of X-chromosome 
usage may represent a stochastic occurrence due to an age related decrease in 
HSC numbers resulting in reliance on a smaller number of stem cells to maintain 
haematopoiesis. Such skewing has been observed in felines undergoing 
autologous transplantation with small numbers of cells181. Alternatively, 
polymorphisms in X-chromosome genes may impart a subtle survival benefit, 
such that either the maternal or paternal allele is selected for over the lifetime of 
the individual. Evidence for this model again comes from the study of cats, 
where breeding experiments demonstrated a consistent selection of the same 
parental X-chromosome as the cats aged182. Moreover, in a study of skewed X-
chromosome usage in human monozygotic twins, the over-represented X-allele 
was concordant between twin pairs183. Skewing has also been observed in T-
cells from older females, albeit to a lesser degree than in granulocytes180. In 
feline studies, increasing X-chromosome skewing in granulocytes was not 
mirrored by skewing in T-cells. Following autologous bone marrow 
transplantation, however, reconstituted cats showed skewing of both 
granulocytes and T-cells182. This result is consistent with the notion that skewing 
occurs at the HSC level, with the long survival of T-cells maintaining a non-
skewed pattern in some individuals102. 
 
Discordant clonality has also been reported in patients harbouring a JAK2 
mutation and a deletion of chromosome 20q, where granulocyte clonality 
measured by JAK2 mutant allele burden was less than clonality assessed by the 
size of the 20q deleted clone177. The clonal relationship of the two genetic 
lesions, however, was not known in these cases.  
 
Patients with a JAK2 V617F-positive MPD may progress to acute myeloid 
leukaemia, and in a proportion of such cases the leukaemia is negative for the 
JAK2 mutation102,103. Similarly erythropoietin independent erythroid colonies 
(endogenous erythroid colonies: EEC) cultured from patients with a JAK2 
V617F-positive MPD may be negative for the JAK2 mutation184,185. It has been 
hypothesised in such cases that both the JAK2 mutant MPD and JAK2 wild-type 
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disease (AML or EEC) arise from a shared clonal expansion. In a single case of 
JAK2 wild-type AML, fluorescent in-situ hybridisation studies suggested the 
presence of the same clonal cytogenetic abnormality in both the JAK2-mutant 
MPD and JAK2 wild-type AML103. However analysis of single progenitor 
colonies was not performed, and as such this finding cannot be taken as 
definitive proof that the two stages of disease arose from a shared clonal 
expansion.  
Of interest, similar lines of evidence have been cited in support of a pre-BCR-
ABL1 phase of clonal haematopoiesis in CML. In a proportion of females with 
CML, a skewed X-chromosome inactivation pattern was detected in BCR-ABL1 
negative immortalised B cells, with the over-represented allele being the same 
as the allele expressed by the BCR-ABL1 clone186,187. Moreover in one patient 
chromosomal abnormalities were detected in immortalised B-cell lines 
expressing the same X-linked allele as the BCR-ABL1 clone, but not in lines 
expressing the alternative allele, suggesting the presence of a genetically 
unstable clone prior to the acquisition of BCR-ABL1. CML patients may develop 
BCR-ABL1 negative clones harbouring acquired chromosomal abnormalities, 
with a proportion of such patients developing BCR-ABL1 negative 
myelodysplasia or acute leukaemia. Such clones were observed more 
frequently in patients who had received prior cytotoxic therapy but have also 
been reported in patients treated solely with the tyrosine kinase inhibitor 
imatinib188-190. The BCR-ABL1 fusion gene has also been detected in individuals 
without an overt MPD191, leading to the suggestion that BCR-ABL1 alone may 
be insufficient to cause disease in humans.  
 
In summary, biochemical and mouse model data suggests that JAK2 mutations 
are central to the phenotype of their associated disease. However studies have 
suggested a degree of genetic complexity in human disease which may be 
interpreted as evidence for the establishment of clonal haematopoiesis prior to 
the acquisition of these lesions. Thus far, however, evidence for such a pre-
JAK2 phase of clonal haematopoiesis remains circumstantial and direct 
evidence for or against this hypothesis is lacking.  
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Chapter 2  
 
Materials and Methods  
 
 
2.1  Preparation of human blood cells 
 
Blood samples were obtained from MPD patients and normal controls after 
obtaining informed consent. The acquisition, storage and analysis of these 
samples was covered under the project entitled ‘The causes of clonal blood cell 
disorders’ which was approved by the Regional Ethics Committee (MREC 
03/5/22 & 07/MRE05/44). Venous blood (10-50mls) was obtained by 
venepuncture from the antecubital fossa after application of tourniquet pressure. 
Blood was collected into tubes containing either ethylenediaminetetraacetic acid 
(EDTA), preservative free heparin or sodium citrate as an anticoagulant. All 
samples were processed within 24 hours of venepuncture. 
 
2.1.1  Separation of platelets from peripheral blood 
 
The following protocol was developed by Dr George Vassiliou as part of his PhD 
project. The protocol has been optimised to give a platelet recovery of 38% ± 
6.2%, with an average of 0.32 white blood cells per 106 platelets. Given that 109 
platelets contain approximately 1µg RNA, with 107 T-cells or granulocytes 
containing approximately 14.4µg or 5.9µg RNA respectively, RNA isolated using 
this protocol is >99% platelet derived.  
 
Whole blood taken into EDTA was placed into a 15mL polypropylenetube (BD 
Bioscience, CA, USA) and centrifuged at 150g for 20 minutes at room 
temperature. The upper phase of platelet-rich plasma (PRP) was removed down 
to 1.5mL from the cell pellet, placed into a clean 15mL tube and centrifuged at 
150g for 20 minutes. The PRP was again removed down to 0.5mL from the cell 
pellet, placed in a clean 15mL tube and centrifuged for a third time at 150g for 
20 minutes. The PRP was removed down to 0.5mL from the cell pellet and 
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aliquoted into 2mL eppendorf tubes, each containing 35µL of prewashed anti-
CD45 magnetic beads (Dynabeads, Dynal AS, Norway). The tubes were 
incubated for 30 minutes at room temperature with mixing. The tubes were then 
applied to a magnet and inverted 10 times to allow binding of white cells. The 
PRP was carefully removed whilst the tubes were still applied to the magnet, 
and placed into clean 2mL eppendorf tubes. These tubes were then reapplied to 
the magnet and inverted 10 times, following which the PRP was removed and 
pooled in a clean 15mL tube. The PRP was centrifuged at 1,600g for 10 minutes 
to pellet the platelets. The platelets were washed once in phosphate-buffered 
saline (PBS), re-pelleted, lysed in Tri-reagent (Sigma, MO, USA) at 108 -109 
platelets/mL and stored at -80oC.  
 
2.1.2  Separation of mononuclear cells and granulocytes from peripheral 
blood 
 
20mls of sodium diatrizoate/polysaccharide density gradient (Lymphoprep, Axis-
Shield, Norway) at room temperature was aliquoted into a 50mL conical falcon 
tube. 25mls of peripheral blood was then layered slowly over the Lymphoprep 
using a pipette on the gravity-only setting, followed by centrifugation at 800g for 
20 minutes with the centrifuge brake switched off. The interface layer, containing 
mononuclear cells, was then collected using a Pasteur pipette, placed in a clean 
50mL Falcon tube and washed once in PBS. The mononuclear cells were 
resuspended in 1-3mls PBS and a cell count was performed using an 
automated counter (ABC Vet, ABX Montpellier, France). The cells were then 
used for purification of T-cells or CD34-positive cells, or for plating into semi-
solid media. 
 
The remaining plasma and Lymphoprep was removed down to the red 
cell/granulocyte layer. The red cell layer was resuspended in ice cold red cell 
lysis buffer (0.15M NH4Cl, 10mM NaHCO3 and 0.1mM EDTA in H2O) and 
incubated on ice for 10-30 minutes. The cells were then centrifuged at 800g for 
10 minutes and resuspended in 5mls PBS. In the event of incomplete red cell 
lysis, the above steps were repeated. A cell count was performed. In order to 
assess granulocyte purity, 105 cells in 100µL PBS were used to prepare a 
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cytospin slide. The cells were applied to a cytospin funnel mounted on a 
prelabelled glass slide and spun at 450rpm for 5 minutes on a cytocentrifuge 
(Cytospin 3, Shandon, UK). Following air-drying, the slides were fixed in 
methanol for 30sec and stained sequentially with haematoxylin (30sec) and 
methylene blue (30sec), and excess stain was rinsed off with tap water. 
Differential cell counts were performed by light microscopy in order to ensure 
that granulocyte purity was >95% before proceeding to cell lysis. Granulocytes 
were then pelleted by centrifugation and lysed in either Tri-reagent, DNA lysis 
buffer (containing 10mM EDTA, 50mM Tris-Cl and 0.5% sarkosyl) or RLT buffer 
(Qiagen, Hilden, Germany) and stored at -80oC for RNA or -20oC for DNA. 
 
2.1.3  Purification of CD2-positive T-cells 
 
Aliquots of 107 mononuclear cells in 1mL PBS were added to 25µL of 
prewashed anti-CD2 magnetic beads (Dynabeads, Dynal AS, Norway) in 2mL 
eppendorf tubes. Samples were incubated at 4oC for 20 minutes with mixing. 
The tubes were applied to a magnet and inverted 10 times to capture the CD2-
positive cells, allowing the PBS to be removed. Each sample was washed 5 
times in PBS in this manner. A cell count was then performed using a Neubauer 
ruled haemocytometer, in order to enumerate total cells and the percentage 
bound to magnetic beads. If the bead-bound percentage was <95%, further 
washes were performed as above and the purity reassessed. Cells were then 
pelleted by centrifugation and lysed in either Tri-reagent, DNA lysis buffer or 
RLT buffer and stored at -80oC for RNA or -20oC for DNA. 
 
2.1.4  Purification of CD34-positive progenitor cells 
 
Aliquots of up to 108 mononuclear cells were resuspended in 300µL of buffer 
(containing 0.5% bovine serum albumin and 2mM EDTA in PBS), to which 
100µL blocking reagent and 100µL CD34 magnetic beads were added (MACS 
system, Miltenyi, Germany). Samples were incubated on ice for 30 minutes, 
washed once in ice cold buffer and resuspended in 500µL ice cold buffer. A MS 
cell separation column (Miltenyi, Germany) was inserted into the magnet and 
rinsed with ice cold buffer. The sample was then applied to the column and 
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rinsed 3 times with 500µL aliquots of ice cold buffer. The column was removed 
from the magnet, 1mL buffer was added and the cells eluted off the column 
using the plunger. The eluted cells were washed once in Iscove's modified 
Dulbecco’s medium (IMDM; Sigma, MO, USA) and a cell count was performed 
using a Neubauer ruled haemocytometer. Samples were then either lysed in 
RLT buffer or plated in semi-solid media. 
 
 
 
2.2  Culture of human blood cells 
 
2.2.1  Culture of erythroid and granulocyte-macrophage progenitors in 
semi-solid medium 
 
The culture medium used was either Methocult GF H4531 (StemCell 
Technologies, Vancouver, Canada) containing 1% methylcellulose, 30% foetal 
bovine serum, 1% bovine serum albumin, 10-4 M 2-mercaptoethanol, 2 mM L-
glutamine and 10% agar leukocyte conditioned media (Agar-LCM) in Iscove's 
MDM; or Methocult GF H4534 (StemCell Technologies, Vancouver, Canada) 
containing 1% methylcellulose, 30% foetal bovine serum, 1% bovine serum 
albumin, 10-4M 2-mercaptoethanol, 2mM L-glutamine, 50ng/mL recombinant 
stem cell factor, 10 ng/mL recombinant GM-CSF and 10ng/mL recombinant IL-3 
in Iscove's MDM. 4mL aliquots of Methocult medium were prepared in 15mL 
tubes. Mononuclear cells in PBS obtained as per section 2.1.2 were adjusted to 
6 x106/mL and 66-200µL cell suspension was added to each 4mL aliquot of 
medium (final concentration 1-3 x105/mL). Alternatively, CD34-positive cells 
were added to give a final concentration of 500-2,000/mL. Other cytokines and 
reagents were added as indicated. For blood samples sent from other 
institutions, penicillin and streptomycin were added to the culture medium (final 
concentration 1%). In no case was more than 10% volume added to the 
Methocult medium, in order to maintain optimal viscosity. Samples were 
vortexed for 30 seconds and allowed to stand for 5min to allow air bubbles to 
escape. Samples were then aliquoted into 6-well plates at 1.1mL per well, using 
a 5mL syringe and an 18g needle. Sterile water was dispensed between the 
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wells, and the plate was incubated at 37oC with 5% CO2 and high humidity for 
14 days. 
 
Erythroid and granulocyte colonies were identified by morphological 
characteristics and the red colour of the former. Individual colonies were 
harvested by visualising the plate under a dissecting microscope, and carefully 
aspirating individual colonies using a P200 pipette. For DNA extraction, 
individual colonies were lysed in 50µL of water, heated to 95oC for 8min and 
stored at 4oC. For RNA extraction, individual colonies were lysed in RLT buffer 
and stored at -80oC. 
 
 
2.2.2  Culture of megakaryocyte progenitors in semi-solid medium 
 
The culture medium used was Megacult-C (StemCell Technologies, Vancouver, 
Canada). Mononuclear cells in PBS obtained as per section 2.1.2 were adjusted 
to 6 x106/mL and 50-200µL cell suspension was added to 1.7mL Megacult base 
medium. Cytokines were added as indicated at the following final 
concentrations: thrombopoietin 50ng/mL, IL-11 50ng/mL and IL-3 10ng/mL; the 
volume was then adjusted to 2.1mL with Iscove's MDM. 1.2mL of collagen 
solution was added to each sample to give a final concentration of 1.1 mg/mL 
bovine collagen, 1% bovine serum albumin, 10 mg/mL recombinant insulin, 200 
mg/mL human transferrin (iron saturated), 10-4 M 2-Mercaptoethanol, 2 mM L-
glutamine and 3-12 x105/mL mononuclear cells in Iscove’s MDM. Samples were 
vortexed, aliquoted into slide chambers (StemCell Technologies, Vancouver, 
Canada) and incubated at 37oC with 5% CO2 and high humidity for 14 days. 
 
After 14 days, the sides of the chambers were removed, and the gel matrix was 
dehydrated by layering a spacer and piece of pre-cut blotting paper over the 
slide. Slides were then fixed in 1:3 methanol:acetone solution for 20 minutes on 
ice. The spacers and blotting paper were carefully removed, and the fixed slides 
stored at -20oC until staining. Before staining, slides were brought to room 
temperature and rehydrated with rinse buffer (containing 0.05M Tris and 0.135M 
NaCl at pH 7.6) for 20 minutes. Care was taken to ensure that the slides 
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remained covered with the relevant solution at all stages of the staining protocol. 
After each stage of the staining protocol, the applied solution was tipped off the 
slide, and the new solution was overlaid. Blocking buffer (containing 5% human 
serum in rinse buffer) was applied to the slides for 20 minutes in order to inhibit 
non-specific binding of the primary antibody. Mouse anti-human GPIIb/IIIa 
antibody (lgG2a) at 10 µg/mL (in 5% human serum, 0.05M Tris and 0.135M 
NaCl) was then applied to the slides for 30 minutes, following which the slides 
were rinsed three times with rinse buffer (3min per application). Biotin 
conjugated goat anti-mouse lgG at 10 µg/mL (in 1% bovine serum albumin, 
0.05M Tris and 0.135M NaCl) was then applied to the slides for 30 minutes, 
following which the slides were rinsed three times with rinse buffer (3min per 
application). Avidin-Alkaline Phosphatase conjugate at 18 µg/mL (in 1% bovine 
serum albumin, 0.05M Tris and 0.135M NaCl) was then applied to the slides for 
30 minutes, followed by three washes with rinse buffer (3min per application). 
Alkaline phosphatase substrate was prepared fresh and applied to the slides for 
15 minutes, followed by three washes with rinse buffer (3min per application). 
Slides were counterstained for 10 minutes with 1% Evans blue in methanol and 
rinsed with distilled water until the water ran clear. Slides were then air-dried 
and kept at 4oC until analysis. 
 
Megakaryocytes colonies were identified by pale pink staining of their 
cytoplasm. They were differentiated from platelets which stain darker pink and 
appear as small anuclear fragments.  
 
2.2.3  Culture and replating of acute myeloid leukaemia cells in semi-solid 
medium 
 
Mononuclear cells from patients with AML (obtained from protocol 2.1.2) were 
plated in Methocult GF H4534 at a concentration of 103 to 105 cells/mL as 
outlined in section 2.2.1. Plates were examined for the presence of colonies 
after 7-14 days. Cytospins were prepared by dispersing single colonies in 100µL 
PBS as stained and outlined in section 2.1.2. 
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For replating experiments, each well was washed out twice with 3mL IMDM and 
transferred to a 15mL tube. The tube was made up to 14mL with IMDM and the 
cells pelleted by centrifugation at 800g for 8 minutes. The supernatant was 
removed down to 1ml above the cell pellet using a Pasteur pipette, and 
discarded. Following the addition of 12mL IMDM, the cell suspension was 
vortexed for 30sec and repelleted by centrifugation at 800g for 8 minutes. The 
supernatant was completely removed, the cells were resuspended in 500µL 
IMDM and a cell count was performed using an automated blood counter. Cells 
were then plated in fresh semi-solid media at a density dependent on the results 
of the initial plating experiment. Replating was repeated up to a further three 
times, and cytospin slides of individual colonies were prepared. 
 
2.2.4  Propagation of acute myeloid leukaemia cells in liquid culture 
 
Mononuclear cells from patients with AML (obtained from protocol 2.1.2) were 
cultured in IMDM containing 20% foetal calf serum, 100U/mL penicillin, 
100mg/mL streptomycin and 10ng/mL IL-3 at 37oC with 5% CO2 and high 
humidity. Every 2-3 days the cells were transferred into a 15mL tube, pelleted by 
centrifugation at 800g for 8 minutes and resuspended in fresh culture medium. 
Cell counts were performed using a haemocytometer, and cell viability checked 
by trypan blue exclusion. Cytospins were prepared and stained as outlined in 
section 2.1.2. 
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2.2.5  Storage of viable human cells 
 
For freezing of viable human cells, mononuclear cells at 1-5 x106 cells/mL in 
IMDM were chilled on ice. Cells were mixed in a one to one ratio with ice cold 
20% dimethyl sulfoxide (DMSO) in 5% human albumin solution, and frozen 
slowly by insulating in a polystyrene casing at -80oC. Cells were transferred to 
liquid nitrogen after around 3 days. To thaw viable cells, 1mL aliquots were 
rapidly thawed in a water bath at 37oC, and diluted immediately on thawing into 
14mL IMDM, followed by pelleting by centrifugation at 800g for 8min. Cells were 
then resuspended in IMDM and viability checked by trypan blue exclusion. 
 
2.2.6  Obtaining images of progenitor colonies and cytospins 
 
Images of erythroid and blast colonies were acquired from whole culture plates 
using a SMZ800 microscope (Nikon, Japan) with a Plan x1-x6.3 objective lens 
(Nikon, Japan) and Pro150ES camera (Pixera, California). Images of cytospins 
and stained megakaryocyte colonies were acquired using a U-TVO.5XC-2 
microscope (Olympus, Japan) with a UplanApo 40x/0,85 objective lens 
(Olympus, Japan) and Penguin 600CL camera (Pixera, California). All images 
were captured using Viewfinder and Studio Software (Pixera, California). 
 
2.3  Nucleic acid extraction from human blood cells 
 
2.3.1  DNA extraction from DNA lysis buffer 
 
Cell samples for DNA extraction were lysed in DNA lysis buffer (containing 
10mM EDTA, 50mM Tris-Cl and 0.5% sarkosyl), incubated overnight at 55oC 
and stored at -20oC. Samples were allowed to come to room temperature before 
DNA extraction. 500µL of cell lysate was mixed with an equal volume of phenol-
chloroform in a 2mL eppendorf tube and vortexed gently until the solution 
became cloudy. The sample was then centrifuged at 12,000g for 5min at room 
temperature. The supernatant (approximately 500µL) was transferred to a clean 
tube to which 1mL 100% ethanol and 150µL 3M sodium acetate was added. 
The sample was mixed by inversion. In most cases (with ≥106 cells) the DNA 
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could then be visualised as a stringy white precipitate, which was removed using 
a bacteria spreader and washed twice in 70% ethanol. The DNA pellet was then 
dried on the end of the bacteria spreader until just translucent and dissolved in 
200µL of water. When the DNA could not be visualised, the sample was place at 
-80oC for 30min and the DNA precipitated by centrifugation at 12,000g for 
15min. The DNA pellet was then washed twice with 70% ethanol, air dried until 
just translucent and dissolved in 100µL water. DNA quantity and purity was 
assessed using a NanoDrop spectrophotometer (LabTech, UK). Purity was 
assessed by the λ260/λ280 absorbance ratio, with optimal values being in the 
range 1.7-2.0. DNA samples were stored at 4oC. 
 
2.3.2  DNA and RNA extraction from Tri-reagent 
 
Samples in Tri-reagent were thawed at room temperate. 200µL chloroform was 
added to 1mL of sample in Tri-reagent followed by vigorous shaking for 15sec. 
The sample was allowed to stand for 10min at room temperature, followed by 
centrifugation at 12,000g at 4oC for 20min. The upper phase was transferred to 
a clean tube, to which 500µL isopropanol and 1µL glycogen (Ambion, TX, USA) 
was added and mixed by inversion. After standing for the 10min at room 
temperature, the RNA was precipitated by centrifugation at 12,000g for 20min. 
The supernatant was discarded and the RNA pellet washed once with 70% 
ethanol in RNAse free water, followed by centrifugation at 12,000g for 10min. 
The RNA pellet was then air dried until just translucent and dissolved in 10-30µL 
RNAse free water. Samples that were not reverse-transcribed immediately were 
stored at -80oC.  
 
For DNA extraction, all traces of the upper phase were carefully removed. The 
lower phase was then mixed with 150µL 100% ethanol and 1µL glycogen by 
inversion and allowed to stand for 5min at room temperature. DNA was 
precipitated by centrifugation at 12,000g for 15min at 4oC. The supernatant was 
discarded, 1mL 70% ethanol was added and the pellet washed by flicking the 
tube. The sample was allowed to stand for 15min at room temperature and 
repelleted by centrifugation at 12,000g for 10min. The wash step was repeated, 
following which all traces of ethanol were removed by pipetting and the DNA 
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pellet air dried until just translucent. 20-50µL water was added and the sample 
incubated at 55oC until the DNA had fully dissolved. DNA quantity and purity 
was assessed as outlined in section 2.3.1. DNA samples were stored at 4oC. 
 
2.3.3  DNA and RNA extraction using spin columns 
 
Qiagen RNeasy spin columns were used to isolate RNA from samples in RLT 
buffer. Samples were allowed to come to room temperature and mixed with an 
equal volume of 70% ethanol in RNAse free water. 700µL of sample was then 
applied to the spin column and centrifuged at 12,000g for 15sec. The flow-
through was discarded and the process repeated as necessary until the whole 
sample had been applied to the column. The column was rinsed with 700µL 
RW1 buffer and two applications of 500µL RPE buffer, with centrifugation at 
12,000g for 15sec and discarding of the follow-through after each application. 
Following the rinses, the column was placed in a clean collection tube and 
centrifuged for a further 1min to remove all traces of wash buffer. RNA was then 
eluted off the column into a clean tube in 30µL RNAse free water by 
centrifugation at 12,000g for 1min. Samples that were not reverse transcribed 
immediately were stored at -80oC.  
 
Qiagen AllPrep spin columns were used to isolate DNA and RNA in RLT or RLT 
plus buffer from small amounts of starting material, for example single erythroid 
colonies. Samples were thawed to room temperature and applied to the AllPrep 
column by centrifugation at 12,000g for 30sec. The AllPrep column, containing 
the DNA fraction, was set aside. The flow-through, containing the RNA fraction, 
was mixed with an equal volume of 70% ethanol in RNAse free water and 
applied to a RNeasy MiniElute column by centrifugation at 12,000g for 15sec. 
The column was rinsed sequentially with 700µL RW1 buffer, 500µL RPE buffer 
and 500µL 80% ethanol in RNAse free water by centrifugation at 12,000g for 
15sec. The column was then transferred into a clean collection tube and 
centrifuged at 12,000g for 5min to removed residual traces of ethanol. RNA was 
eluted off the column into a clean tube in 12µL RNAse free water by 
centrifugation at 12,000g for 1min. Samples that were not reverse transcribed 
immediately were stored at -80oC. The DNA bound to the AllPrep column was 
45
rinsed sequentially with 500µL AW1 buffer and 500µL AW2 buffer by 
centrifugation at 12,000g for 15sec. The DNA was then eluted off the column 
into a clean tube in 50µL elution buffer at 70oC by centrifugation at 12,000g for 
1min. DNA samples were stored at 4oC. 
 
2.3.4  Preparation of complementary DNA (cDNA) 
 
Frozen RNA samples were thawed at room temperature. 9.7µL of RNA solution 
was mixed with 2µL of 100µM random hexamers (Invitrogen, Paisley, UK). 
Following incubation for 5min at 70oC, samples were placed immediately on ice 
for 2min. To each sample was added 4µL 5x reaction buffer, 2µL 100mM 
dithiothreitol, 0.8µL 25mM dNTP, 0.5µL 40U/L RNAse inhibitor (Rnasin, 
Promega, Southampton, UK) and 1µL reverse transcriptase (from murine 
Moloney leukaemia virus, Invitrogen, Paisley, UK). A control sample containing 
water instead of RNA template was also prepared in the same way to control for 
contamination of the reverse transcription reagents. Samples were incubated at 
37oC for 90min followed by an enzyme inactivation step of 70oC for 10min. 
cDNA samples were stored at -20oC. 
 
2.4  Polymerase chain reaction (PCR) methods 
 
2.4.1  Primers for direct sequencing: design, optimisation and sequencing 
protocol 
 
Primers were designed using the Whitehead Institute on-line ‘Primer 3’ software 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi) on default settings 
with a product size of 150-500 bases. All DNA sequences were screened for 
regions of interspersed repeats of low complexity using an on-line repeat 
masker (http://www.repeatmasker.org/). In addition, primers were checked using 
an on-line in-silico PCR programme (http://genome.ucsc.edu/) to check that a 
single amplicon would be obtained. In assays designed to amplify intronic 
regions containing single nucleotide polymorphisms (SNPs), the predicted 
product was also checked for homology using an on-line bioinformatics site 
(http://genome.ucsc.edu/). In assays designed to amplify a cDNA product, the 
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primers were placed in different exons separated by an intron of at least 500 
bases.  
 
The basic PCR reaction consisted of 50µL volume containing 10-50ng template 
DNA or cDNA, 0.5U AmpliTaq Gold hot start taq polymerase (Applied 
Biosystems, CA, USA), 1µM dNTPs, 10mM Tris-Cl (pH 8.3), 50nM KCl, 1.5 mM 
MgCl2 and 0.2 µM forward and reverse primers. Standard PCR conditions were 
94oC for 10min followed by 35 cycles of denaturing at 94oC for 30sec, annealing 
at 55-65oC for 30sec and extension at 72oC for 30sec, followed by a final 
extension step of 72oC for 10min. The optimum annealing temperature for each 
pair of primers was assessed by means of a 55-65oC temperature gradient. 
Further optimisation was performed in the event of poor amplification, such as 
increasing the MgCl2 concentration to 2-2.5mM, including 10% DMSO to the 
reaction or increasing the primer concentration. All PCR reactions included a 
positive control (a DNA or cDNA sample known to amplify well), a no-template 
control and in the case of cDNA amplification, a no-template control sample 
from the original reverse transcription reaction (as outlined in section 2.3.5). 
PCR products were visualised under ultraviolet light after running 10µL of the 
reaction on a 1-2% agarose electrophoresis gel stained with ethidium bromide. 
 
For direct sequencing of PCR amplified DNA, the PCR product was first treated 
with ExoSAP-IT (USB, OH, USA), a mixture of Exonuclease 1 and Shrimp 
Alkaline Phosphatase to remove unincorporated primers and dNTPs, by 
incubating 5µL of PCR product with 2µL of ExoSAP-IT at 37oC for 15min, 
followed by 80oC for 15min to inactivate the enzyme. 2µL of treated PCR 
product was then added to the sequencing reaction, comprising 3µL reaction 
buffer (80mM Tris pH 9.0, 10mM MgCl2), 1µL BigDye reaction mix (Applied 
Biosystems, CA, USA), 2.5µL of sequencing primer at 10µM concentration and 
1.5µL H2O. Standard PCR conditions for the sequencing reaction were 25 
cycles of denaturing at 96oC for 10sec, annealing at 50oC for 5sec and 
extension at 60oC for 4min. Products were then precipitated with 1µL 3M sodium 
acetate and 25µL 95% ethanol for 15min at room temperature, followed by 
centrifugation at 2,250g for 40min. Products were washed once with 70% 
ethanol, followed by centrifugation at 2,250g for 10min, and resuspended in 
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10µL formamide. Sequencing was performed on a 3730xL analyser (Applied 
Biosystems, CA, USA). Sequence traces were analysed manually using 
Chromas Lite software (version 2.0, Technelysium Pty Ltd, MN, USA). 
 
2.4.2  Primers for pyrosequencing: design and optimisation 
 
Pyrosequencing was used when accurate quantitation of alternative alleles was 
required, for example in the measurement of mutant allele burden or the 
genotyping of individual progenitor colonies for a specific mutation or SNP. 
Primers were designed using PSQ assay design software version 1.0.6 
(Biotage, Uppsala, Sweden). Annealing temperature and primer conditions were 
optimised and PCR products examined after gel electrophoresis as outlined in 
section 2.4.1. For the pyrosequencing reaction, 3µL Streptavidin Sepharose HP 
beads (Amersham Biosciences, Chalfont St Giles, United Kingdom) were 
incubated with 37µL Binding buffer (10mM Tris-Cl pH 7.6, 2 M NaCl, 1mM 
EDTA and 0.1% Tween 20), 20µL PCR product and 20µL water for 10 minutes 
at room temperature with agitation. Biotinylated PCR products were then 
captured onto the filter probes of the Pyrosequencing Vacuum Prep Tool 
(Biotage, Uppsala, Sweden), washed with 70% ethanol for 5sec, denatured with 
0.2M NaOH for 5sec and washed with10mM Tris-acetate pH 7.6 for 5sec. The 
vacuum was then released and the beads and bound single-stranded DNA 
template was dropped into a PSQ 96 Plate Low (Biotage) containing 45µL 
annealing buffer (20mM Tris-acetate, 2mM magnesium acetate, pH 7.6) with 
0.3µM sequencing primer. The samples were heated to 80°C for 2 minutes and 
then allowed to cool to room temperature. Pyrosequencing reactions were 
performed using the PSQ 96 single nucleotide polymorphism reagent kit 
(Biotage), which contained the enzyme, substrate mixture and nucleotides.  
 
Individual pyrosequencing assays were optimised by studying the following 
controls: biotinylated DNA template only to look for template looping and self 
priming, sequencing primer only and biotinylated primer only to look for primer 
dimerisation and extension, biotinylated primer and sequencing primer to look 
for aberrant extension from a primer-only template, and no template control from 
the original PCR reaction to look for interference from primer dimers. The 
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performance of each individual assay was assessed using PCR products cloned 
into the pGem-Teasy vector (see section 2.4.5) to generate a standard curve. 
For assays designed to quantitate mutant alleles where two or three adjacent 
bases were changed, a standard curve was generated using one of the 
following formulae: 
 
two adjacent bases changed:   three adjacent bases changed: 
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2
      
TA
A
+
3
3
 
 
where A and T are the pyrosequencing peak heights for the mutant and wild-
type alleles respectively. The relative quantitation of the allele was then read 
from the graph.  
 
2.4.3  Allele-specific polymerase chain reaction: design and optimisation 
 
Allele-specific PCR assays were used as a sensitive method of detecting 
mutations in DNA and cDNA samples. Each assay consisted of a pair of control 
primers designed to produce an amplicon of around 400bp with both wild-type 
and mutant material, and an internal mutation specific primer designed to 
produce an amplicon of around 200bp with mutant samples. To ensure the 
specificity of the mutation specific primer, the 3’ end was placed over the 
mutated base. In some instances, mismatches were introduced close to the 3’ 
end of the primer to destabilise annealing and improve specificity for the mutant 
allele. It was generally necessary to screen many different mutation specific 
primers using different annealing temperatures to ensure both the sensitivity and 
specificity of the assay. 
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2.4.4  Real-time polymerase chain reaction (QPCR): design and 
optimisation 
 
Real-time PCR (QPCR) was performed on a Stratagene Mx3000P machine and 
analysed using MxPro version 3.20 (Stratagene, CA, USA). Primers were 
designed using the Whitehead Institute on-line ‘Primer 3’ software 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi) on default settings 
with a product size of 80-110 bases for cDNA analysis, and a product size of 
around 50 bases for DNA copy number analysis. In assays designed to amplify 
a cDNA product, the primers were placed in different exons separated by an 
intron of at least 500 bases in order to avoid amplification of contaminating DNA. 
All reactions were run using Brilliant SYBR green 2x master mix (Stratagene, 
CA, USA), 30nM ROX reference dye, 100-300nM primers and 10-50ng 
template. No template controls were run for every primer pair to check for 
contamination and primer dimer formation. Cycling conditions used were 95oC 
for 10min followed by 40 cycles of 95oC for 15sec and 600C for 60sec followed 
by measurement of the dissociation curve with collection of fluorescence data 
for every 1oC rise in temperature from 55oC to 95oC. Primers were optimised by 
preparing five serial 1 in 5 dilutions of a suitable template which was run in 
duplicate for each primer pair. This data was then used to generate a standard 
curve using the machine software. Such experiments were considered 
acceptable only where there was high precision between replicates (Rsq 
≥0.985). Primers were considered acceptable where the slope of the curve gave 
a primer efficiency of 90-110% (Y value between -3.1 and -3.6 with optimum -
3.3). The dissociation curve was examined for the presence of a single sharp 
peak (indicating the presence of a single amplified product). Primers producing 
more than one peak or a single poorly defined peak were redesigned. No 
template controls were studied for primer dimers, as suggested by the presence 
of poorly defined peaks at lower temperatures in the dissociation curve analysis. 
In such cases, optimisation was repeated with lower primer concentration or the 
primers were redesigned.  
 
ABL and GUSB were used as housekeeping genes as studies have 
demonstrated little variability in their expression across different haematopoietic 
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cell types, both in normal and leukaemic samples192. One or more housekeeping 
genes were assessed in every experiment to control for the amount of input 
material, along with one or more genes of interest. All samples were run in 
duplicate, and an average was taken for the threshold value (Ct value).  
 
In experiments looking for trends in gene expression relative to a specific 
sample (normaliser or calibrator sample), the expression of the gene of interest 
relative to the housekeeping gene was calculated using the ∆∆Ct formula as 
below: 
 
∆∆Ct = 2-(Ct gene of interest - Ct housekeeping gene)
 
2.4.5  Cloning of polymerase chain reaction amplified products 
 
DNA was amplified in a standard PCR reaction using a taq polymerase that 
leaves an A-overhang, such as AmpliTaq Gold. The PCR product was purified 
using a QiaQuick spin column (Qiagen, Germany) and visualised on an ethidium 
bromide stained agarose gel. A ligation reaction was then set up containing 2-
4µL PCR product, 5µL 2x reaction buffer, 1µL T4 ligase, 1µL pGem-T Easy 
vector (Promega, WI, USA), and water to bring the reaction to 10µL. The 
reaction was left at room temperature for 1-4 hours. JM109 highly competent E-
coli bacteria (Stratagene, CA, USA) were thawed on ice. 50µL of cells was 
mixed with 5µL of ligase reaction and incubated on ice for 30min. The sample 
was then heat shocked in a water bath at 42oC without agitation for exactly 
45sec, then transferred directly onto ice for 2min. 600µL of SOCS medium was 
added to each sample, which was then incubated at 37oC for 45min. 100µL of 
10mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) and 100µL of 2% 5-
bromo-4-chloro-3-inodlyl-β-D-galactopyranoside (X-gal) was added to each 
sample, mixed by inversion and tipped onto individual LB agar plates containing 
ampicillin. The sample was spread evenly over the surface of the plate using a 
sterile bacterial spreader and left to dry completely at room temperature. The 
agar plates were then inverted and incubated overnight at 37oC.  
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The pGem-T Easy vector contains an ampicillin resistance cassette such that 
only successfully transformed bacteria will produce colonies on an ampicillin 
impregnated plate. Successful ligase of DNA into the vector disrupts a β-
galactosidase expression cassette, such that bacterial colonies that have taken 
up an empty vector will appear blue in the presence of X-gal and IPTG, whereas 
bacterial colonies containing the vector plus an insert will appear white. 
Individual white bacterial colonies were transferred into 50µL of SOCS medium 
using a pipette tip. To sequence the vector insert, a standard PCR reaction was 
set up using M13 primers (which anneal to the vector and allow amplification 
across the insert) and 2µL of bacterial colony in SOCS reagent. The PCR 
product was then prepared for direct sequencing.  
 
When a bacterial colony containing the correct insert was identified, 10µL of the 
bacterial colony in SOCS medium was added to 3mL LB medium and incubated 
overnight at 37oC with agitation at ~250rpm. Bacteria were pelleted from 2mL of 
culture by centrifugation at 6,000g for 5min and resuspended in 200µL ice cold 
resuspension buffer containing 50mM Tris-Cl pH 8.0, 10mM EDTA and 
100µg/mL RNAse A. This was mixed by inversion with 200µL lysis buffer at 
room temperature, containing 200mM NaOH and 1% SDS, and left to stand at 
room temperature for 5min. 300µL ice cold neutralization buffer was then added, 
containing 3M potassium acetate pH 5.5, mixed by inversion and incubated on 
ice for 5min. Cellular debris was removed by centrifugation at 12,000g for 10min 
at 4oC, and the supernatant transferred to a clean tube. DNA was precipitated 
by the addition of 900µL isopropanol, followed by incubation at room 
temperature for 20min and centrifugation at 12,000g for 20min at room 
temperature. The DNA pellet was washed once with 70% ethanol, repelleted by 
centrifugation at 12,000g for 5min and air dried until just translucent. The DNA 
was then dissolved in water, and quantity and purity of DNA were assessed as 
outlined in section 2.3.1. The sequence of the plasmid insertion was checked by 
direct sequencing using the M13 primer site within the vector. 500µL of bacterial 
culture were mixed with 500µL glycerol and stored at -20oC for future use. 
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2.5  Summary of reagents used 
 
Procedure Reagent Supplier 
Density separation Lymphoprep Axis-Shield, Norway 
Leucocyte depletion CD45 magnetic beads Dynal AS, Norway 
HSC/AML enrichment CD34 magnetic beads MACS, Miltenyi, Germany 
T-cell selection CD2 magnetic beads Dynabeads, Dynal AS, Norway 
DNA & RNA isolation TRI-reagent Sigma, MO, USA 
RNA isolation RLT buffer & spin columns Qiagen, Hilden, Germany 
cDNA synthesis Reverse transcriptase Invitrogen, Paisley, UK 
cDNA synthesis RNAse inhibitor Promega, Southampton, UK 
Liquid cell culture IMDM Sigma, MO, USA 
Semi-solid colony assays Methocult StemCell, Vancouver, Canada 
Megakaryocyte colony assay Megacult StemCell, Vancouver, Canada 
PCR primers Oligonucleotides Sigma-Aldrich, Poole, UK 
PCR reaction AmpliTaq gold Applied Biosystems, CA, USA 
Sequencing clean-up ExoSAP-IT USB, OH, USA 
Sequencing reaction Big Dye reagents Applied Biosystems, CA, USA 
Pyrosequencing Pyro reagents Biotage, Uppsala, Sweden 
Real-time PCR SYBR green 2x master mix Stratagene, CA, USA 
Cloning of PCR products pGem-Teasy vector Promega, WI, USA 
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2.6  Statistical analysis 
 
Unpaired two-tailed t tests were used to compare the mean value of continuous 
variables between two groups. Fisher’s exact test was used to compare 
categorical data in a 2x2 contingency table. Both tests were performed using 
Microsoft Excel 2002 and/or GraphPad Prism  
(http://www.graphpad.com/quickcalcs/).  
 
Analysis of clinical and laboratory variables in the PT-1 cohort (Chapter 3, 
Tables 3.3, 3.4 and 3.5) was performed by Dr Peter Campbell. Pairwise 
univariate analyses comparing diagnostic variables between the MPL-mutant 
and either JAK2 V617F-positive or JAK2 V617F-negative groups were 
performed using the t test for continuous variables, Fisher’s exact test for 2×2 
tables, and Cochran-Armitage test for trend with exact p values for ordinal 
variables. Multivariate analyses for the associations of ordinal variables with 
mutation status, accounting for the effects of age, were performed using 
proportional odds logistic regression. Complication rates during follow-up were 
assessed using Kaplan-Meier life tables and log-rank analyses. Confidence 
intervals for odds ratios of complications in the year prior to diagnosis were 
calculated using the asymptotic formula 1/a + 1/b + 1/c + 1/d to estimate the 
variance of the log (OR). Multivariate survival analyses were performed using 
Cox proportional hazards models. S-plus v7.0 (Insightful Corp, Seattle, WA) was 
used for all statistical analyses, apart from the exact methods, for which SAS 
v9.0 (SAS, NC, USA) was used. 
 
 
 
54
Chapter 3 
 
Characterisation of mutations in MPL, the thrombopoietin 
receptor, in the human myeloproliferative disorders 
 
 
3.1  Introduction 
 
Gain of function mutations in MPL, encoding the thrombopoietin receptor, have 
been reported in both inherited and acquired myeloid disorders, affecting the 
transmembrane and juxtamembrane regions of the protein (Figure 3.1A). An 
inherited mutation in the transmembrane domain (MPL S505N) has been 
reported in Japanese and Italian kindreds with familial thrombocytosis, but was 
not observed in cases of sporadic ET172,193. Although the precise molecular 
consequences of this alteration are unclear, expression of the MPL S505N allele 
conferred cytokine independent growth to the cytokine dependent BaF3 cell 
line172. Acquired mutations in the juxtamembrane region (MPL W515L/K) have 
been reported in 5-8% of patient with IMF174,175. This region, which is absent 
from the erythropoietin receptor (Figure 3.1A), is thought to play a role in 
negative regulation of MPL signalling173. Retrovirally-induced expression of the 
MPL W515L allele in murine bone marrow resulted in an MPD phenotype in vivo 
characterised by splenomegaly and marked thrombocytosis174. In IMF patients, 
MPL mutations are associated with lower haemoglobin levels and an increased 
risk of dependence on red cell transfusion when compared to both JAK2 V617F-
positive and mutation negative patients194. The MPL W515L mutation was 
subsequently reported in around 1% of ET patients, although the small number 
of patients (n=4) precluded further phenotypic analysis175. 
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  Figure 3.1. Mutations in MPL exon 10 in patients with a myeloproliferative
disorder. (A) MPL structural domains and partial sequence alignment with
murine MPL and the human erythropoietin receptor (EPOR). Residues mutated
in patients with a myeloproliferative disorder are underlined. (B) Sequence
traces showing the S505N allele as an acquired mutation, the previously
reported W515L allele, and two different alleles resulting in a W515K
substitution. TM: transmembrane; JM: juxtamembrane; NA: no sample
available. 56
3.2  Aims of this chapter 
 
This chapter addresses the following questions relating to MPL mutations in 
patients with an MPD: 
 
1) Are mutations in MPL other than those previously described associated with 
the development of an MPD? 
2) Are MPL mutations limited to the megakaryocyte lineage in a proportion of 
patients? 
3) Are MPL mutations found in patients with polycythaemia vera? 
4) What is the prevalence of MPL mutations in ET? 
5) Do MPL mutations in ET define a distinct subset of patients with regard to 
laboratory, histological or clinical features?  
6) Are MPL mutations associated with genuine ET or do MPL mutant ET 
patients represent an early stage of IMF? 
 
3.3  Characterisation of mutations in MPL 
 
To address the possibility that mutations in MPL may be restricted to the 
megakaryocyte lineage, or may occur elsewhere in the gene, platelet cDNA was 
prepared from 20 patients with a JAK2 V617F-negative MPD (18 ET and 2 IMF). 
The entire MPL coding region, spanning approximately 2Kb, was amplified by 
PCR in four overlapping fragments and assessed for mutations by bi-directional 
sequencing. Within this cohort, a single patient with an acquired MPL W515L 
mutation was identified, indicating that mutations outside exon 10 or mutations 
restricted to the megakaryocyte lineage are not a common cause of JAK2 
V617F-negative MPD.  
 
4 of 20 patients harboured a non-synonymous MPL V114M SNP. This SNP has 
been previously reported (rs12731981), but at a lower rate than observed in this 
cohort (heterozygous proportion 0.052, HapMap European cohort, n=116). As a 
non-synonymous SNP has previously been associated with higher platelet 
counts in a black-American cohort195, further information was sought from the 
Bloodomics consortium. In their cohort of normal blood donors, the 
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heterozygosity rate for the rs12731981 SNP was 0.048 (Nick Watkins personal 
communication, n=291), in keeping with published data and significantly lower 
than observed in this MPD cohort (p=0.02, Fisher’s exact test). In the 
Bloodomics cohort, however, the presence of the SNP was not associated with 
any difference in platelet count. In order to accurately characterise the frequency 
of this SNP in MPD patients, 381 ET patients from the PT-1 cohort were 
genotyped for the SNP using a pyrosequencing assay (Table 3.1). In the PT-1 
cohort, the heterozygous proportion was no different from normal controls in 
Bloodomics cohort, suggesting that the over-representation of the SNP in the 
original cohort of 20 patients was a chance occurrence. 
 
Table 3.1. Genotyping for the MPL V114M SNP in ET patients from the PT-1 
cohort 
 
 G/G 
(V/V) 
G/A 
(V/M) 
Heterozygous 
proportion 
    
V617F-positive  198 10 0.048 
    
V617F-negative 163 10 0.058 
    
All patients 361 20 0.052 
    
 
MPL exon 10 was further assessed in a retrospective cohort of 200 unselected 
patients with ET or IMF by direct sequencing of granulocyte-derived DNA. Exon 
10 encodes both the transmembrane and juxtamembrane regions of the protein, 
and includes the S505 and W515 residues previously reported as sites of 
human mutation. This cohort was also genotyped for the JAK2 V617F mutation 
by allele-specific PCR29. MPL mutations were found in 8 IMF patients (7.1%) 
and 3 ET patients (3.4%), all of whom were negative for the JAK2 V617F 
mutation (Table 3.2). 
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Table 3.2. JAK2 V617F and MPL exon 10 mutations in a retrospective cohort of 
200 MPD patients. 
 
 MPL exon 10 
 
JAK2 
V617F-
positive S505N W515L W515K 
Mutation 
negative 
IMF - no. 57 1 5 2 47 
ET - no. 41 1 2 0 44 
Total 98 2 7 2 91 
 
Three different alleles resulting in two different amino acid changes at the W515 
residue were seen (Figure 3.1B), comprising the previously reported MPL 
W515L and W515K alleles. Two patients carried an MPL S505N mutation, 
previously reported as an inherited allele172,193. Constitutional material was 
available from one ET patient, and showed absence of the mutation in T-cell 
and buccal derived DNA, demonstrating that the mutation was acquired in this 
patient (Figure 3.1B). Moreover, the patient had had a number of normal blood 
counts in the years prior to diagnosis with ET, consistent with the presence of an 
acquired MPD. 
 
To investigate the possibility that mutations in MPL are also present in patients 
with PV, 120 patients were screened for mutations at MPL W515 using a 
pyrosequencing assay with a sensitivity 10%. None of the PV patients, all of 
whom were positive for the JAK2 V617F mutation, harboured mutations in MPL, 
indicating that such mutations are limited to MPD patients with ET or IMF.  
 
3.4  Development of sensitive assays for the detection and quantitation 
of MPL mutations 
 
At the time of this study, nothing was known about the precise prevalence or 
clinical significance of MPL mutations in patients with ET. Mutations in MPL 
were therefore assessed in samples taken from patients entered into the PT-1 
studies, for whom comprehensive diagnostic and prospectively acquired follow-
up data was available. Although patients enrolled into the PT-1 trials had DNA 
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banked at trial entry, the samples were from unfractionated whole blood. 
Previous studies have indicated that in patients with a JAK2 V617F associated 
MPD, the clonal burden may be low, particularly in ET29. Moreover, JAK2 and 
MPL mutations are absent from the majority of lymphocytes58,196. It was 
important, therefore, to develop sensitive assays for each mutant MPL allele. 
For genotyping of the PT-1 samples, allele-specific PCR assays were developed 
for each of the three MPL mutations, with the MPL W515K assay being able to 
detect both alleles found in the retrospective cohort.  
 
In order to assess the sensitivity of each allele-specific PCR assay, 
pyrosequencing assays were developed to accurately quantitate the mutant 
allele burden in patient samples (Figure 3.2A). Each pyrosequencing assay was 
validated using a dilution series made by mixing cloned wild-type and mutant 
PCR products. Results from this analysis were then used to plot a standard 
curve, from which the allele burden was read (Figure 3.2B). 
 
The pyrosequencing assays were used to assess the mutant allele burden in 
patient samples, and allele-specific PCR was then performed on dilutions 
corresponding to 1-9% mutant allele burden. The assays for MPL S505N and 
MPL W515L could detect a mutant allele burden of ~1%, whereas the assay for 
the MPL W515Ki and MPL W515Kii allele could detect a mutant allele burden of 
~3-5% (Figure 3.3). 
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Figure 3.2. Pyrosequencing assays used for the quantitation of MPL exon
10 mutations. (A) Representative pyrograms for MPL exon 10 mutations
showing the nucleotide dispensation order for the individual assays. Mutation
sites are highlighted in grey. (B) Standard curves for the quantitative MPL exon
10 pyrosequencing assays generated by mixing cloned MPL wild-type and
mutant PCR products.  
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Figure 3.3. Allele-specific PCR assays used for the detection of MPL exon
10 mutations. (A) Primer design strategy for allele-specific PCR showing the
common forward and reverse intronic primers and the allele-specific primer lying
within MPL exon 10. (B) Mixing experiments performed with normal and mutant
DNA demonstrating the sensitivity of each individual allele-specific PCR assay.
PCR: polymerase chain reaction; Pt: patient sample; WT: wild-type control;
NTC: no template control.  
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3.5  Clinical and laboratory features of MPL mutations in patients with  
essential thrombocythaemia 
 
DNA samples were available from 776 patients enrolled into the PT-1 trials, 
comprising a randomised trial of hydroxycarbamide versus anagrelide in high 
risk ET, a randomised trial of hydroxycarbamide versus no cytoreductive therapy 
in intermediate risk ET and an observation trial of low risk ET (Figure 3.4A). 
Samples were genotyped for the MPL S505N, MPL W515L and MPL W515K 
mutations using allele-specific PCR. MPL mutations were detected in 32 
patients, accounting for 4.1% of all ET patients (95% CI 2.9%-5.8%, Table 3.5) 
and 8.5% of JAK2 V617F-negative ET patients (Figure 3.4B). MPL W515L was 
the most common mutation, seen in 24 patients; 5 patients had MPL W515K (all 
MPL W515Ki allele) and 3 patients had MPL S505N mutations (Figure 3.4C).  
 
In all patients with MPL W515K or MPL S505N alleles, the presence of the 
mutation was confirmed by both direct sequencing and pyrosequencing. Of the 
24 MPL W515L mutations, 19 were detected by both direct sequencing and 
pyrosequencing, 3 were detected by pyrosequencing but not direct sequencing, 
and 2 were detected by allele-specific PCR alone. In these 2 patients, the 
presence of the mutation was confirmed by cloning an MPL exon 10 PCR 
amplicon, which was used for transformation of competent bacteria. Individual 
bacterial colonies were then picked and genotyped by direct sequencing. In both 
patients the mutant allele was detected in <1% of bacterial colonies screened, 
consistent with a low mutant allele burden. The allele-specific PCR result was 
also confirmed in both of these patients using an independent DNA sample. Of 
the 32 MPL-mutant patients, one also carried the JAK2 V617F mutation, and is 
included in the MPL-mutant group in the statistical analysis. No patient was 
positive for more than one MPL-mutant allele. 
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Figure 3.4. The PT-1 cohort: study design and mutation prevalence. (A)
Study design of the three PT-1 trials. (B) Prevalence of MPL exon 10 and JAK2
V617F mutations within the PT-1 cohort. (C) Relative distribution of individual
MPL exon 10 mutations within the PT-1 cohort. ET: essential
thrombocythaemia.  
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Laboratory and clinical features of the MPL-mutant group were compared to 
both the JAK2 V617F-positive and JAK2 V617F-negative groups, both of which 
lack MPL mutations. The statistical analyses presented in Tables 3.3, 3.4 and 
3.5 were performed by Dr Peter Campbell. MPL-mutant patients were 
significantly older at diagnosis than JAK2 V617F-negative patients. Compared 
to JAK2 V617F-positive patients, MPL-mutant patients had lower haemoglobin 
and higher platelet levels at diagnosis. There were no differences, however, in 
diagnostic blood counts between the MPL-mutant and JAK2 V617F-negative 
groups. There were also no significant differences in the presence of 
splenomegaly or bone marrow cytogenetic abnormalities between the groups 
(Table 3.3). 
 
Two patients with MPL mutations harboured bone marrow cytogenetic 
abnormalities. A patient with an MPL S505N mutation harboured monosomy 7 
and additional material on chromosome 6, and a patient with MPL W515L 
harboured trisomy 14. In both cases the abnormalities were detected at 
diagnosis prior to cytoreductive therapy, and neither case showed evidence of 
progression to myelofibrosis or acute leukaemia during trial follow-up. Trisomy 
14 is a recognised recurrent abnormality in myeloid malignancy, although the 
majority of cases comprise either acute myeloid leukaemia or myelodysplasia197. 
Monosomy 7 is a frequent abnormality in myeloid malignancy, but again is 
generally associated with acute myeloid leukaemia or myelodysplasia.  
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Table 3.3. Laboratory and clinical features at diagnosis of 776 ET patients 
enrolled in the PT-1 trials. 
 
 MPL negative 
 MPL mutant V617F positive 
V617F 
 negative 
p value 
(vs V617F 
pos) 
p value 
(vs V617F 
neg) 
Number 32 1 411 333   
Percentage  
 –  (95% CI) 
4.1% 
(2.9-5.8) 
53.0% 
(49.4-56.5) 
42.9% 
(39.4-46.5) 
  
Risk category      
Low risk2 0 26 31 0.2 0.09 
Intermediate risk3 4 68 46 0.8 1.0 
High risk4 28 339 273 0.6 0.6 
  Hydroxyurea + Aspirin 13 168 139 
  Anagrelide + Aspirin 15 171 134 0.9 0.8 
      
Demographics      
Female – no. (%) 17 (53%) 255 (62%) 192 (58%) 
Male – no. (%) 15 (47%) 156 (38%) 141 (42%) 0.3 0.7 
Age (yr.)      
 – median (10th-90th centile) 67 (48-77) 60 (39-77) 52 (32-74) 0.09 <0.0001 
Disease duration5 (mths.)       
 – median (10th-90th centile) 18 (0-956) 38 (0-1106) 57 (0-2699) 0.2 0.7 
      
Laboratory and clinical features at diagnosis    
Haemoglobin (g/L) 
 – mean ± SD 
 
133 ± 12 
 
145 ± 14 
 
135 ± 14 
 – median 
 –  (10th-90th centile) 
136 
(119 - 147) 
145 
(128 - 163) 
136 
(117 - 153) 
<0.0001 0.3 
      
White cells (x109/L)  
 – mean ± SD 
 
9.9 ± 2.4 
 
10.6 ± 3.4 
 
9.3 ± 2.7 
 – median  
 –  (10th-90th centile) 
9.7  
(7.0 - 13.3) 
10.0 
(7.0 - 14.6) 
8.8 
(6.2 - 12.8) 
0.2 0.2 
      
Neutrophils (x109/L) 
 – mean ± SD 
 
6.7 ± 2.1 
 
7.4 ± 3.0 
 
6.2 ± 2.2 
 – median  
 –  (10th-90th centile) 
6.9  
(4.4 - 9.6) 
6.8 
(4.2 - 11.0) 
5.8 
(3.8 - 9.1) 
0.3 0.2 
      
Platelet count (x109/L)  
 – mean ± SD 
 
1040 ± 272 
 
900 ± 274 
 
1032 ± 350 
 – median  
 –  (10th-90th centile) 
962  
(752 - 1505) 
840 
(632 - 1221) 
963 
(666 - 1550) 
0.006 0.9 
      
Splenomegaly – no. (%) 
 
0/27 (0%) 11/326 (3%) 11/262 (4%) 0.7 0.6 
Abnormal cytogenetics  
 – no. (%) 
2/24 (8%) 14/312 (4%) 10/262 (4%) 0.3 0.2 
 
1 One patient had both JAK2 V617F and MPL W515L mutations, and is included in the MPL-
mutant group  
2 Includes 4 patients who subsequently enrolled in the intermediate risk arm, and 10 in the high 
risk arm 
3 Includes 4 patients who were previously enrolled in the low risk arm and 25 who subsequently 
enrolled in the high risk arm 
4 Includes 10 and 25 who were previously enrolled in the low and intermediate risk arms, 
respectively 
5 Refers to time elapsed between diagnosis and trial entry 
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Bone-marrow trephine biopsies at diagnosis were available from 311 patients, 
including 13 patients with MPL mutations, comprising 2 S505N, 2 W515K and 9 
W515L patients. These were assessed independently by three 
haematopathologists (Dr Wendy Erber, Dr David Bareford and Dr Bridgit 
Wilkins) who were aware of the patient’s age and sex but unaware of JAK2 or 
MPL mutation status (Table 3.4). Given the known association between age and 
bone marrow cellularity, patient age was included as a variable in the statistical 
analyses for cellularity. There were no differences in the mean reticulin grade, 
megakaryocyte cellularity or the presence of megakaryocyte clusters and atypia 
between the MPL-mutant, JAK2 V617F-positive and JAK2 V617F-negative 
groups. However, trephine biopsies from the MPL-mutant group were less 
cellular than both the JAK2 V617F-positive and JAK2 V617F-negative groups 
(p=0.0001 (0.0003 with age) and p=0.005 (0.003 with age) respectively). 
Compared to the JAK2 V617F-positive group, both erythroid and granulocytic 
cellularity were reduced in the MPL-mutant group (p=0.0008 (0.0007 with age) 
and p=0.009 (0.02 with age) respectively). Compared to the JAK2 V617F-
negative group, the MPL mutant group showed reduced erythroid cellularity 
(p=0.005 (0.004 with age)). Thus MPL-mutant patients exhibited a more isolated 
megakaryocytic proliferation at diagnosis, with a reduction in overall cellularity 
compared to both the JAK2 V617F-positive and JAK2 V617F-negative groups. 
There was, however, considerable overlap between the histological 
appearances observed in the three groups of patients, with MPL-mutant patients 
showing many features typical of ET, including increased megakaryocyte 
number with clustering and nuclear hyperlobation (Figure 3.5). As such, these 
results indicate that MPL mutations as a whole do not define a distinct 
histological subtype of ET. It remains formally possible that specific MPL 
mutations are associated with particular histological features, but the number of 
patients with each individual MPL mutation was too small to address this issue. 
Two MPL mutant patients developed IMF during trial follow-up (one MPL S505N 
and one MPL W515K). Of note, all MPL-mutant ET patients were classified as 
‘true-ET’ at diagnosis, according to WHO criteria74, with no cases showing 
features of pre-fibrotic or cellular phase myelofibrosis.  
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Table 3.4. Bone marrow trephine histology, erythropoietin levels and iron stores in 
patients enrolled in the PT-1 trials. 
 
 MPL negative 
 MPL mutant V617F positive 
V617F 
negative 
p value 
(vs V617F 
pos) 
p value 
(vs V617F 
neg) 
Bone marrow trephine 
histology1
 
n=13 n=168 n=130   
Reticulin grade – mean ± SD 1.8 ± 1.0 1.8 ± 0.8 1.9 ± 0.9 0.9 0.6 
      
Megakaryocyte clusters and nuclear morphology    
Clusters 
 (absent/loose/tight) 
1 / 6 / 6 22 / 99 / 47 12 / 67 / 51 0.3 0.8 
Pyknotic  
(absent/pres/predom) 
6 / 6 / 1 55 / 112 / 1 48 / 79 / 3 0.8 0.9 
Staghorn  
(absent/pres/predom) 
2 / 10 / 1 31 / 132 / 5 23 / 102 / 5 0.7 0.7 
Cloud-like (absent/pres/predom) 5 / 8 / 0 46 / 118 / 4 44 / 85 / 1 0.4 0.8 
Dysplastic (absent/pres/predom) 4 / 8 / 1 57 / 110 / 1 48 / 80 / 2 0.6 0.6 
      
  Cellularity2      
Overall (dec/normal/inc) 3 / 5 / 5 1 / 36 / 131 2 / 43 / 85 0.0003 0.003 
Erythroid (dec/ normal/inc) 3 / 9 / 1 5 / 90 / 73 6 / 77 / 47 0.0007 0.004 
Granulocytic (dec/normal/inc) 3 / 6 / 4 3 / 74 / 91 2 / 76 / 52 0.02 0.07 
Megakaryocytic (+/++/+++)  3 / 9 / 1 32 / 88 / 47 25 / 58 / 47 0.3 0.2 
      
  Erythropoietin levels and iron stores     
      
Erythropoietin3 (U/L) 
   – mean ± SD 
  – median (10th-90th centile) 
 
20.7 ± 16.2
17.4  
 
9.8 ± 10.8 
6.9 
 
23.8 ± 28.9 
14.9  
 
<0.0001 
 
0.6 
  (6.3–33.8)  (3.2–17.3)  (7.9–42.7)   
      
Mean cell volume4 (fL) 
  – mean ± SD 
  – median (10th-90th centile) 
 
89.6 ± 5.5 
89.5 
 
87.6 ± 6.4 
88.3  
 
89.4 ± 6.1 
89.4  
 
0.08 
 
0.8 
 (83.1–96.9) (79.8–94.2)  (83.5–95.2)   
      
Mean cell volume < 80fL3 
  – no. (%) 
2/32  
(6.3%) 
41/391 
(10.5%) 
4/312 
(1.3%) 
0.4 0.2 
      
Ferritin5 (µg/L) – mean ± SD 94 ± 79 90 ± 91 90.7 ± 90 0.8 0.9 
  – median 
  – (10th-90th centile) 
54         
(19 – 213)
58  
(23 – 192) 
91  
(29 – 201) 
  
 
1 All bone marrow trephine biopsies were obtained at diagnosis 
2 Dec, decreased; inc, increased; +, ++, +++, increasing cellularity  
3 Based on 707 serum samples from trial entry. Normal range for serum erythropoietin, 5-25U/L 
4 Normal range for mean cell volume, 80-100fL 
5 Based on serum samples taken within 3 months of diagnosis (n=182). Normal range for ferritin, 
20-300µg/L 
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 Figure 3.5. Bone marrow histology of MPL exon 10 mutations in essential
thrombocythaemia . Haematoxylin and eosin stained bone marrow trephine
biopsies from (A) an untreated 60 year old male with an MPL W515L mutation,
showing increased megakaryocyte frequency with clustering (inset), and (B) an
untreated 77 year old male with an MPL S505N mutation, showing reduced
cellularity and occasional small megakaryocyte clusters (inset).  69
Serum erythropoietin levels at trial entry in MPL-mutant patients were 
significantly higher than JAK2 V617F-positive but not JAK2 V617F-negative 
patients. There were no significant differences in iron status between MPL-
mutant patients and both comparator groups, as assessed by serum ferritin and 
erythrocyte mean cell volume (Table 3.4). 
 
As part of the PT-1 studies, comprehensive clinical and outcome data were 
collected prospectively. Clinical events were independently adjudicated 
according to pre-defined criteria by a panel of experts blinded to treatment 
allocation4. The median follow-up was 36.5 months, although the relatively small 
numbers of patients in the MPL-mutant cohort meant that only a few end-point 
events were recorded in this group. There were no significant differences 
between the three comparator groups in rates of arterial thrombosis either 
before or after trial entry (Table 3.4). When compared to JAK2 V617F-negative 
patients, MPL-mutant patients had a higher rate of venous thrombosis after trial 
entry (odds ratio 34.3, 95% CI: 1.6-725, p=0.02). However, this association 
appeared weaker in multivariate analysis including patient age, sex and past 
history of venous thrombosis (Hazard ratio (HR), 4.7; 95% CI, 0.7-29.5; p=0.09), 
and there was no increased rate of venous thrombosis in the year before 
diagnosis. MPL-mutant patients had an increased rate of death compared to the 
JAK2 V617F-negative group on univariate analysis, but this was due to the 
significantly older age of the MPL-mutant patients (HR, 1.2; 95% CI, 0.5-3.5 
after correction for patient age and history of arterial thrombosis; p=0.7). 
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Table 3.5. Thrombotic, haemorrhagic and transformation events after trial entry 
and in the year before diagnosis. 
 
 MPL negative 
 
MPL 
mutant V617F
pos 
V617F 
neg 
 n=32 n=411 n=333 
OR vs  
V617F 
pos 
(95% CI) 
OR vs  
V617F 
neg 
(95% CI) 
p value1 
(vs 
V617F 
pos) 
p value1 
(vs 
V617F 
neg) 
Arterial thrombosis        
  In year before diagnosis2 4 38 20 1.4 2.2 0.5 0.2 
  Myocardial infarction 0 6 5 (0.5-4.2) (0.7-7.0)   
  Stroke 1 10 4     
  Transient ischaemic attack 3 23 13     
        
  After trial entry2 2 25 19 1.0 1.1 0.9 0.9 
  Myocardial infarction 1 7 6 (0.2-4.3) (0.2-5.2)   
  Unstable angina 0 5 1     
  Stroke 1 7 7     
  Transient ischaemic attack 1 5 6     
  Other3 0 2 1     
        
Venous thromboembolism       
  In year before diagnosis2 1 10 2 1.3 5.3 0.6 0.2 
  Deep vein thrombosis 0 3 1 (0.2-10.4) (0.5-60.6)   
  Pulmonary embolism 0 3 1     
  Splanchnic vein thrombosis 0 2 0     
  Retinal vein thrombosis 1 2 1     
  Cerebral sinus thrombosis 0 1 0     
        
  After trial entry2 2 11 3 2.6 34.3 0.3 0.02 
  Deep vein thrombosis 2 5 3 (0.4-19.3) (1.6-725)  (0.09)4
  Pulmonary embolism 0 5 0     
  Splanchnic vein thrombosis 0 2 0     
        
Major haemorrhage        
  After trial entry2 2 18 12 1.3 1.9 0.7 0.5 
  Gastrointestinal 2 6 6 (0.3-6.8) (0.3-12.1)   
  Intracranial 0 3 4     
  Epistaxis 0 5 0     
  Other5 0 4 2     
        
Death 5 34 18 1.8 4.5 0.3 0.04 
    (0.6-5.5) (1.1-18.4)  (0.7)6
  Myelofibrosis 2 7 11 6.2 2.5 0.1 0.4 
    (0.6-66.6) (0.3-17.7)   
  Acute leukaemia/ MDS 0 5 2 0.3 0.3 0.5 0.7 
    (0.02-7.2) (0.01-47.0)   
  Polycythaemia vera 0 6 0 0.3 NA 0.5 NA 
    (0.02-6.5)    
 
1 Assessed by Pearson’s chi-squared test with Yates’ continuity correction for events preceding 
diagnosis and log-rank test for events after trial entry 
2 Indicates total patients rather than total events; some patients had more than one event  
3 Lower limb arterial embolus (2); upper limb arterial thrombosis 
4 Multivariate analysis including patient age, sex and previous history of venous thrombosis 
5 Pericardial (2), urinary (2), post-operative and obstetric 
6 Multivariate analysis including patient age and previous history of arterial thrombosis 
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3.6  Biological aspects of MPL mutations 
 
Cytokine-independent colony formation is one of the hallmark features of the 
MPD, with the presence of both endogenous megakaryocyte and erythroid 
colonies reported in patients carrying the JAK2 V617F mutation29,198. To 
investigate the association of MPL mutations and cytokine-independent colony 
formation, colony assays were performed using peripheral blood from two 
hydroxycarbamide-treated ET patients, and an IMF patient receiving transfusion 
support only, all of whom carried the MPL W515L mutation. These 
investigations demonstrated the presence of thrombopoietin-independent 
megakaryocyte colony growth in all three patients studied. In contrast to the 
JAK2 V617F mutation, however, endogenous erythroid colonies were not 
observed in 4 ET patients or 1 IMF patient with the MPL W515L mutation 
(Figure 3.6A).  
 
To investigate possible differences between the MPL W515L and MPL W515K 
alleles, mutant allele burden was quantitated by pyrosequencing using whole 
blood DNA obtained at PT-1 trial entry. ET patients with MPL W515K had a 
significantly higher mutant allele proportion than those with MPL W515L (mean 
mutant allele burden 0.66 ± 0.26 versus 0.17 ± 0.11 respectively, p=<0.0001, 
Figure 3.6B). There were no significant differences in age at diagnosis (p=0.6), 
disease duration (p=0.5), use of cytoreductive therapy (p=0.2) or proportion of 
peripheral blood neutrophils at time of sampling (W515L, 0.67 ± 0.11; W515K, 
0.75 ± 0.05; p=0.2) to account for this difference.  
 
In order to examine the phenotypic correlates of the higher MPL W515K mutant 
allele burden, blood counts at diagnosis were compared between MPL W515L 
and MPL W515K ET patients in the PT-1 cohort. Despite the higher mutant 
allele burden in the MPL W515K group, there were no significant differences in 
diagnostic haemoglobin level, neutrophil count or platelet count (Table 3.6). 
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 Figure 3.6. Progenitor assays, mutant allele burden and genotyping of
progenitor colonies from essential thrombocythaemia patients with MPL
exon 10 mutations. (A) Representative progenitor assays from an MPL W515L
mutant ET patient showing cytokine independent megakaryocyte but not
erythroid colony growth. (B) Assessment of peripheral blood mutant allele
burden showing a higher mean mutant allele proportion in ET patients with the
MPL W515K mutation. (C) Genotyping of individual erythroid colonies from 5 ET
patients, 4 with MPL W515L and 1 with MPL S505N mutations; a single
homozygous colony was identified in patient 3. Tpo: thrombopoietin; Epo:
erythropoietin. 73
Table 3.6. Comparison of blood counts at diagnosis from ET patients carrying 
MPL W515L and W515K mutations. 
 
 
 
MPL W515L 
n=24 
MPL W515K 
n=5 
p-value 
Haemoglobin (g/L) 
 - mean ± SD 
13.2 
± 1.1 
13.5 
± 1.6 0.7 
    
White cell count (x109/L) 
- mean ± SD 
9.7 
± 2.5 
11.3 
± 2.8 0.2 
    
Neutrophil count (x109/L) 
- mean ± SD 
6.5 
± 2.0 
8.7 
± 2.7 0.07 
    
Platelet count (x109/L) 
- mean ± SD 
1010 
± 242 
1124 
± 397 0.4 
 
3 of 5 ET patients with MPL W515K mutations had a mutant allele burden of 
greater than 50%, indicating the presence of a subclone in which either the wild-
type allele had been deleted, or the mutant allele amplified, for example by 
mitotic recombination. Although none of 24 patients in the PT-1 cohort carrying 
the MPL W515L mutation had a mutant allele burden of greater than 50%, this 
does not exclude the presence of a subclone homozygous for the mutation70. 
Genotyping of single erythroid colonies was therefore used to look for the 
presence of such a subclone in 4 ET patients with MPL W515L mutations (Figure 3.6C). In one of the four patients, a single homozygous colony was 
found out of 94 colonies analysed; the other three patients had only 
heterozygous colonies, with or without wild-type colonies. Taken together with 
the mutant allele quantitation, these data suggest that ET patients carrying the 
MPL W515K allele commonly harbour clones in which the ratio of wild-type to 
mutant allele is reduced, but that such clones are less common in ET patients 
with the MPL W515L allele.  
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In contrast to patients with ET, 4 of 6 IMF patients with an MPL W515L mutation 
had a mutant allele burden of greater than 50%, indicating that subclones with 
reduced or lost wild-type allele can occur with this mutation, and may be 
associated with progression to myelofibrosis. There are four mechanisms by 
which such subclones may arise: (a) mitotic recombination, (b) loss of the wild-
type allele, (c) duplication of the chromosome bearing the mutant allele, or (d) 
second mutation (Figure 3.7A). These mechanisms were investigated in a 
W515L-positive IMF patient with a mutant allele burden of 90%. Purified 
constitutional material was not available from this patient, and although 
peripheral blood mononuclear cells contained a significant proportion of MPL-
mutant DNA, comparison with granulocyte DNA revealed loss of heterozygosity 
for four informative SNPs close to the MPL gene, thus excluding models (c) and 
(d) (Figure 3.7B). In order to distinguish between models (a) and (b), MPL copy 
number was assessed by a real-time PCR assay using patient granulocyte 
DNA. Two independent samples from this patient showed no change in MPL 
copy number compared to normal controls (Figure 3.7C). Taken together, these 
data indicate that in this patient mitotic recombination had led to duplication of 
the mutant allele (model (a), Figure 3.7A). 
 
Three ET patients in the PT-1 cohort harboured an MPL S505N mutation, with 
mutant allele burdens of 62%, 47% and 17%. Further samples were available 
from the latter patient which demonstrated the absence of the mutation in buccal 
cells, and the presence of both wild-type and heterozygous erythroid colonies 
(Figure 3.6C), indicative of an acquired mutation. 
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Figure 3.7. Duplication of the MPL W515L allele by mitotic recombination.
(A) Models to explain the development of a clone with a mutant allele proportion
of greater than 0.5. (B) Direct sequencing of granulocyte and mononuclear cell
(MNC) derived DNA from a patient with an MPL W515L mutation showing loss
of heterozygosity for two single nucleotide polymorphisms (SNPs) close to the
MPL gene. (C) Real-time PCR analysis demonstrating no alteration in MPL copy
number, confirming mitotic recombination (model a) as the mechanism for MPL
W515L homozygosity in this patient.   
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3.7  Progression to acute myeloid leukaemia in an MPL W515L-positive  
ET patient 
 
A 64 year old female patient with MPL W515L-positive ET developed rapidly 
progressive pancytopaenia without clinical splenomegaly. She had been 
diagnosed with ET 5 years previously, and was treated with hydroxycarbamide. 
Bone marrow cytogenetic analysis was normal at diagnosis, and there was no 
history of thromboembolic or haemorrhagic complications. At the time of disease 
progression, analysis of peripheral blood showed haemoglobin 8.0 g/dl, white 
cell count 32 x109/l, blast cell count 8.64 x109/L and platelet count 15 x109/L. 
Bone marrow could not be aspirated. Cytogenetic analysis performed on 
peripheral blood showed complex karyotypic abnormalities†. Bone marrow 
trephine biopsy showed markedly increased cellularity with abundant dysplastic 
and immature megakaryocytes, grade III reticulin fibrosis and clusters of CD34+ 
progenitor cells (Figure 3.8A), in keeping with a diagnosis of acute panmyelosis 
with myelofibrosis, a subtype of acute myeloid leukaemia74.  
 
The patient had been found to harbour an MPL W515L mutation in a sample 
taken 1 year prior to transformation. Erythroid colony analysis performed 1 year 
prior to transformation had shown wild-type and heterozygous colonies only 
(Patient 1, Figure 3.6C). At the time of transformation to acute leukaemia, blast 
colonies were cultured from peripheral blood mononuclear cells. Cytospin 
preparations from individual blast colonies confirmed the absence of 
differentiation after 14 days in culture. Moreover, blast colonies cultured over 4 
rounds of serial replating retained an undifferentiated appearance (Figure 
3.8B&C), confirming transformation to an acute leukaemia. Sequencing of DNA 
and cDNA derived from single blast colonies indicated the leukaemic 
transformation was heterozygous for the MPL W515L mutation (Figure 3.8C).  
                                                          
† 44-49,XX,-5,+6,del(6)(q?21q?23),+8,t(11;21)(q13;q22),+der(11)t(11;21),del(13)(q?14q?22), 
+del(13)(q?14q?22),der(15;17)t(15;17)(q?15;p?12),-17,+1-4mar[cp11]/46,XX[4] 
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  Figure 3.8. Transformation to acute myeloid leukaemia following MPL
W515L positive essential thrombocythaemia. (A) Bone marrow trephine
biopsy at the time of transformation showing panmyeloisis, reticulin fibrosis and
clusters of CD34+ cells by immunostaining (arrow). (B) Representative blast
colony grown in methylcellulose; serial replating studies demonstrating colony
growth to the fourth plate. (C) Cytospin preparation of blast colony following 4
rounds of replating showing lack of cellular differentiation; sequencing of MPL
exon 10 from blast colony derived cDNA showing heterozygosity for the MPL
W515L mutation.   
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Analysis of blast colony DNA for mutations known to be associated with acute 
myeloid leukaemia (Table 5.4) revealed a homozygous mutation within the p53 
DNA binding domain (TP53 R248Q). These data demonstrate that an MPL 
W515L-positive MPD may progress to acute leukaemia which harbours the MPL 
W515L mutation. 
 
3.8  Discussion 
 
These studies identified four mutant MPL alleles in patients with an MPD. No 
mutations were detected outside exon 10 despite analysis of platelet cDNA, 
which excludes the possibility that such mutations might be restricted to the 
megakaryocyte lineage. These results are consistent with and extend two 
previous studies using genomic DNA from 14 adults with an MPD199 and 9 
children with ET200, both of which failed to identify mutations in MPL, and 
demonstrate that mutations outside MPL exon 10 are not a common cause of 
JAK2 V617F-negative ET. Changes elsewhere in MPL have recently been 
reported, although it is not yet clear if they are acquired mutations or inherited 
polymorphisms201. Previous studies have reported the W515L and W515K 
alleles in IMF175,194 but only the W515L allele in ET175. This work demonstrates 
the presence of the W515K allele in patients with ET and also two different 
mutations capable of generating a W515K substitution.  
 
In two patients with ET, an MPL S505N allele, previously reported as an 
inherited mutation172,193, was detected in granulocytes but was absent from 
buccal cells. Moreover in one of the patients the mutation was only present in a 
minority of erythroid colonies, and the other patient had a normal platelet count 
over several years prior to presentation with ET, making germline mosaicism 
unlikely. Taken together, these findings strongly suggest that the MPL S505N 
allele can occur as both an inherited and acquired mutation. Mutations in the 
KIT gene have been reported in patients with both sporadic and familial mast 
cell proliferations. However the alleles involved are different, with inherited 
mutations not seen in acquired disease and vice versa202-211. Other inherited 
alleles associated with familial MPD, including mutations in the thrombopoietin 
and erythropoietin receptor genes, have not been reported in patients with an 
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acquired MPD212,213. To my knowledge, this is the first example of a single allele 
being associated with both acquired and inherited forms of an MPD. 
 
MPL mutations were detected in 7% of IMF patients, comprising 15% of JAK2 
V617F-negative patients. These data are similar to previous reports describing a 
prevalence of 5.5% or 8.5% in all patients175,194 and 9% in JAK2 V617F-negative 
patients174. In ET the prevalence of MPL mutations was 3.4% in the 
retrospective cohort and 4.1% in the prospective PT-1 cohort, accounting for 
8.5% of JAK2 V617F-negative patients. These results are somewhat higher than 
the 1% overall prevalence previously reported in ET175, and likely reflect the use 
of more sensitive assays for mutation detection in this study.  
 
ET patients with the W515K allele had significantly higher mutant allele burdens 
than those with the W515L allele. This result is reminiscent of the observation 
that most PV patients with a JAK2 V617F mutation harbour a homozygous 
clone70, whereas such clones are rarer in PV patients with a JAK2 exon 12 
mutation105. JAK2 exon 12 mutations appear to signal more strongly than JAK2 
V617F mutations105 but it is not clear whether the difference between the W515L 
and W515K mutations reflects quantitative or qualitative alterations in signalling. 
Interestingly a mutant allele burden of >50% was found in 0/24 ET patients with 
the W515L allele, but in 4/6 IMF patients. An allele burden of >50% indicates the 
existence of one or more additional events giving rise to homozygous or 
hemizygous mutant clones. In one patient where suitable material was available, 
duplication of the MPL W515L allele had arisen by mitotic recombination, giving 
rise to a W515L-homozygous clone. These results suggest that duplication of 
the MPL W515L allele may be associated with progression to IMF. A patient 
with MPL W515L-positive ET developed acute myeloid leukaemia which also 
harboured the MPL mutation. Thus the MPL W515L allele may be associated 
with ET, IMF and progression to acute leukaemia. 
 
The development of sensitive assays for each MPL mutation allowed analysis of 
samples from the PT1 cohort together with an assessment of the clinical and 
laboratory features. This large cohort includes ET patients in all risk categories, 
with centralized review of endpoints, comprehensive follow-up and the 
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participation of a large number of secondary and tertiary centres. As such, these 
results are likely to be of general relevance to ET patients with MPL mutations. 
Compared to JAK2 V167F-positive patients, those carrying an MPL mutation 
exhibited lower haemoglobin levels and higher platelet counts at diagnosis, 
higher serum erythropoietin levels and reduced bone marrow erythroid and 
overall cellularity. Moreover it was possible to grow thrombopoietin-independent 
megakaryocyte colonies but not erythropoietin-independent erythroid colonies 
from ET patients with an MPL mutation, an observation consistent with previous 
data from patients with IMF196,214. Taken together, these features suggest that 
patients with MPL mutations have a lower drive towards erythroid differentiation, 
accompanied by a more isolated megakaryocyte proliferation. There were no 
consistent differences in other histological features including megakaryocyte 
morphology and reticulin grade. Compared to JAK2 V617F-negative patients, 
those carrying an MPL mutation were older at diagnosis with reduced bone 
marrow cellularity that remained significant when patient age was taken into 
account. However, it was not possible to identify other clinical, histological or 
additional laboratory features which allowed the MPL-mutant subgroup to be 
distinguished from the remaining JAK2 V617F-negative patients. Furthermore, 
MPL-mutant patients did not exhibit altered rates of thrombosis, major 
haemorrhage, transformation or death when compared to V617F-positive or 
V617F-negative patients. 
 
Known mutations in MPL and JAK2 account for 57% of the PT-1 patients 
presented here. Comparisons between this group and the remaining 43% who 
lack an identified mutation did not reveal any significant differences in the 
prevalence of splenomegaly, abnormal cytogenetics, myelofibrotic 
transformation or acute myeloid leukaemia. There were also no differences 
between the mutation-negative and mutation-positive groups in histological 
features other than cellularity. Taken together these findings suggest that 
mutation-negative patients do have a genuine myeloproliferative disorder, the 
molecular basis for which remains obscure. 
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Chapter 4 
 
Clonal diversity in the myeloproliferative disorders 
 
 
4.1 Introduction 
 
Neoplasia is thought to be initiated in a single cell, with step-wise accumulation 
of genetic lesions leading to a malignant phenotype215. However, divergent 
clones bearing dissimilar patterns of somatic mutation have been observed in 
epithelial malignancies including multifocal bladder tumours and Barrett’s 
disease, a premalignant tumour of the lower oesophagus216-220. In some cases, 
an overlap in somatic mutation pattern was observed, indicating that divergent 
clones were the phylogenetically related progeny of a shared founder 
clone216,217. In other cases, no such overlap could be identified, raising the 
possibility that some tumours are comprised of more than one genetically 
unrelated clone220. 
 
In the human MPD, recurrent genetic alterations, other than those activating a 
tyrosine kinase, are uncommon in early disease, but genetic events accumulate 
with progression through an accelerated phase of disease to acute 
leukaemia69,221-226. As such, these disorders serve as an experimentally tractable 
paradigm for the study of early stage tumourigenesis. Circumstantial evidence 
suggests that some MPD patients harbour genetically dissimilar clones: 
cytogenetically abnormal but BCR-ABL1 negative clones have been reported in 
patients with CML following imatinib therapy190; patients with JAK2-mutant 
disease can progress to a JAK2 wild-type acute leukaemia102,103; and two 
different tyrosine kinase mutations may be found in the same patient60,175,185,227. 
With respect to the latter observation, analysis of individual progenitor colonies 
has been reported in only two cases, and although one case suggested the 
presence of biclonal disease, evolution from a shared founder clone could not 
be excluded185,227.  
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4.2  Aims of this chapter 
 
This chapter addresses the following questions relating to the presence of clonal 
diversity in the MPD: 
 
1) In patients with two or more acquired genetic events, what is the clonal 
relationship of the lesions? 
2) When two lesions are acquired sequentially within the same clone, is there a 
predictable order of mutation acquisition? 
3) When a second clonal expansion is present, what is the phylogenetic 
relationship of the two clones?  
 
4.3  Identification and analysis of patients with two or more acquired 
genetic lesions 
 
Patients were sought with either a tyrosine kinase pathway mutation and a 
cytogenetic abnormality or two tyrosine kinase pathway mutations. Cytogenetic 
data were screened from patients attending clinics in Cambridge, London, 
Birmingham and Belfast and from those enrolled in the PT-1 studies. This 
information was then compared to JAK2 and MPL mutation status. Following the 
identification of an ET patient harbouring mutations in both JAK2 and MPL, 
JAK2 V617F-positive ET and IMF patients in the Cambridge cohort were 
screened for mutations in MPL exon 10 by allele specific PCR as described in 
Chapter 3 (part of this screening was performed by Dr Elaine Boyd). Patients 
harbouring mutations in MPL or JAK2 exon 12 were also screened for the JAK2 
V617F mutation by Dr Anthony Bench and Miss Andrea Goday-Fernandez using 
a highly sensitive real-time PCR assay178, an approach that identified 3 patients 
with two tyrosine kinase pathways mutations. 
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Table 4.1. Clinical features of patients with two or more acquired genetic 
lesions. 
 
 
   At diagnosis     
Pt Diagnosis Sex Age yrs 
Hb 
g/L 
WCC 
x109/L 
Plts 
x109/L 
Prior 
Therapy
Disease 
duration Lesion 1 Lesion 2 
           
1 PV F 61 158† 20.2 671 HC 3 yrs JAK2 V617F Trisomy 9 
           
2 PV F 65 198† 7.2 542 HC 8 yrs JAK2 V617F 
Trisomy 9 
Trisomy 8 
           
3 PV M 71 182 10.4 977 HC 1 yr JAK2 V617F Trisomy 9 
           
4 PV M 34 182 64.3 200 HC 12 yrs JAK2 V617F Trisomy 9 
           
5 PV M 66 177† 10.6 553 HC 4 yrs JAK2 V617F Trisomy 8 
           
6 CML M    52 134 26.8 167 IM 9 yrs BCR-ABL1     del(20q) 
           
7 IMF M 59 94 3.3 68 None 9 yrs JAK2 V617F del(20q) 
           
8 ET M 69 135 7.9 1016 HC 12 yrs JAK2 V617F del(20q) 
           
9 ET F 92 134 10.8 1240 HC 2 yrs JAK2 V617F 
MPL 
W515L 
           
10 ET F 28 140 12.8 1221 HC, AN 20 yrs JAK2 V617F 
MPL 
W515L 
           
11 ET M 72 128 6.7 1258 HC 1.5 yrs JAK2 V617F 
MPL 
W515L 
           
12 ET M 74 140 6.6 979 None 0 yrs JAK2 V617F 
MPL 
W515L 
           
13 SM M 43 147 10.1 306 NL, PK, HC 3.5 yrs 
JAK2 
V617F 
KIT 
D816V 
           
14 PV F 73 172† 5.3 314 Ven 8 yrs JAK2 V617F 
JAK2 
E543-
D544del 
           
 
Pt: patient number; Hb: haemoglobin; WCC: white cell count; Plts: platelet count; PV: 
polycythaemia vera; CML: chronic myeloid leukaemia; ET: essential thrombocythaemia; SM: 
systemic mastocytosis; HC: hydroxycarbamide; IM: imatinib; AN: anagrelide; NL: nilotinib; PK: 
PKC412; Ven: venesection alone; † increased red cell mass confirmed by radio-isotope studies 
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Progenitor colonies were cultured from peripheral blood mononuclear cells 
obtained from 14 patients harbouring two or more acquired genetic lesions 
(Table 4.1). In patients with trisomy 8 or trisomy 9, colonies were cultured from 
CD34+ progenitor cells isolated from the peripheral blood mononuclear fraction 
in order to reduce the number of contaminating cells present in each individual 
colony and thereby improve the accuracy of colony genotyping. Patient 12 was 
enrolled in the PT-1 study, and colonies were cultured from a sample of 
cryopreserved bone marrow obtained 10 years previously, at the time of 
diagnosis with ET.  
 
4.4  Analysis of patients with a tyrosine kinase mutation and a 
cytogenetic abnormality 
 
A previously reported pyrosequencing assay64 was validated for the quantitation 
of the JAK2 V617F allele by mixing experiments using cloned mutant and wild-
type PCR products (Figure 4.1A). The assay was then used to measure the ratio 
of wild-type to mutant JAK2 in individual erythroid colonies from 4 JAK2 V617F-
positive PV patients with trisomy 9 (Figure 4.1B). All four patients harboured 
colonies with a 1:2 ratio of wild-type to mutant allele, indicating (i) the JAK2 
mutation and trisomy 9 were in the same clone, and (ii) trisomy 9 reflected 
duplication of the chromosome carrying the mutant JAK2 allele (Figure 4.1C).  
 
In patients 1-3, V617F-homozygous colonies were not identified. This is contrast 
to PV patients without trisomy 9, the majority of whom harbour a V617F-
homozygous clone70. In patient 4, however, colony genotyping identified an 
additional clone with loss of wild-type JAK2. There are at least three different 
models to explain this occurrence (Figure 4.2A). In model (i) mitotic 
recombination within a trisomy 9 cell leads to duplication of the mutant allele 
resulting three copies of mutant JAK2. In model (ii) mitotic recombination within 
a V617F-heterozygous cell leads to duplication of the mutant allele resulting in 
two copies of mutant JAK2. In model (iii) the chromosome 9 bearing the wild-
type JAK2 allele is lost. In order to distinguish these possibilities, a 
pyrosequencing assay was developed to assess the allelic ratio of an 
informative SNP on chromosome 9q. As expected, colonies with a 1:2 wild-type 
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to mutant JAK2 ratio also had a 1:2 ratio of the 9q SNP, consistent with the 
presence of three copies of chromosome 9. A 1:2 9q SNP ratio was also 
observed in all V617F-homozygous colonies, indicating these colonies also had 
three copies of chromosome 9. These findings indicate that in patient 4, non-
dysjunction for chromosome 9 was followed by mitotic recombination in a 
trisomy 9 cell, giving rise to a clone in which cells harboured three copies of the 
mutant JAK2 allele (model (i), Figure 4.2A). 
 
Quantitative pyrosequencing also allowed discrimination of colonies disomic or 
trisomic for chromosome 8 in two JAK2 V617F-positive patients. Two 
pyrosequencing assays were developed for SNPs on chromosome 8, and 
validated by mixing experiments using whole blood DNA from individuals known 
to be homozygous for alternative alleles of each SNP (Figure 4.3A). The two 
assays were used to quantitate the mean allelic ratio of each chromosome 8 
SNP in individual erythroid colonies. Colonies with a mean allele proportion of 
0.45 - 0.55 were classed as disomic, and those with a mean allele proportion of 
0.61 - 0.71 were classed as trisomic (Figure 4.3B). In both patients the two 
molecular lesions were present within the same clone, and in both patients all 
V617F-negative colonies were chromosome 8 disomic. In patient 2, who 
harboured a JAK2 mutation with trisomy 8 and trisomy 9, a proportion of trisomy 
8 colonies were disomic for chromosome 9 and a proportion were trisomic for 
chromosome 9 (Table 4.2). Thus acquisition of trisomy 8 had preceded the 
acquisition of trisomy 9 (Figure 4.3C).  
 
 
Table 4.2. Genotyping of erythroid colonies from a patient 2. 
 
  JAK2 V617F  
 Wild-type Heterozygous Trisomy 9 
Disomy 8 38 0 0 
Trisomy 8 0 8 85 
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 Figure 4.1. Duplication of the JAK2 V617F allele in patients with trisomy 9.
(A) Standard curve for the quantitative JAK2 V617F pyrosequencing assay
generated by mixing cloned JAK2 wild-type and mutant PCR products. (B)
Quantitation of wild-type to mutant JAK2 ratio in individual erythroid colonies
from 4 patients with trisomy 9; analysis of erythroid colonies from a PV patient
without trisomy 9 is shown as a control. (C) Mechanism of clonal evolution in
trisomy 9 patients, with chromosome 9 non-dysjunction leading to duplication of
the mutant JAK2 allele. 
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  Figure 4.2. Mechanism of clonal evolution in a patient with trisomy 9 and a
JAK2 V617F homozygous clone. (A) Models to explain the coexistence of
trisomy 9 and a JAK2 V617F homozygous clone. (B) Quantitation of both JAK2
V617F and a chromosome 9q single nucleotide polymorphism (SNP) in
individual erythroid colonies, demonstrating a 2:1 9q SNP ratio in all JAK2
V617F homozygous colonies, consistent with model (i).  88
Figure 4.3. Coexistence of trisomy 8 and the JAK2 V617F mutation in the
same clone. (A) Standard curve for the quantitative chromosome 8 single
nucleotide polymorphism (SNP) pyrosequencing assays generated by mixing
DNA from normal individuals homozygous for the alternative alleles. (B) Mean
chromosome 8 SNP proportion in individual erythroid colonies from 2 patients
with trisomy 8; analysis of erythroid colonies from a patient without trisomy 8 is
shown as a control. (C) Mechanism of clonal evolution in patient 2, with
sequential duplication of chromosome 8 and chromosome 9.   
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Three patients were identified with a deletion of chromosome 20q in association 
with a tyrosine kinase alteration. Granulocyte-macrophage colonies from a 
patient with CML (Patient 6, Table 4.1) were genotyped for the deletion of 20q 
by loss of heterozygosity (LOH) studies (Figure 4.4A) and for BCR-ABL1 using 
an RT-PCR assay (Figure 4.4B). Although colonies were identified harbouring 
both the 20q deletion and BCR-ABL1, the 20q deletion was also present on its 
own in a proportion of colonies (Table 4.3).  
 
Table 4.3. Genotyping of granulocyte-macrophage colonies from patient 6. 
 
 BCR-ABL1 
 Negative Positive 
20q wild-type 25 0 
del(20q) 7 3 
 
 
 
 
 
There are two models to explain this result (Figure 4.4C). In model (i), the 20q 
deletion preceded the acquisition of BCR-ABL1. In model (ii), BCR-ABL1 was 
the first event, followed by the 20q deletion, with subsequent mitotic 
recombination involving chromosome 22q giving rise to a del(20q) BCR-ABL1 
negative daughter clone. As such a clone would also harbour loss of 
heterozygosity for chromosome 9q, individual colonies were genotyped for an 
informative 9q SNP distal to the ABL1 locus. All del(20q) BCR-ABL1 negative 
colonies were heterozygous for the 9q SNP, indicating that the 20q deletion had 
arisen before BCR-ABL1 (model (i) Figure 4.4C). Although deletions of 20q are 
occasionally seen in CML patients, often with progression to accelerated phase 
disease228, to my knowledge a 20q deletion preceding acquisition of BCR-ABL1 
has not previously been reported. Subsequent to these studies the patient 
received therapy with the tyrosine kinase inhibitor nilotinib. After 12 months of 
treatment, the BCR-ABL1 clone was no longer detectable by fluorescent in-situ 
hybridisation analysis, whereas the del(20q) clone persisted (Table 4.4), 
consistent with the del(20q) occurring prior to BCR-ABL1 (analysis performed by 
Bridget Manasse, Department of Haematology, Addenbrooke’s Hospital). 
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Figure 4.4. Deletion of chromosome 20q may precede acquisition of a
BCR-ABL1 fusion in chronic myeloid leukaemia. (A) Examples of individual
granulocyte-macrophage colonies (CFU-GM) with and without a deletion of
chromosome 20q, as assessed by loss of heterozygosity (LOH) for two single
nucleotide polymorphisms (SNP) within the 20q common deleted region. (B)
Primer strategy for detection of BCR-ABL1 by reverse-transcriptase PCR;
examples of individual colonies demonstrating a single ABL1 control band in a
BCR-ABL1 negative colony (CFU-GM 1) and two additional BCR-ABL1-specific
bands in a BCR-ABL1 positive colony (CFU-GM 2). (C) Models to explain the
coexistence of BCR-ABL1 and a deletion of chromosome 20q; 9q LOH was not
seen in any BCR-ABL1 negative colony, consistent with the 20q deletion
preceding the acquisition of BCR-ABL1 (model (i)). WT: wild-type; Ph:
Philadelphia chromosome; neg: negative. 
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Table 4.4. Bone marrow fluorescent in-situ hybridisation studies from patient 6. 
 
 Pre-treatment 12 months nilotinib 
BCR-ABL1 67% 0% 
del(20q) 77% 20% 
   
In an IMF patient with JAK2 V617F and a 20q deletion (Patient 7, Table 4.1), the 
two lesions were found within the same clone. A single V617F-positive 20q wild-
type colony was identified, indicating the JAK2 mutation preceded acquisition of 
the 20q deletion (Table 4.5).  
 
Table 4.5. Genotyping of individual erythroid colonies from patient 7. 
 
 JAK2 V617F 
 Negative Heterozygous 
20q wild-type 434 1 
del(20q) 0 34 
 
 
 
 
 
 
By contrast to the previous seven cases, JAK2 V617F and a 20q deletion were 
present in separate clones in a patient with ET (Table 4.6, Figure 4.5A). There 
are two possible explanations for these findings (Figure 4.5B). In model (i) the 
two lesions arose in separate clones. In model (ii) the two lesions were initially in 
the same clone, with mitotic recombination affecting chromosome 9p giving 
rising to V617F-homozygous and V617F-negative daughter clones, both of 
which would carry the 20q deletion and loss of heterozygosity for 9p. These 
mechanisms were further investigated by genotyping del(20q) colonies for 9p 
LOH using an informative SNP close to the JAK2 locus. No del(20q) colonies 
harboured 9p LOH, thus proving that the two lesions were present in separate 
clones, consistent with model (i) in Figure 4.5B.  
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 Figure 4.5. Deletion of chromosome 20q and a JAK2 V617F mutation in
separate clones. (A) Examples of individual erythroid colonies with and without
a deletion of chromosome 20q, as assessed by loss of heterozygosity for two
single nucleotide polymorphisms (SNP) within the 20q common deleted region.
(B) Models to explain the coexistence of deletion of chromosome 20q and a
JAK2 V617F mutation; 9p LOH was not seen in any del(20q) colonies,
consistent with the 20q deletion and JAK2 mutation arising in separate clones
(model (i)). WT: wild-type; het: heterozygous; hom: homozygous; neg: negative.
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Table 4.6. Genotyping of individual erythroid colonies from patient 8. 
 
 JAK2 V617F 
 Negative Heterozygous 
20q wild-type 2 12 
del(20q) 59 0 
 
 
 
 
 
 
Taken as a whole, this analysis of patients with a tyrosine kinase mutation and a 
cytogenetic aberration demonstrates that cytogenetic lesions generally occur 
within the clone carrying an oncogenic kinase mutation. However in one of eight 
cases the cytogenetic abnormality reflected the presence of a separate clonal 
expansion. 
 
4.5  Analysis of patients with two tyrosine kinase pathway mutations 
 
Studies were performed on a further six patients who harboured JAK2 V617F 
together with a second tyrosine kinase pathway mutation (4 MPL W515L, 1 KIT 
D816V and 1 JAK2 E543-D544del; patients 9-14, Table 4.1). Analysis of 
colonies from patient 13 was performed by Dr Amy Jones in the laboratory of 
Professor Nick Cross in Salisbury, UK. Individual progenitor colonies were 
genotyped for the relevant mutations by either direct sequencing or 
pyrosequencing. In all six cases, analysis of individual colonies demonstrated 
that JAK2 V617F and the second mutation were mutually exclusive (Figure 
4.6A). Thus in all six patients, the two lesions were present in separate clones.  
 
Differences were apparent in the proportion of colonies harbouring each 
mutation. The JAK2 V617F-positive clone was smaller than the second mutation 
bearing clone in all of the six cases, and the mean proportion of JAK2 V617F 
mutant colonies was significantly smaller overall (proportion of mutant colonies: 
JAK2 V617F 0.11 ± 0.08, second mutation 0.37 ± 0.23; p=0.03) (Figure 4.6B).  
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Figure 4.6. Genotyping of progenitor colonies from patients with two
tyrosine kinase pathway mutations. (A) Examples of single colonies from
patient 9 showing genotyping for JAK2 V617F and MPL W515L by direct
sequencing, from patient 13 showing genotyping for JAK2 V617F and KIT
D816V by pyrosequencing and from patient 14 showing genotyping for JAK2
V617F and JAK2 E543-D544del (exon 12) by direct sequencing. (B) Proportion
of wild-type and mutant colonies in patients with two different tyrosine kinase
pathway mutations.  
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Figure 4.7. Bone marrow histology of two patients with a biclonal
myeloproliferative disorder. Haematoxylin and eosin stained bone marrow
trephine biopsies from (A) a hydroxycarbamide treated 42 year old female with
MPL W515L and JAK2 V617F mutations showing increased cellularity and large
megakaryocytes, and (B) an untreated 42 year old male with JAK2 V617F and
KIT D816V mutations showing hyperlobated megakaryocytes typical of essential
thrombocythaemia (black arrow) and mast cell aggregates typical of systemic
mastocytosis (red arrow).  96
Bone marrow trephine sections were examined to assess the morphological 
features of patients with a biclonal MPD. In patients harbouring JAK2 V617F 
and MPL W515L or a JAK2 exon 12 mutation, no unusual histological features 
were identified (Figure 4.7A). This is not surprising given the considerable 
overlap in bone marrow appearances in ET patients with JAK2 V617F or MPL 
W515L (Chapter 3) and the lack of specific morphological features associated 
with JAK2 exon 12 mutations105. By contrast coexisting JAK2-mutant and KIT-
mutant clones were associated with distinctive histological features, showing 
typical features of both ET (large, hyperlobated megakaryocytes) and systemic 
mastocytosis (discreet infiltrates of mast cells embedded in fibrotic tissue) 
(Figure 4.7B). In such cases, therefore, the presence of biclonal disease may be 
suspected from the unusual bone marrow morphology. 
 
There are two possible explanations to explain the existence of biclonal disease 
in these patients: either the two clones are the related progeny of a shared 
founder clone, or the two genetics lesions arose independently in unrelated 
HSCs (Figure 4.8A). To distinguish between these possibilities, X-chromosome 
inactivation patterns were studied in the three female patients with biclonal 
disease (Figure 4.8B). In patient 9 both MPL-mutant and JAK2-mutant erythroid 
colonies expressed the same allele of the X-linked LANCL3 gene, a result 
consistent with either model in Figure 4.8A. However in patient 10, the MPL-
mutant and JAK2-mutant colonies expressed different alleles of the X-linked IDS 
gene. Furthermore, in patient 14 the JAK2 V617F-positive and exon 12-positive 
colonies expressed different alleles of the MAGED2 gene. These data provide 
formal proof that patients 10 and 14 both harbour two clones that arose 
independently and not from a shared founder clone.  
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 Figure 4.8. Independent origins of genetically distinct clones in patients
with a myeloproliferative disorder. (A) Models to explain the coexistence of
two mutation-bearing clones, showing clonally related proliferations derived from
a shared founder clone and clonally unrelated proliferations derived from
independent haematopoietic stem cells. (B) X-chromosome inactivation patterns
in the mutation-bearing clones from patients 9, 10 and 14. In patients 10 and 14
the mutation-bearing clones express different alleles of an X-linked single
nucleotide polymorphism, indicating that the mutations had arisen in unrelated
haematopoietic stem cells.  mut: mutant.  
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4.6 Discussion  
 
In these studies, 14 patients with two or more acquired genetic lesions were 
identified, and the clonal relationship of the two lesions was investigated. An 
additional cytogenetic abnormality was present in the same clone as a tyrosine 
kinase mutation in 7 of 8 patients (Figure 4.9). In three patients with a deletion of 
chromosome 20q, no consistent pattern was observed in the timing of the 
cytogenetic abnormality, with the 20q deletion acquired before or after the 
tyrosine kinase mutation, or present in a separate clone (patients 6, 7 and 8 
respectively). Although 20q deletions are amongst the most common recurrent 
genetic aberrations in myeloid malignancy229, their pathological consequences 
are currently unknown. Moreover differences in disease phenotype or clinical 
outcome between patients with and without a 20q deletion have not been 
identified78-80. The acquisition of a 20q deletion prior to BCR-ABL1 (patient 6) or 
in a separate clone to JAK2 V617F (patient 8) raises the possibility that 
deletions of 20q may act as clone-initiating events, and that the onset of clonal 
haematopoiesis may precede the acquisition of an oncogenic tyrosine kinase in 
some patients. The occurrence of a 20q deletion after the acquisition of a JAK2 
V617F mutation, however, is consistent with a role for del(20q) in modulation of 
oncogenic tyrosine kinase activity. Alternatively deletions of 20q may serve as 
markers of a genetically unstable clone, with little or no direct effects on disease 
biology. Consistent with the heterogeneity observed in this study, a recent report 
identified 20q deletions occurring before or after acquisition of a JAK2 V617F 
mutation230.  
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Figure 4.9. Clonal relationship of genetic lesions in patients with more than
one acquired genetic event. Summary of individual colony analysis
demonstrating that a cytogenetic aberration usually occurred within the same
clone as a tyrosine kinase mutation, whereas the presence of two tyrosine kinase
pathway mutations indicated the presence of biclonal disease. 
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In contrast to patients with an additional cytogenetic aberration, detection of a 
second tyrosine kinase pathway mutation reflected the presence of a separate 
clonal expansion in all six cases studied, with the two mutations being mutually 
exclusive in single haematopoietic colonies (Figure 4.9). This is consistent with 
a previous single case report, where different JAK2 mutations were present in 
separate clones185. It is possible that additional signalling pathway mutations 
may not confer any further clonal advantage, as is the case in acute myeloid 
leukaemia231 and juvenile myelomonocytic leukaemia232 where different tyrosine 
kinase pathway mutations are generally mutually exclusive232. However this may 
be counter-intuitive given that homozygosity for the JAK2 V617F mutation may 
confer such a selective advantage70,233, and in a single case report, JAK2 V617F 
and BCR-ABL1 were found within the same clone227.  
 
The number of patients in this study harbouring a second clonal expansion 
appears surprisingly high. Seven such cases were identified from around 1,000 
patients screened. Although the precise denominator is unclear, this seems 
much greater than expected, either from the prevalence of each individual MPD8 
or considering the probability of an individual acquiring two independent 
mutations by chance alone234. Given that the molecular cause for around half of 
patients with ET or IMF is currently unknown, the true prevalence of multiple 
clones may be even higher.  
 
The presence of diverse clones could account for several observations which 
are currently unexplained, including (1) patients in whom the proportion of 
V617F-positive granulocytes is less than the proportion that appear clonally-
derived by X-chromosome inactivation patterns or a cytogenetic marker177,178; 
(2) patients who develop a V617F-negative acute leukaemia following a V617F-
positive MPD102,103 and (3) the culture of V617F-negative erythropoietin-
independent erythroid colonies from V617F-positive patients184,185. It is possible 
that such cases represent biclonal disease in which the second clonal 
expansion is negative for the JAK2 V617F mutation.  
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Most importantly, analysis of X-chromosome inactivation patterns were used to 
demonstrate that patients may harbour diverse clones that have arisen 
independently and not from a shared founder clone. This phenomenon has been 
observed in multifocal thyroid carcinoma235, but to my knowledge this is the first 
demonstration of coexisting, genetically unrelated clones in haematological 
malignancy. These data suggest a role for either an inherited allele or an 
environmental mutagen in promoting the acquisition or survival of such clones. 
A familial association with MPD has been reported236 and often shows 
incomplete penetrance15,16, and a recent report has implicated environmental 
exposure in MPD pathogenesis12.  
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Chapter 5 
 
Progression to acute myeloid leukaemia following a JAK2-
mutant myeloproliferative disorder 
 
 
5.1 Introduction 
 
Progression to AML occurs in 2-5% of patients with ET or PV76,77,92 and 15-30% 
of patients with IMF75,83. Risk of AML in ET and PV increases with patient age92 
and prior use of genotoxic agents92-94 particularly when used sequentially with 
hydroxycarbamide92,95,96. The leukaemogenic potential of hydroxycarbamide 
when used as single agent therapy remains controversial97. In IMF, risk factors 
for transformation include karyotypic abnormalities (other than del(20q) or 
del(13q))83,101, higher peripheral blood blast count84 and prior splectomy84. Acute 
leukaemia has been reported in several MPD patients who have never received 
cytotoxic therapy92,98-100, suggesting that progression to leukaemia is part of the 
natural history of these disorders.  
 
In contrast to CML, where the blastic phase of disease almost invariably 
harbours the BCR-ABL1 fusion223, a significant proportion of leukaemic 
transformations occurring in patients with a JAK2-mutant MPD are negative for 
the JAK2 mutation102,103. At present, however, the mechanisms leading to the 
development of JAK2 wild-type leukaemia are not known. Data on the genetic 
events associated with evolution to post-MPD leukaemia are limited, with an 
AML1-ETO fusion reported in a JAK2-mutant transformation237 and mutations in 
NPM or FLT3 reported in single cases of JAK2 wild-type transformation103,104. 
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5.2 Aims of this chapter 
 
This chapter addresses the following questions relating to AML following a 
JAK2-mutant MPD: 
1) What proportion of AML transformations are negative for the JAK2 mutation? 
2) What are the mechanisms leading to development of a JAK2 wild-type 
leukaemia following a JAK2-mutant MPD? 
3) What are the genetic events involved in the progression from MPD to AML? 
4) Are there any clinical or biological differences between patients who progress 
to JAK2 wild-type versus JAK2-mutant leukaemia? 
 
5.3  Sample preparation and JAK2 genotyping 
 
Samples were obtained from 16 patients with AML and evidence of a preceding 
JAK2-mutant MPD (15 patients with JAK2 V617F and 1 patient with a JAK2 
exon 12 mutation: N542-E543del; Table 5.1). In order to ascertain the JAK2 
status of each AML, it was important to obtain a sample of leukaemic blasts free 
from contamination by the preceding MPD. Where possible, peripheral blood 
samples were collected prospectively and leukaemia cells were purified by 
magnetic selection of CD34+ cells from the mononuclear fraction. Mononuclear 
cells were also plated in semi-solid medium in order to obtain individual blast 
colonies; in some cases erythroid progenitor colonies were also obtained 
(Figure 5.1A). In all cases, leukaemia samples consisted of at least 90% blast 
cells by morphological criteria (Figure 5.1B). In the majority of cases, material 
representative of the preceding MPD was also available (Table 5.1). 
 
Each sample was genotyped for the relevant JAK2 mutation by direct 
sequencing of blast cell DNA. Of the 16 AML transformations, 1 was JAK2 
V617F-heterozygous, 6 were JAK2 V617F-homozygous and 9 were JAK2 wild-
type, including the patient with a preceding JAK2 exon 12 mutant MPD (Figure 
5.3). Therefore in over half the cases studied the leukaemic transformation was 
negative for the JAK2 mutation.  
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 Table 5.1. Clinical details and sample availability of 16 patients progressing to acute leukaemia following a JAK2-mutant 
myeloproliferative disorder. 
Pt   Diagnosis Sex JAK2 mutation 
Age at 
diagnosis 
(years) 
Therapy Time to AML (years) MPD sample AML sample 
1 IMF M V617F 65 HC, AN 2 Diagnostic BM PB CD34+ cells 
       
     
       
     
     
     
     
     
     
     
      
      
     
    
     
     
  
2 ET->IMF M V617F 63 HC 16 Grans 1 yr before AML
 
PB CD34+ cells 
   
3 PV->IMF F V617F 57 HC, IFN 10 Grans 1 yr before AML
 
PB CD34+ cells 
   
4 IMF M V617F 59 none 1 Not available 
 
PB CD34+ cells 
   
5 Probable IMF M V617F 70 none - Erythroid colonies 
 
PB CD34+ cells 
   
6 IMF M V617F 80 HC 8 Grans 1 yr before AML
 
PB CD34+ cells 
   
7 ET->IMF M V617F 73 HC 6 Grans 1 yr before AML
 
PB CD34+ cells 
   
8 PV M exon 12 69 P32, BU 26 Not available 
 
PB CD34+ cells 
   
9 IMF M V617F 82 HC 3 Grans 1 yr before AML
 
PB CD34+ cells 
   
10 PV F V617F 87 HC 12 Not available 
 
PB MNC 
  
11 PV F V617F 78 HC 14 PB 1 yr before AML 
 
BM 
  
12 RARS-T M V617F 84 HC 8 Grans 1 yr before AML
 
PB CD34+ cells 
   
13 PV M V617F 93 HC, BU, P32 
 
26 Grans 3 yr before AML
 
PB CD34+ cells 
   
14 PV M V617F 75 HC 10 PB 1 yr before AML 
 
PB CD34+ cells 
   
15 PV F V617F 61 HC 3 Grans 1 yr before AML
 
PB CD34+ cells 
   
16 ET F V617F 86 HC, BU 10 PB 1 yr before AML BM 
Pt: patient; IMF: idiopathic myelofibrosis; ET: essential thrombocythaemia; PV: polycythaemia vera; RARS-T: refractory anaemia with ringed 
sideroblasts and thrombocytosis; M: male; F: female; HC: hydroxycarbamide; IFN: interferon-alpha; AN: anagrelide; P32: radioactive phosphorous; 
BU: busulphan; BM: bone marrow; Grans: purified granulocytes; PB: peripheral blood; MNC: mononuclear cells.  
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Figure 5.1. Purification of leukaemic blasts from patients developing acute
myeloid leukaemia following a JAK2-mutant myeloproliferative disorder.
(A) Strategy for purification of leukaemia cells. (B) Cytospin preparations of
leukaemia cells obtained by different purification methods. MNC: mononuclear
cells. 
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5.4  Clonal origins of JAK2 wild-type AML 
 
The clonal origin of JAK2 wild-type AML following a JAK2-mutant MPD is currently 
unknown. A proportion of patients with a JAK2-mutant MPD harbour clones that 
are homozygous for the JAK2 V617F mutation70, with such clones generated by a 
process of mitotic recombination in a V617F-heterozygous cell28-31 which gives rise 
to both V617F-homozygous and JAK2 wild-type daughter clones (Figure 5.2A). It 
is possible, therefore, that a mitotically recombined JAK2 wild-type clone could 
represent the cell of origin for a subsequent JAK2 wild-type leukaemia. As both the 
V617F-homozygous and JAK2 wild-type mitotically recombined clones will harbour 
loss of heterozygosity (LOH) around the JAK2 locus, LOH studies were used to 
investigate whether such clones persist in vivo. Individual erythroid progenitors 
from a separate cohort of PV patients known to harbour a V617F-homozygous 
clone were genotyped for the JAK2 V617F mutation and an informative SNP within 
or close to the JAK2 locus. LOH was not identified in any of 1,195 JAK2 wild-type 
erythroid colonies from 10 PV patients (Table 5.2). These data suggest that 
following mitotic recombination, the JAK2 wild-type daughter clone does not 
commonly expand to detectable levels.  
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Table 5.2. Genotyping of individual erythroid colonies from patients with 
polycythaemia vera for 9p loss of heterozygosity.  
 
  Individual erythroid colonies 
  JAK2 wild-type  V617F-het  V617F-hom 
Patient 9p SNP 9p het 9p LOH  9p het 9p LOH  9p het 9p LOH 
          
a rs465514 160 0  0 0  0 5 
          
b rs428111 154 0  19 0  0 5 
          
c rs428111 56 0  2 0  0 2 
          
d rs428111 78 0  9 0  0 6 
          
e rs2230724 64 0  3 0  0 5 
          
f rs428111 58 0  3 0  0 1 
          
g rs428111 64 0  5 0  0 1 
          
h rs7847141 119 0  15 0  0 1 
          
i rs428111 334 0  2 0  0 49 
          
j rs428111 108 0  9 0  0 1 
          
          
Total  1195 0  67 0  0 76 
          
 
 
 
LOH studies were also performed on leukaemic blasts using multiple informative 
SNPs within or close to the JAK2 locus (Figure 5.2B). As expected all informative 
V617F-homozygous leukaemias showed 9p LOH, consistent with prior mitotic 
recombination. No evidence for LOH, however, was found in any of 9 JAK2 wild-
type leukaemias (Figure 5.2C and Figure 5.3). These data exclude reversion to 
wild-type either by mitotic recombination, consistent with 3 cases previously 
reported102,103, or by a more localised gene conversion or gene deletion event.   
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 Figure 5.2. Reversion to wild-type is not a common mechanism of progression
from a JAK2-mutant myeloproliferative neoplasm to a JAK2 wild-type leukemia.
(A) Mitotic recombination in a JAK2 V617F-heterozygous cell gives rise to both
V617F-homozygous and JAK2 wild-type daughter cells, both of which harbor
LOH for chromosome 9p. (B) Summary of SNP analysis, showing SNP location
relative to the JAK2 locus and genotyping results in post-MPN leukemias;
whereas all informative JAK2 V617F-homozygous leukemias showed LOH
close to JAK2, this was not observed in any of 9 JAK2 wild-type leukemias.
Patient 1 is not included in this analysis as leukemic blasts were heterozygous
for the JAK2 V617F mutation. SNP: single nucleotide polymorphism; LOH: loss
of heterozygosity. 
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Figure 5.3. JAK2 mutation status and 9p loss of heterozygosity in
leukaemic blasts. Genotyping for the JAK2 V617F (highlighted in yellow) or
JAK2 exon 12 mutation (patient 8) and examples of single nucleotide
polymorphisms used in 9p loss of heterozygosity studies. NI: not informative;
ND: not done.  110
 In order to assess the clonal relationship of JAK2-mutant  leukaemia and JAK2 
wild-type MPD, X-inactivation patterns (XCIP) were studied in a female patient 
from whom the necessary material was available (patient 15, Table 5.1). In this 
patient, the same XCIP was observed in JAK2-mutant erythroid colonies, 
peripheral blood granulocytes obtained prior to transformation and JAK2 wild-type 
leukaemic blasts (Figure 5.4A), a result consistent with the MPD and AML arising 
either from a shared founder clone or from independent stem cells. 
 
 5.5  Additional genetic events involved in progression to AML 
5.5.1  Amplification of JAK2 
 
In CML, progression to accelerated and blastic phase disease has been 
associated with an increase in both BCR-ABL1 copy number and expression238. 
JAK2 copy number was therefore assessed in JAK2-mutant leukaemic blasts by 
comparing amplification of the JAK2 locus by real-time PCR with amplification of 
control regions on chromosomes 13q and 1p (Figure 5.4B). No increase in JAK2 
copy number was seen in any of 7 JAK2-mutant leukaemias compared to normal 
controls. Analysis of two cells lines known to harbour a chromosome 9p deletion 
(MDA-MB-361 & NB16) and a cell line known to harbour multiple copies of JAK2 
(HEL) are shown as controls. 
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Figure 5.4. Clonality studies, JAK2 copy number and JAK2 expression in
leukaemic blasts. (A) X-chromosome inactivation patterns in a patient
progressing to JAK2 wild-type leukaemia following a JAK2 V617F-positive MPD.
(B) Real-time PCR showing no alterations in JAK2 copy number in JAK2 mutant
leukaemic blasts. (C) Analysis of JAK2 expression in leukaemic blasts by real-
time PCR showing a 12 fold increase in a patient with JAK2 V617F-homozygous
leukaemia. Gran: granulocytes; BFUe: burst forming unit erythroid; AML: acute
myeloid leukaemia. 
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Real-time PCR was also used to quantitate expression of total JAK2 in JAK2-
mutant and JAK2 wild-type leukaemias. Expression of ABL1 was used as a 
housekeeping gene, and JAK2 expression was normalised to two independent 
samples of buffy coat derived CD34+ cells. No significant alterations in JAK2 
expression were seen in any JAK2 wild-type leukaemia. A single V617F-
homozygous leukaemia, however, showed a 12-fold increase in JAK2 expression 
compared to normal CD34+ cells (Figure 5.4C). There are several possible 
explanations for the over-expression of JAK2 observed in this patient, including (a) 
leukaemic differentiation towards a high JAK2 expressing lineage such as 
erythroid (although this was not apparent morphologically; see Figure 5.1B), (b) 
genetic rearrangement placing JAK2 under the control of a stronger promoter or 
enhancer, or (c) epigenetic alteration of the JAK2 promoter/enhancer region. It is 
therefore possible that amplification of JAK2 expression plays a role in disease 
progression in a proportion of patients. 
 
5.5.2 Karyotypic abnormalities 
 
Cytogenetic analysis at the time of transformation to AML was available for 8 of 
the 16 patients (Table 5.3). Of these patients, 7 harboured unbalanced karyotypic 
abnormalities, including two patients with complex chromosomal rearrangements. 
Patient 7 harboured an unbalanced translocation resulting a loss of material from 
chromosome 17p including the TP53 locus, an abnormality often associated with 
mutation of the remaining TP53 allele. Although patient 8 harboured a deletion of 
chromosome 20q at the time of transformation, the abnormality was absent from 
the JAK2 wild-type leukaemia as assessed by LOH studies (Figure 5.5A), 
suggesting the presence of del(20q) in the preceding JAK2-mutant MPD. Similarly 
in patient 15, detection of trisomy 9 at transformation represented the preceding 
JAK2-mutant MPD (Chapter 4, patient 1). 
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A single patient harboured a balanced inversion of chromosome 3 (patient 2, 
Table 5.3). This rearrangement is associated with increased expression of EVI1 
due to translocation of the entire reading frame of EVI1 in proximity to the 
enhancer of RPN1, a constitutively expressed housekeeping gene239 (Figure 
5.5B). Analysis of leukaemic blasts from patient 2 confirmed a 17-fold increase in 
EVI1 expression compared to normal CD34+ cells, with the remaining AML 
samples showing either no expression of EVI1, or expression comparable to 
normal CD34+ cells (Figure 5.5C).  
 
Table 5.3. JAK2 mutation status and cytogenetic analysis of leukaemic blasts from 
16 patients with a preceding JAK2-mutant myeloproliferative disorder. 
 
At transformation to AML Pt Prior MPD Prior  therapy Sex JAK2 mutation Cytogenetics 
1 IMF HC, AN M heterozygous add(21) 
      
2 ET->IMF HC M homozygous inv(3), del(7) 
      
3 PV->IMF HC, IFN F homozygous ND 
      
4 IMF none M homozygous ND 
      
5 Probable IMF none M homozygous add(8), del(7q) 
      
6 IMF HC M homozygous ND 
      
7 ET->IMF HC M homozygous der(5)t(5;17) 
      
8 PV P32, BU M wild-type del(20q) 
      
9 IMF HC M wild-type ND 
      
10 PV HC F wild-type ND 
      
11 PV HC F wild-type ND 
      
12 RARS-T HC M wild-type complex¶
      
13 PV HC, BU, P32 M wild-type ND 
      
14 PV HC M wild-type complex∆
      
15 PV HC F wild-type add(9) 
      
16 ET HC, BU F wild-type ND 
Pt: patient; IMF: idiopathic myelofibrosis; ET: essential thrombocythaemia; PV: polycythaemia vera; 
RARS-T: refractory anaemia with ringed sideroblasts and thrombocytosis; HC: hydroxycarbamide; 
IFN: interferon-alpha; AN: anagrelide; P32: radioactive phosphorous; BU: busulphan; M: male; F: 
female; ND: not done 
¶ 43,XY,del(5)(q1q3),-7,-12,-16 [5], 43,XY,idem,del(6)(q1q2) [3], 46,XY [2] 
∆ 45-46,XY,del(5)(q1?),add(16)(q2?), -17, -17, -22, +2~3 mar [10] 
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Figure 5.5. Deletion of chromocomse 20q and rearrangement of EVI1 in
two patients with acute leukaemia. (A) Single nucleotide polymorphism
studies in a patient with a 20q deletion and JAK2 wild-type leukaemia showing
no loss of heterozygosity for 20q in leukaemic blasts. (B) Schematic
representation of inv(3) whereby expression of EVI1 comes under the control of
the RPN1 enhancer. (C) Expression of EVI1 in leukaemic blasts relative to
normal CD34+ cells showing a 17 fold increase in a patient harbouring inv(3). 
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5.5.3 Mutations in leukaemia associated genes 
 
To further investigate the genetic events involved in progression to acute 
leukaemia, DNA from leukaemic blasts was assessed for known leukaemia 
associated mutations involved in increased proliferation (KRAS, NRAS and FLT3), 
block in differentiation (CEBPA, RUNX1, GATA2, NPM and WT1) or genomic 
instability (TP53) (Table 5.4). 2 of 7 JAK2-mutant leukaemias harboured mutations 
in NRAS, (NRAS G12S and NRAS G12D, patients 1 & 2 respectively). Both 
mutations were heterozygous and affected a conserved residue within the GTP-
binding domain of the protein (Figure 5.6A & B). A single JAK2 wild-type 
leukaemia harboured a FLT3-ITD (Figure 5.6C).  
 
Point mutations in RUNX1 were identified in 1 of 9 JAK2 wild-type and 4 of 7 JAK2 
mutant leukaemias. In all cases, RUNX1 mutations were acquired and affected the 
DNA binding domain of the protein, with retention of the wild-type allele (Figure 
5.7A & B).  
 
Mutations in TP53 were detected in 1 of 7 JAK2 mutant and 3 of 9 JAK2 wild-type 
leukaemias. In all cases the mutations were acquired and affected the p53 DNA 
binding domain, with loss of the wild-type allele in the leukaemia samples (Figure 
5.7C & D). 
 
In summary, in JAK2-mutant leukaemias genetic alterations associated with a 
block in cellular differentiation were detected in 5 of 7 cases, comprising 4 patients 
with RUNX1 point mutations and 1 patient with over-expression of EVI1. Two 
patients with JAK2-mutant leukaemia also harboured activating mutations in 
NRAS. Mutations of TP53 with loss of the wild-type allele were detected in 25% of 
this cohort.  
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Table 5.4. Screening for leukaemia associated mutations in acute leukaemia 
following a myeloproliferative disorder  
 
Gene Mutation frequency in  de novo AML 
Structural domain 
altered  Region screened 
    
Proliferation    
KRAS 5% AML240 GTP binding domains  Codons 12, 13 & 61 
     
NRAS 12% AML240,241 GTP binding domains  Codons 12, 13 & 61 
     
FLT3 30% NC-AML241 Juxtamembrane domain  Exon 11 
     
Differentiation    
CEBPA 15% NC-AML242 DNA binding domain or Loss of full-length protein  Exon 1 
     
RUNX1 33% CML-BC with +21
243 
1-5% AML244,245 DNA binding domain  Exons 3 - 5 
     
GATA2 10% CML-BC246 DNA binding domain  Exon 4 
     
NPM 50% NC-AML247 C-terminus  Exon 12 
     
WT1 10% NC-AML 248,249 DNA binding domain  Exons 7 & 9 
     
Genomic stability    
TP53 50-70% AML with complex karyotype250,251 DNA binding domain  Exons 4-8 
     
 
AML: acute myeloid leukaemia; NC-AML: acute myeloid leukaemia with normal cytogenetics; CML-
BC: chronic myeloid leukaemia in blast crisis 
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Figure 5.6. Alterations of NRAS and FLT3 in patients progressing to acute
myeloid leukaemia. (A) Heterozygous mutations in NRAS in two patients with a
JAK2-mutant leukaemia. (B) Location of NRAS mutations within the GTP
binding domain of the protein. (C) PCR analysis showing an internal tandem
duplication (ITD) of FLT3 in a patient with a JAK2 wild-type leukaemia.  118
Figure 5.7. Mutations in RUNX1 and TP53 in patients progressing to acute
myeloid leukaemia. (A) Acquired mutations in RUNX1 in patients progressing
to acute leukaemia. (B) Position of RUNX1 mutations within the DNA binding
domain of the protein. (C) Acquired mutations of TP53 in patients progressing to
acute leukaemia. (D) Position of TP53 mutations within the DNA binding domain
of the protein. TD: transactivation domain; ID: inhibitory domain.  
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 5.6  Acquisition timing of additional genetic events 
 
In patient 1, an NRAS mutation was present in both leukaemic blasts and in bone 
marrow DNA obtained 2 years prior to the development of AML (Figure 5.8A). In 
patient 2 an NRAS mutation was present in both leukaemic blasts and erythroid 
colonies at the time of transformation, but absent from granulocyte DNA obtained 
1 year prior to AML as assessed by both direct sequencing and allele-specific 
PCR (Figure 5.8B & C). The presence of an NRAS mutation prior to the 
development of AML or in erythroid colonies suggests that oncogenic RAS may be 
involved in the pathogenesis of the preceding MPD rather than progression to 
AML. 
 
In patients 1, 4 and 5, RUNX1 mutations were present in leukaemic blasts only 
and not in samples representative of the preceding MPD (Figures 5.8A & 5.9A), 
indicating that such mutations are associated with evolution to acute leukaemia. In 
patient 1, in whom cytogenetic analysis had indicated duplication of chromosome 
21, direct sequencing of RUNX1 in leukaemic blasts showed a predominant 
mutant peak, consistent with duplication of the mutant RUNX1 allele (Figure 5.8A). 
In patients 7 and 13, TP53 mutations were similarly present in leukaemic blasts 
and absent from the preceding MPD. By contrast in patient 10 a TP53 mutation 
could be detected in peripheral blood obtained 1 year prior to transformation to 
AML, at which time the patient was well and the full blood count was normal 
(Figure 5.9B).  
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Figure 5.8. Sequential acquisition of mutations in NRAS and RUNX1 in
patients progressing to acute leukaemia. (A) Sequence of acquisition of
mutations in NRAS and RUNX1 in a patient with JAK2 V617F-heterozygous
leukaemia. (B) Sequence of acquisition of an NRAS mutation in a patient with
JAK2 V617F-homozygous leukaemia. (C) Allele-specific PCR analysis showing
absence of NRAS mutation in granulocytes obtained 1 year prior to
transformation in patient 2.  
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 Figure 5.9. Sequential acquisition of mutations in RUNX1 and TP53 in
patients progressing to acute leukaemia. (A) Sequence of acquisition of
mutations in RUNX1 in two patients with JAK2 V617F-homozygous leukaemia.
(B) Sequence of acquisition of mutations in TP53 in three patients progressing
to acute leukaemia.  
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At the time of presentation with AML, patient 5 gave no history of a prior blood 
disorder. However, the presence of splenomegaly palpable to the umbilicus raised 
the possibility of an undiagnosed preceding MPD. Erythroid colonies were cultured 
from a peripheral blood sample obtained at transformation to AML. Whereas 
leukaemic blasts harboured mutations in both JAK2 and RUNX1, erythroid 
colonies were either JAK2 V617F-homozygous (n=43) or JAK2 wild-type (n=3), 
but none were positive for the RUNX1 mutation (Figure 5.9A), demonstrating the 
presence of an established JAK2-mutant clone prior to the acquisition of the 
RUNX1 mutation. Bone marrow trephine biopsy at time of AML showed clusters of 
hyperlobated megakaryocytes and dense reticulin fibrosis (Figure 5.10A & B). 
Taken together, these findings strongly suggest the presence of a JAK2-mutant 
MPD prior to the development of acute leukaemia. 
 
5.7  Clinical characteristics of patients progressing to JAK2-mutant and 
JAK2 wild-type AML. 
 
There was no difference in age at diagnosis of initial MPD between the 16 patients 
who progressed to AML when compared to JAK2-mutant patients in the 
Cambridge MPD cohort (AML patients 65 ± 11 yrs, Cambridge cohort 60 ± 16 yrs; 
p=0.2). There were no differences between the JAK2-mutant and wild-type 
leukaemias with regard to gender (p=0.6), age at diagnosis (p=0.5) or prior use of 
cytoreductive therapy (p=0.2). Although not statistically significant, it should be 
noted that therapeutic use of known leukaemogenic agents (radioactive 
phosphorous or busulphan) was associated with progression to a JAK2 wild-type 
leukaemia in all 3 cases. In contrast to a previous study103, no significant 
differences were observed in the duration of the preceding MPD (JAK2-mutant 
AML 7 ± 6yrs, JAK2 wild-type AML 12 ± 9yrs; p=0.2). Patients with a JAK2 wild-
type leukaemia, however, were significantly older at time of progression to AML 
(JAK2-mutant AML 67 ± 8yrs, JAK2 wild-type AML 79 ± 10yrs; p=0.02).  
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Figure 5.10. Bone marrow histological appearances of a patient with JAK2
V617F-homozygous de novo acute myeloid leukaemia. (A) Haematoxylin
and eosin stained trephine section showing large hyperlobated megakaryocytes
surrounded by leukaemic blasts. (B) Silver stained trephine section showing a
dense network of coarse reticulin fibres. 
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Figure 5.11. Blood counts obtained 1 year prior to transformation to acute
leukaemia in patients with a preceding myeloproliferative disorder. Hb:
haemoglobin; WCC: white cell count; Plt: platelet count; *: p=<0.05. 
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A striking contrast was observed between JAK2-mutant and JAK2 wild-type 
leukaemias with respect to the phenotype of the preceding MPD. All 6 patients 
with JAK2-mutant AML and a characterised preceding MPD had prior evidence of 
either post ET/PV myelofibrosis or de novo IMF (Table 5.3), compared to only 1 of 
9 patients with JAK2 wild-type AML (p=0.001; Fisher’s exact test). Consistent with 
this difference in prior disease phenotype, patients progressing to JAK2-mutant 
AML had significantly lower haemoglobin levels (a finding not explained by a 
difference in gender distribution) and higher white cell counts one year prior to 
transformation when compared to those who developed a JAK2 wild-type 
leukaemia (JAK2-mutant AML: Hb 10.8 ± 2.0g/dl, JAK2 wild-type AML: Hb 12.9 ± 
1.0g/dl; p=0.03; JAK2-mutant AML: WCC 19.0 ± 17.0x109/L, JAK2 wild-type AML: 
WCC 6.5 ± 1.5x109/L; p=0.045) (Figure 5.11). Therefore whereas patients with PV 
or ET generally transformed directly to a JAK2 wild-type AML, JAK2-mutant 
leukaemia was usually preceded by evidence of disease evolution to 
myelofibrosis. 
 
5.8 Discussion 
 
This study examined 16 patients with AML and evidence of a preceding JAK2-
mutant MPD. In over half of the cases, the leukaemia was negative for the JAK2 
mutation, a proportion consistent with two previous reports102,103. Differences were 
observed in the phenotype of the preceding MPD, with JAK2-mutant leukaemias 
evolving from either de novo or secondary myelofibrosis and JAK2 wild-type 
leukaemias usually arising directly from ET or PV. This finding suggests that the 
mechanism of disease evolution is different in JAK2-mutant versus JAK2 wild-type 
leukaemia.  
 
In JAK2-mutant AML, the sequential acquisition of mutations suggests that 
accumulation of genetic events within the JAK2-mutant clone is associated with 
progression from ET/PV to myelofibrosis and eventually acute leukaemia. 6 of 7 
JAK2-mutant leukaemias were homozygous for the JAK2 mutation (Table 5.5), 
suggesting that either loss of wild-type or gain of mutant JAK2 is important in 
disease evolution. This finding is consistent with two previous series describing 6 
patients with a JAK2-mutant AML, all of whom had a mutant allele burden of 
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greater than 50%102,103. 2 of 7 JAK2-mutant leukaemias also harboured activating 
mutations in NRAS, which is perhaps surprising given that genetic alterations with 
similar biological consequences are generally mutually exclusive in de novo 
AML231. The detection of mutant RAS prior to transformation in patient 1 and in 
erythroid colonies at the time of transformation in patient 2, however, suggests 
these mutations may be involved in the pathogenesis of the preceding MPD rather 
than progression to AML. 
 
 
Potential cooperating genetic lesions were identified in 5 of 7 JAK2-mutant 
leukaemias, comprising 1 patient with rearrangement of EVI1 and 4 patients with 
point mutations in RUNX1 (Table 5.5). EVI1 is an important haematopoietic 
transcription factor252, with over-expression resulting in differentiation block and 
accumulation of immature cells253,254. Increased expression of EVI1 in seen in de 
novo AML255, CML blast crisis256 and juvenile myelomonocytic leukaemia (JMML) 
with progressive disease257. Of note, JMML is commonly associated with gain-of-
function mutations in the RAS signalling pathway232, suggesting possible 
cooperation between mutant RAS and EVI1 over-expression in the development of 
acute leukaemia.  
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Table 5.5. Summary of genetic lesions in patients progressing to acute leukaemia 
following a JAK2-mutant myeloproliferative disorder 
 
 
Pt  Type 1 lesion (Cellular proliferation) 
 Type 2 lesion 
(Differentiation block) 
 TP53 mutation 
(genomic instability)
       
1  JAK2 V617F (het) NRAS G12S  RUNX1 D171N   
       
2  JAK2 V617F (hom) NRAS G12D  ↑EVI1 expression   
       
3  JAK2 V617F (hom)  RUNX1 N119K   
       
4  JAK2 V617F (hom)  RUNX1 G138V   
       
5  JAK2 V617F (hom)  RUNX1 D171N   
       
6  JAK2 V617F (hom) ↑JAK2 expression      
       
7  JAK2 V617F (hom)     R248Q 
       
8         
       
9         
       
10  FLT3 ITD  RUNX1 Q127X   
       
11        S90X 
       
12        V173M 
       
13        C238F 
       
14         
       
15         
       
16         
       
Pt: patient; hom: homozygous; het: heterozygous; ↑: increased 
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The RUNX1 transcription factor complex is essential for the initiation of definitive 
haematopoiesis in the embryo258. Loss of RUNX1 expression in adult bone 
marrow results in impaired differentiation and accumulation of immature cells259. 
Alteration of RUNX1 activity is common in de novo AML, due to chromosomal 
translocations in 15-25% of cases (AML1-ETO or CBFB-MYH11) or point 
mutations in 1-5% of cases244,245,260. The functional consequences of these 
alterations appear similar, resulting in defective DNA binding and dominant 
negative effects over the wild-type RUNX1 protein complex260-262, although 
additional genetic events appear necessary for the development of a fully 
malignant phenotype263. The association of JAK2 V617F with both RUNX1 
rearrangements in de novo AML61,65,66 and RUNX1 point mutations in post-MPD 
AML (present study) suggests that alterations of the RUNX1 complex cooperate 
with mutant JAK2 in the development of acute leukaemia.   
 
The sequential acquisition of genetic events associated with progression from ET 
or PV to IMF and subsequently acute leukaemia is reminiscent of the disease 
pattern observed in CML, where patients progress from chronic phase via an 
accelerated phase to blastic phase disease. Of note, patients with CML 
occasionally have features of accelerated or blastic phase disease at initial 
presentation. Thus patients with IMF may be considered as presenting with 
accelerated phase disease, and patient 5 in this study as presenting in blast crisis.  
 
The mechanisms involved in progression from a JAK2-mutant MPD to a JAK2 
wild-type AML are currently unknown. To investigate the possibility that the two 
phases of disease are clonally related by reversion to wild-type of a heterozygous 
JAK2-mutant clone, LOH studies were performed on both erythroid colonies from 
PV patients and JAK2 wild-type leukaemia samples. These data indicate that (1) 
mitotically recombined, JAK2 wild-type daughter clones do not commonly persist 
in vivo, and (2) reversion to wild-type is not a common mechanism for the 
development of JAK2 wild-type leukaemia. These data extend the findings of 3 
reported cases where reversion to wild-type by mitotic recombination was 
excluded102,103. Moreover, analysis of SNPs close to the JAK2 locus also excludes 
a more localised gene conversion or gene deletion event in the 9 cases presented 
herein.  
 129
 As such, there are two models to explain the development of JAK2 wild-type 
leukaemia (Figure 5.12). In model (i), the JAK2-mutant MPD and JAK2 wild-type 
AML arise in independent stem cells, as a result of either a shared environmental 
insult, an inherited predisposition to develop myeloid malignancies or secondary to 
the clastogenic effects of drugs used to manage the MPD phase of disease. 
Environmental exposures such as radiation and proximity to toxic waste dumps 
have been implicated in the development of an MPD9,11,12, and exposure to 
radiation and benzene have been implicated in the pathogenesis of AML264. 
Studies of both registry data and affected kindreds have indicated a familial 
tendency to develop an MPD, although the inherited alleles have yet to be 
identified15-19. A familial tendency to AML is also recognised, and includes kindreds 
with inherited mutations in CEBPA or RUNX1, and kindreds in whom an inherited 
allele has not been identified265. The use of alkylating and radiomimetic agents in 
MPD therapy increases the risk of progression to AML92-94. In this study, 3 of 9 
patients with JAK2 wild-type AML had received such agents (busulphan or 
radioactive phosphorous). The remaining 6 cases, however, had received only 
hydroxycarbamide therapy. The association of hydroxycarbamide and acute 
leukaemia remains controversial97 and definitive prospective data are lacking. 
Hydroxycarbamide does not appear leukaemogenic when used to treat sickle cell 
disease, an inherited non-clonal disorder of erythroid cells130, although the 
younger age and shorter treatment duration of these patients may mask a true 
leukaemogenic effect. Hydroxycarbamide use has been linked to mutations in 
TP53132,266, which were present in 1 of 7 JAK2-mutant and 3 of 9 JAK2 wild-type 
leukaemias in this study (Table 5.5). Although all 4 TP53-mutant patients in this 
series had received therapy with hydroxycarbamide, the common usage of this 
drug in both the present cohort (13 of 16 patients) and in MPD patients in general 
means that a direct link between hydroxycarbamide use and TP53 mutations, or 
indeed progression to acute leukaemia, will be difficult to establish. 
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Figure 5.12. Models to explain the development of a JAK2 wild-type
leukaemia following a JAK2-mutant myeloproliferative disorder. In model
(i), the JAK2-mutant MPD and JAK2 wild-type AML arise in independent stem
cells, due to an inherited predisposition, an environmental insult or an iatrogenic
insult by an agent used to treat the MPD. In model (ii), the JAK2-mutant MPD
and JAK2 wild-type AML arise from a shared founder clone, initiated by an
unknown mutation.  
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In model (ii), the JAK2-mutant MPD and JAK2 wild-type AML are clonally related, 
having both arisen from a shared founder clone initiated by an unknown genetic 
event. In a female patient in this study, patterns of X-chromosome inactivation in 
the JAK2-mutant MPD and JAK2 wild-type AML were consistent with either model 
(i) or (ii). At the present time, direct evidence supporting either of these two models 
is lacking.  
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Chapter 6 
 
Molecular events in the myeloproliferative disorders: relationship 
of mutation genotype to disease phenotype 
 
 
6.1  Introduction 
 
The JAK2 V617F mutation is found in the majority of patients with PV and around 
half of those with ET, posing the question: how is the same mutation associated 
with two apparently distinct phenotypes? Studies of progenitor colonies from MPD 
patients identified JAK2 V617F-homozygous clones in the majority of patients with 
PV, but not in patients with ET70. This difference suggests that duplication of the 
mutant JAK2 allele and/or loss of wild-type JAK2 may play a role in the 
determination of disease phenotype. In keeping with this observation, studies of 
transgenic mice have suggested that JAK2 V617F expression level modulates the 
disease phenotype, with a high mutant to wild-type ratio associated with 
erythrocytosis and low mutant to wild-type ratio associated with 
thrombocytosis53,54. In vitro studies of normal human progenitors have identified 
STAT5, an important downstream target of both wild-type and mutant JAK2, as a 
dynamic modulator of lineage determination, with higher levels of activated STAT5 
favouring erythroid differentiation and lower levels favouring megakaryocyte 
differentiation71. Taken together, these studies imply a role for mutant JAK2 gene 
dosage in determining whether an individual patient manifests an ET or PV 
phenotype. However a proportion of ET patients have a mutant allele burden of 
greater than 50%123,267, and homozygous colonies were not identified in some 
patients with PV49,70, suggesting that determination of disease phenotype may be 
more complex than the presence or absence of a homozygous clone.  
 
Although activating mutations in JAK2 or MPL are found in the majority of patients 
with an MPD, the molecular cause of around a third of ET and IMF is unknown. 
Recently, mutations elsewhere in JAK2 and MPL have been reported in patients 
with acute lymphoblastic leukaemia, acute megakaryocytic leukaemia and in an 
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acute megakaryocytic leukaemia cell line. Of note, these mutations gave rise to an 
MPD phenotype when expressed in a murine bone marrow transplant system, 
raising the possibility that such mutations may be associated with human MPD106-
108,268. Previous studies have also identified oncogenic RAS mutations in a 
proportion of MPD patients, although patient numbers were small and the 
relationship of mutant RAS to mutations in JAK2 or MPL is not known269,270. 
 
6.2  Aims of this chapter 
 
This chapter addresses the following questions concerning the association 
between genetic mutation and disease phenotype in the MPD: 
 
1) What is the relationship of JAK2 V617F-positive ET to JAK2 V617F-positive PV 
with respect to haematological parameters and the presence of a homozygous 
clone? 
2) Does the association of mutations elsewhere in JAK2 or MPL with an MPD 
phenotype in mouse models predict their association with a human MPD? 
3) What is the role of oncogenic RAS in the phenotype of the human MPD?  
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Figure 6.1. Haemoglobin levels in patients with ET or PV show overlap in
female but not male patients. Haemoglobin and haematocrit levels for (A)
male and (B) female patients with ET or PV diagnosed according to PVSG
criteria. (C) Model to explain the overlap in haemoglobin levels between female
ET and PV patients. Het: heterozygous JAK2 V617F clone; Hom: homozygous
JAK2 V617F clone; α: ET patients with a JAK2 V617F homozygous clone; β: PV
patients without a JAK2 V617F heterozygous clone.  135
6.3  Homozygosity for the JAK2 V617F mutation in polycythaemia vera and  
essential thrombocythaemia: relationship of genotype to phenotype 
 
To investigate the phenotypic relationship of ET to PV, blood parameters were 
analysed from JAK2 V617F-positive patients in the Cambridge MPD cohort, all of 
whom met the PVSG diagnostic criteria for ET or PV271,272. Graphical plots of 
haemoglobin and haematocrit levels for male patients indicated good 
discrimination of ET from PV (Figure 6.1A). In females, however, there was an 
overlap in haemoglobin and haematocrit levels between patients with ET and PV 
(Figure 6.1B). These data would be consistent with a model whereby disease 
phenotype is related to the presence or absence of a homozygous clone (Figure 
6.1C). Moreover the overlap in haemoglobin levels seen in female patients would 
predict that ET patients falling in the α region in Figure 6.1C may harbour a 
homozygous clone, and that such patients will have higher haemoglobin levels 
than ET patients without a homozygous clone. Conversely patients within the β 
region in Figure 6.1C may manifest a PV phenotype in the absence of a 
homozygous clone.  
 
Studies were undertaken to investigate the existence of α region patients (ET 
patients with a homozygous clone). At the time of these studies, the effect of 
cytoreductive therapy such as hydroxycarbamide on mutant allele burden was 
unknown. Analysis of ET patients enrolled in the PT-1 study had indicated that 
JAK2 V617F-positive ET patients are more sensitive to the effects of 
hydroxycarbamide when compared to JAK2 V617F-negative patients68, raising the 
possibility that this agent has a differential effect on the V617F-positive clone. 
Therefore only patients who had never received cytoreductive therapy were 
included in the present study. Peripheral blood samples were obtained from 20 
JAK2 V617F-positive patients meeting the PVSG diagnostic criteria for ET. 
Erythroid colonies were cultured in semi-solid medium with saturating 
erythropoietin (1U/mL). Individual colonies were then genotyped for the JAK2 
V617F mutation using a quantitative pyrosequencing assay; colonies with a wild-
type proportion of ≥0.8 were classed as wild-type, 0.4-0.6 as heterozygous and 
≤0.2 as homozygous. The genotype of homozygous colonies was confirmed in all 
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cases using a different assay: by direct sequencing of PCR products generated by 
a different primer pair.  
 
A mean of 88 individual colonies were genotyped for each of 20 treatment naïve 
ET patients (Table 6.1). 5 of 20 patients (25%) harboured at least one colony that 
was homozygous for the JAK2 V617F mutation by both pyrosequencing and direct 
sequencing (Figure 6.2A). Of note, whereas 5 of 10 female patients harboured a 
homozygous clone, such clones were not seen in any of 10 male patients (p=0.03, 
Fisher’s exact test; Table 6.1). Clinical and laboratory features were compared for 
patients with and without a homozygous clone. Given the known sex differences in 
haemoglobin and haematocrit levels, female patients were also analysed 
separately (Table 6.2). When compared to female patients without a homozygous 
clone, females with a homozygous clone had significantly higher haemoglobin and 
haematocrit levels (Table 6.2, Figure 6.2B). No differences in other clinical or 
laboratory features were identified (Table 6.2, Figure 6.2C). 
 
In summary, these data indicate that JAK2 V617F-homozygous clones are present 
in a significant proportion of females with ET, but appear rare in male ET patients. 
Moreover, females with a homozygous clone have a higher mean haematocrit 
level compared to those without. The proportion of female patients harbouring a 
homozygous clone appears higher than would be predicted from the overlap in 
haematocrit levels observed between ET and PV patients. It is likely, therefore, 
that other factors are at play to restrain erythropoiesis in female ET patients 
bearing a JAK2 V617F-homozygous clone. 
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Table 6.1. Comparison of untreated JAK2 V617F-positive ET patients with and without a homozygous clone. 
  
   At time of study At diagnosis 
 
 
Colonies 
genotyped Female
Age at 
diagnosis
(years) 
Thrombotic 
event 
Disease 
duration 
(months)
Hb 
(g/dL) Hct   MCV
WCC 
(x109/L)
Neut 
(x109/L)
Plts 
(x109/L)
Ferritin
(µg/L) Retic
                
het only Mean              
         
            
              
          
            
             
89 33% 52 7% 24 14.6
 
 0.43 86 7.8 5.4 844 76 1.1
n=15 ±SD ±5 ±15 ±40 ±1.4 ±0.04
 
±4
 
 ±1.4
 
±1.2 ±177 ±62 ±0.9
 
het & hom Mean 85 100% 65 40% 1 14.2 0.43 87 9.2 6.4 768 95 1.9
n=5 ±SD ±7 ±11 ±0 ±0.7 ±0.02
 
±3
 
 ±2.7
 
±2.2 ±209 ±67 ±0.5
 
p-value 0.2 0.03 0.1 0.2 0.2 0.6 0.8 0.5 0.2 0.2 0.4 0.6
Table 6.2. Comparison of untreated female JAK2 V617F-positive ET patients with and without a homozygous clone 
At time of study  At diagnosis   
      
Colonies 
genotyped 
Age at 
diagnosis
(years) 
Thrombotic 
event 
Disease 
duration 
(months) 
Hb 
(g/dL) Hct MCV
WCC 
(x109/L)
Neut 
(x109/L)
Plts 
(x109/L)
 Ferritin 
(µg/L ) Retic
                
het only Mean           
         
             
           
         
             
               
89 47 0% 18 13.2 0.39 88 7.3 5.1 840  48 1.0
n=5 ±SD
 
±5 ±22 ±26 ±0.7 ±0.03 ±4 ±1.6 ±1.3 ±182  ±39 ±0.8
  
het & hom Mean 85 65 40% 1 14.2 0.43 87 9.2 6.4 768  70 1.9
n=5 
 
±SD
 
±7 ±11 ±0 ±0.7 ±0.02 ±3 ±2.7 ±2.2 ±209  ±39 ±0.5
 
p-value 0.2 0.1 0.4 0.2 0.04 0.03 0.7 0.2 0.3 0.6  0.4
 
Hb: haemoglobin; Hct: haematocrit; MCV: mean cellular volume; WCC: white cell count; Neut: neutrophil count; Plts: platelet count; Retic: bone marrow reticulin 
(graded 0 to 4). 
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Figure 6.2. Progenitor colony genotyping and blood parameters from 20
untreated patients with essential thrombocythaemia. (A) Genotyping of
erythroid colonies for the JAK2 V617F mutation. (B) Haemoglobin (Hb) and
haematocrit levels at time of colony analysis. (C) Platelet (Plt) and neutrophil
count (Neut) at time of colony analysis. *: p=<0.05  139
6.4 Genetic lesions in the myeloproliferative disorders: other mutations in 
JAK2 and MPL 
 
Acquired gain-of-function mutations in MPL or JAK2 have been associated with the 
development of ET, PV or IMF. The MPL W515L, JAK2 V617F and JAK2 exon 12 
mutations produce an MPD-like phenotype in vivo when expressed in murine bone 
marrow, with expression of mutant JAK2 leading to erythrocytosis, expression of 
mutant MPL associated with thrombocytosis and expression of either allele 
associated with the development of bone marrow fibrosis28,105,174. As such, 
expression of MPD associated alleles in the mouse can recapitulate features of the 
counterpart human disease. More recently, further mutations in JAK2 and MPL have 
been reported in haematological malignancies (Figure 6.4A & B). An acquired 
mutation in the MPL extracellular domain (MPL T487A) was reported in a single case 
of non-Down’s syndrome childhood acute megakaryoblastic leukaemia268. A mutation 
in the JAK2 kinase domain (JAK2 T875N) was observed in an acute megakaryocytic 
leukaemia cell line106. Finally, a cluster of mutations centred around JAK2 R683 have 
been reported in ALL in patients with Down’s syndrome or in association with an 
additional copy of chromosome 21q107,108. All three mutations conferred cytokine 
independence to cytokine dependent cell lines, although the JAK2 mutations were 
only transforming in the presence of a type 1 homodimeric receptor (as is the case 
for both the JAK2 V617F and JAK2 exon 12 mutations48,105). Of particular note, all 
three alleles produced an MPD-like phenotype in retrovirally-induced murine bone 
marrow transplant models106,108,268. Screening for JAK2 R683 mutations has 
previously been reported in a cohort of ET patients107, although these studies were 
performed using DNA from unfractionated blood which may be diluted by the 
presence of non-clonal lymphoid cells. At the time of writing, there were no reports of 
the other two mutations in human MPDs. 
 
To investigate the possibility that the MPL T487A mutation is associated with an 
MPD phenotype in humans, MPL exon 9 was assessed by direct sequencing using 
granulocyte DNA from 172 unselected patients with IMF or ET (Table 6.3). No 
mutations in exon 9 were detected in this cohort.  
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Table 6.3. Cohort of patients with a myeloproliferative disorder screened for the MPL 
T487A mutation 
 
 JAK2 V617F-
positive 
MPL mutation 
positive 
Mutation 
negative 
Total 
     
IMF 43 8 45 96 
     
ET 19 1 56 76 
     
Total 62 9 101 172 
     
 
 
Direct sequencing of granulocyte DNA was also used to screen for the JAK2 T875N 
and R683 mutations in a cohort of 110 unselected IMF patients. (Table 6.4). No 
mutations were detected in this cohort.  
 
Table 6.4. Cohort of patients with a myeloproliferative disorder screened for the 
JAK2 T875N and R683 mutations. 
 
 JAK2 V617F-
positive 
MPL mutation 
positive 
Mutation 
negative 
Total 
     
IMF 50 7 53 110 
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Figure 6.3. MPL, JAK2 and RAS mutations in haematopoietic malignancy.  (A)
MPL mutations and their associated haematopoietic malignancies. (B) JAK2
mutations and their associated haematopoietic malignancies. (C) Mutations in
KRAS and NRAS in patients with myelofibrosis. AML: acute myeloid leukaemia;
Mk: megakaryocytic; ET: essential thrombocythaemia; IMF: idiopathic
myelofibrosis; PV: polycythaemia vera; ALL: acute lymphoblastic leukaemia; TM:
transmembrane; JM: juxtamembrane; GTP: GTPase binding domain.  
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In summary, MPL T487A, JAK2 T875N or JAK2 R683 mutations were not identified 
in granulocyte DNA from MPD patients. The use of direct sequencing, a relatively 
insensitive method of mutation detection, means that patients with a low mutant allele 
burden may have been missed. For the JAK2 V617F and MPL W515L mutations, 
however, the mutant allele burden in IMF patients is high enough to be detectable by 
direct sequencing in the majority of patients (Chapter 3 and 29). It seems unlikely, 
therefore, that the MPL T487A, JAK2 T875N or JAK2 R683 alleles are a common 
cause of human MPD. 
 
6.5  Genetic lesions associated with accelerated phase disease: a potential 
role for oncogenic RAS mutations 
 
Various lines of evidence suggest that IMF is associated with the accumulation of 
further genetic damage, including an increased prevalence of cytogenetic 
abnormalities, increasing perturbation of haematopoiesis, increased rates of 
progression to AML and significantly worse survival compared to both ET and PV75-
77,81,83,84,224,273. At present, however, the specific genetic events associated with 
disease evolution are unknown. Studies of MPD patients who had transformed to 
acute leukaemia identified two patients who harboured both JAK2 V617F and RAS 
mutations within the leukaemic clone. In one of these patients the RAS mutation was 
present 2 years prior to the development of AML and in the second patient the RAS 
mutation was present in erythroid colonies (Chapter 5), suggesting that mutant RAS 
may be involved in the MPD phase of disease. Of note, both these patients had IMF 
prior to the development of AML. 
 
To investigate the possibility that mutations in RAS are associated with disease 
evolution in the MPD, codons 12, 13 and 61 of NRAS and KRAS were assessed by 
direct sequencing using granulocyte DNA from a cohort of unselected patients with 
ET or IMF (Table 6.5).  
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Table 6.5. RAS mutations in a cohort of patients with ET or IMF 
 
  JAK2 V617F-
positive 
MPL mutation 
positive 
Mutation 
negative Total
      
 RAS mutant 2 1 1 4 
IMF      
 RAS wild-type 49 4 51 104 
      
 RAS mutant 0 0 0 0 
ET      
 RAS wild-type 58 5 60 123 
      
 
Mutations in RAS were found in 4 of 104 IMF patients (including patient 1, Chapter 
5), comprising 3 mutations at NRAS codon 12 and 1 mutation at KRAS codon 12 
(Figure 6.4C). By contrast, RAS mutations were not identified in any of 123 patients 
with ET (p=0.04; Fisher’s exact test). These data suggest that mutations in RAS may 
be preferentially associated with manifestation of a myelofibrosis phenotype.  
 
6.6  Discussion 
 
Analysis of individual progenitor colonies from 20 untreated ET patients identified a 
homozygous clone in 5 of 10 females but in none of 10 males. Of note, females with 
a homozygous clone had significantly higher haemoglobin and haematocrit levels 
compared to those without. Two factors may explain the discrepancy between these 
results and a previous report in which homozygous clones were not identified in ET 
patients70. Firstly, the mean number of colonies genotyped per patient was higher in 
this study (88 versus 40), suggesting that small homozygous clones may have been 
missed in the previous study. Secondly, the majority of patients in the previous study 
were receiving hydroxycarbamide. A recent report has shown a fall in peripheral 
blood JAK2 V617F mutant allele burden during hydroxycarbamide therapy274, raising 
the possibility that this agent may reduce the proportion of homozygous and/or 
heterozygous colonies obtained in progenitor assays. 
 
The observation that 50% of females with JAK2 V617F-positive ET harbour a V617F-
homozygous clone, together with previous studies indicating that a proportion of PV 
patients do not have a homozygous clone49,70, suggests the molecular relationship of 
PV to ET is more complex than the presence or absence of a V617F-homozygous 
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clone. Although biochemical and mouse studies have suggested a role for wild-type 
to mutant JAK2 ratio in determining disease phenotype53,54,71, it is likely that 
additional factors interplay to determine whether MPD patients manifest ET or PV. 
Inter-individual differences in erythropoietin and iron homeostasis may restrict 
erythropoiesis in some individuals, resulting in an ET phenotype despite the 
presence of a homozygous clone. Low iron stores are found in up to 40% of pre-
menopausal and around 10% of post-menopausal females, but are rare in adult 
males275,276, offering a potential explanation for the gender difference observed in this 
study. Genetic background may also play a role in phenotypic modulation, as specific 
single nucleotide polymorphisms in JAK2 or the erythropoietin receptor have been 
associated with preferential development of ET or PV73, and mouse models of JAK2 
V617F associated disease show strain specific differences in phenotype51,277. It is 
also possible that a proportion of patients diagnosed with ET actually have PV, with a 
concomitant increase in plasma volume masking a raised red cell mass. A raised 
plasma volume is present in up to a third of patients with a raised red cell mass, 
particularly in the presence of splenomegaly, and may result in normal peripheral 
blood haemoglobin and haematocrit levels due to haemodilution278-280. Finally, 
although expression of JAK2 V617F is sufficient to produce an ET or PV phenotype 
in mouse models53,54, it remains formally possible that additional acquired genetic 
lesions are present in human disease, and that such lesions play a role in altering the 
disease phenotype. 
 
Despite their association with an MPD-like phenotype in murine models, MPL T487A, 
JAK2 T875N and JAK2 R683 mutations were not identified in a large cohort of MPD 
patients. Mouse models differ from human disease in several important respects. In 
most mouse models, the oncogene is activated in a large number of cells, whereas 
human disease is thought to be initiated in a single cell with subsequent clonal 
expansion leading to manifestation of disease. Moreover in retroviral and transgenic 
models, both the timing and level of oncogene expression may be altered compared 
to expression from the endogenous locus.  
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Expression of the AML associated FLT3-ITD mutation in different mouse models is 
associated with subtle variations in disease phenotype (Table 6.6). This variability is 
likely to reflect differences in both the timing and magnitude of FLT3 expression as 
well as variability in mouse genetic background. Of note, FLT3-ITD mutations have 
not been observed in human MPD, despite producing an ET-like phenotype in a 
transgenic model281-283, but do occur as rare events in chronic myelomonocytic 
leukaemia, an MPD-MDS overlap syndrome with a similar phenotype to the knock-in 
mouse284.  
 
Table 6.6. Mouse models of FLT3-ITD associated disease 
 
Method Mouse strain Phenotype 
Retroviral transduction285  Balb/c Neutrophilia, bone marrow fibrosis, splenomegaly 
   
Transgenic: vav promoter286 FVB Thrombocytosis, splenomegaly 
   
Endogenous locus284,287 C57BL/6 or Balb/c Neutrophilia, monocytosis, splenomegaly 
 
There are several possible explanations for the absence of MPL T487A, JAK2 R683 
and JAK2 T875N mutations in human MPD. The mutations may be unable to initiate 
a clonal expansion when present in a single cell, or may occur only as secondary 
events within a malignant clone. Alternatively, such mutations may give rise to a 
different phenotype in humans to that observed in murine systems. Taken together, 
these findings suggest that mouse models may be limited in their ability to predict the 
precise phenotype of human disease.  
 
RAS proteins are ubiquitously expressed components of intracellular signalling 
pathways. Oncogenic RAS mutations are amongst the most common alterations in 
human malignancy and result in constitutive activation of signalling cascades with 
consequent dysregulation of cellular processes such as proliferation and 
differentiation288. A vital role for RAS proteins in the haematopoietic system is 
suggested by murine knock-out models, with KRAS-/- and KRAS+/-NRAS-/- mice dying 
during early embryogenesis due to severe anaemia289, although both NRAS-/- and 
HRAS-/- mice develop without apparent abnormalities in the blood system290,291. RAS 
signalling downstream of the erythropoietin receptor appears to have a negative 
regulatory effect on erythroid differentiation, with chemical inhibition accelerating 
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erythroid differentiation26 and expression of oncogenic RAS (NRAS G12D292, KRAS 
G12D293,294 or HRAS G12295) inhibiting erythroid differentiation with a block at the late 
erythroblast stage. By contrast, RAS signalling downstream of the MPL receptor 
appears to enhance megakaryocyte differentiation296,297, with chemical inhibition 
leading to alterations in megakaryocyte ploidy298,299 and expression of oncogenic 
RAS (HRAS G12V) promoting megakaryocyte differentiation and reducing nuclear 
ploidy296. Thus expression of oncogenic RAS in the haematopoietic system mimics 
several phenotypic features of human IMF, including suppression of erythropoiesis 
and enhanced megakaryopoiesis with reduced nuclear ploidy. 
 
RAS mutations have previously been reported in a small proportion of patients with 
IMF, but not in association with ET or PV269,270. In this study, RAS mutations were 
detected in IMF patients with JAK2 or MPL mutations, but not in patients with ET. 
Taken together with the effects of mutant RAS on haematopoiesis outlined above, 
these findings suggest that increased signalling via the RAS pathway may cooperate 
with mutations such as JAK2 V617F in the development of an IMF phenotype.  
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Chapter 7 
 
Discussion: Models of disease progression and clonal diversity in 
the myeloproliferative disorders 
 
 
7.1  Introduction 
 
The MPD are a group of stem cell neoplasms with similarities at the phenotypic and 
molecular level (Table 7.1). Phenotypically, these disorders are characterised by 
over-production of one or more mature myeloid elements with a variable tendency to 
develop acute leukaemia. At the molecular level, they are characterised by genetic 
alterations in signalling pathway molecules due to localised mutations or 
chromosomal alterations. Localised mutations result in either increased activity of the 
tyrosine kinase domain (KIT D816V)300 or decreased activity of autoinhibitory regions 
(mutations in JAK2 or MPL)28,173. Chromosomal alterations result in expression of a 
fusion protein which retains the signalling domain of the tyrosine kinase molecule, 
with the fusion partner usually providing a protein-protein interaction domain which 
mediates dimerisation (rearrangement of ABL1, PDGFRB or FGFR1)223,301-307. In 
some cases, however, the fusion partner contains no recognised dimerisation motif; 
rather the rearrangement results in loss of an autoinhibitory region from the tyrosine 
kinase partner (rearrangement of PDGFRA)308. The consequence of these genetic 
events is dimerisation of the signalling pathway molecule in the absence of cognate 
ligand binding, resulting in constitutive activation of downstream pathways and 
consequent dysregulation of vital cellular processes such as proliferation and 
differentiation. 
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Table 7.1. The chronic myeloproliferative disorders 
 
Disease Lineage involvement Molecular lesions 
   
Chronic myeloid leukaemia 
 
Granulocyte 
+/- Platelet 
BCR-ABL1 
   
Chronic neutrophilic leukaemia Neutrophil JAK2 V617F 
  (occasional cases) 
   
Chronic eosinophilic leukaemia Eosinophil 
+/- Mast cell 
Rearrangement of: 
PDGFRA  
PDGFRB 
FGFR1 
   
Polycythaemia vera 
 
Erythrocyte 
+/- Platelet 
+/- Granulocyte 
JAK2 V617F 
JAK2 exon 12 
   
Idiopathic myelofibrosis 
 
Megakaryocyte 
+/- Granulocyte 
JAK2 V617F 
MPL exon 10 
   
Essential thrombocythaemia 
 
Platelet 
+/- Granulocyte 
JAK2 V617F 
MPL exon 10 
   
Systemic mastocytosis Mast cell 
+/- Eosinophil 
+/- Granulocyte 
 
KIT D816V 
 
 
The classical MPD, comprising ET, PV and IMF, share a tendency to undergo 
phenotypic shift, such that patients with ET may develop PV, and either ET or PV 
may progress to IMF. Thus ET, PV and IMF have traditionally been considered as 
three separate but related diseases, with a variable tendency to transform to AML 
(Figure 7.1). The identification of the same JAK2 V617F mutation in patients with ET, 
PV or IMF, however, has led to a rethinking of how these disorders are best 
classified. Specifically, are these three conditions separate diseases, or does the 
occurrence of the same genetic event in all three imply they are different phenotypic 
manifestations of the same disease process? 
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Figure 7.1. Traditional model to explain the relationship of the classical
myeloproliferative disorders. PV: polycythaemia vera; IMF: idiopathic
myelofibrosis; ET: essential thrombocythaemia; AML: acute myeloid leukaemia. 
 
A precedent for a single genetic event in association with different phenotypic 
manifestations comes from CML (Table 7.2). CML is invariably associated with 
expression of a BCR-ABL1 fusion gene, usually due to a balanced translocation 
between chromosomes 9 and 22. Prior to the advent of tyrosine kinase inhibitor 
therapy, the natural history of CML consisted of three phenotypically distinct phases. 
Most patients presented with chronic phase disease, characterised by over-
production of mature myeloid elements with a good response to cytotoxic agents 
such as hydroxycarbamide. At a variable time from presentation, usually between 3 
and 5 years, changes in the disease phenotype were observed, including an increase 
in immature cells or basophils, failure of agents such as hydroxycarbamide to control 
the myeloid proliferation or progressive bone marrow fibrosis. This accelerated phase 
of disease, lasting in the order of 3-6 months, was followed by the development of a 
fully malignant acute leukaemia (blastic phase disease). Of note, patients with CML 
may manifest chronic, accelerated or occasionally blastic phase disease at the time 
of presentation.  
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Table 7.2. Features of triphasic disease in chronic myeloid leukaemia 
 
  
Chronic phase Myeloid hyperplasia 
Good response to cytoreductive therapy 
  
Accelerated phase Increased proportion of immature cells 
Marked basophilia 
Refractory leucocytosis, thrombocytosis or splenomegaly 
Bone marrow fibrosis 
  
Blastic phase Acute leukaemia 
Extramedullary blast proliferation 
  
 
Genetic lesions other than the BCR-ABL1 fusion are uncommon in patients in chronic 
phase, with accumulation of karyotypic abnormalities associated with progression to 
accelerated and blastic phase disease222,223. Although the genetic events involved in 
disease progression are not fully understood223, dysregulation of the WNT/β-catenin 
pathway may play an important role309,310. The gradual accumulation of genetic 
damage appears to be driven in part by the BCR-ABL1 oncogene, expression of 
which leads to increased levels of intracellular reactive oxygen species with resultant 
damage to genomic DNA311. BCR-ABL1 expression also modulates DNA repair 
pathways312,313 and impairs the usual apoptotic response to genomic damage314.  
 
By analogy to CML, JAK2 V617F-positive ET, PV and IMF may also be considered 
as different phases of the same disease process (Figure 7.2). In this model, ET and 
PV represent phenotypic manifestations of chronic phase disease, characterised by 
the over-production of red cells and/or platelets with a good response to cytotoxic 
agents such as hydroxycarbamide (Table 7.3). Development of an IMF phenotype 
represents progression to accelerated phase disease, characterised by progressive 
bone marrow fibrosis and reduced therapeutic efficacy. Finally a proportion of 
patients will develop blastic phase disease, almost invariably AML. In common with 
CML, patients may manifest chronic or accelerated phase disease at initial 
presentation.  
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 Figure 7.2. Triphasic model to explain the relationship of the classical
myeloproliferative disorders.    
Genetic lesions other than the JAK2 V617F mutation and associated chromosome 9p 
uniparental disomy are uncommon in chronic phase69,221, with the prevalence of 
karyotypic aberrations increasing in patients with accelerated phase disease224,273. 
The precise events involved in progression to accelerated and blastic phase disease, 
however, are currently unknown. JAK2 V617F is associated with both increased DNA 
damage and modulation of DNA repair pathways, suggesting that expression of 
mutant JAK2 may lead to the acquisition of further genetic lesions86. It should be 
noted that whereas progression to blastic phase disease was seen in the vast 
majority of CML patients prior to the advent of tyrosine kinase inhibitor therapy, this is 
not the case in the MPD, where blastic phase disease complicates only 2-5% of ET 
or PV76,77,92 and 15-30% of IMF75,83. It is probable, therefore, that BCR-ABL1 and 
JAK2 V167F differ in their ability to drive the accumulation of further genetic damage. 
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Table 7.3. Features of triphasic disease in the classical myeloproliferative disorders 
 
  
Chronic phase Erythrocytosis 
Thrombocytosis 
  
Accelerated phase Bone marrow fibrosis 
Circulating progenitor cells 
Splenomegaly and extramedullary haematopoiesis 
Treatment refractory leucocytosis or splenomegaly 
Cytopenias unrelated to therapy 
  
Blastic phase Acute leukaemia 
Extramedullary blast proliferation 
  
 
 
The first part of this section examines how data presented in this thesis contributes to 
a triphasic model of disease progression in the MPD, with reference to the 
association of JAK2 V617F with both ET and PV, the role of mutant MPL in MPD 
pathogenesis and the genetic lesions involved in progression to accelerated and 
blastic phase disease. The second part of this section discusses work presented in 
this thesis describing clonal diversity in the MPD, and how these findings can be 
integrated into current models of disease pathogenesis.  
 
7.2  Towards a triphasic model of MPD pathogenesis 
 
7.2.1 The JAK2 V617F mutation in chronic phase disease 
 
The JAK2 V617F mutation is found in the majority of patients with PV and around 
half of those with ET. Biochemical studies71 and mouse models53,54 suggest the level 
of mutant JAK2 expression may play a role in modulating disease phenotype, with 
lower levels favouring platelet over-production and higher levels favouring over-
production of erythrocytes. Consistent with these observations, studies of progenitor 
colonies in human disease identified a V617F-homozygous clone in the majority of 
PV patients but not in those with ET70.  
 
Homozygosity for the JAK2 mutation arises through a process of mitotic 
recombination between homologous chromosomes28-31. Background rates of mitotic 
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recombination in normal subjects differ over several orders of magnitude72, 
suggesting that some individuals may be predisposed to undergo mitotic 
recombination and thus generate homozygous clones. Rates of mitotic recombination 
also differ between sexes, with higher rates reported in females72. Given the 
association of PV with the presence of a homozygous clone, however, this difference 
would predict an excess of PV in females; in reality PV appears more common in 
males8. Cell line studies have suggested that JAK2 V617F expression may increase 
the rate of mitotic recombination within the mutant clone86. If mitotic recombination 
was entirely driven by mutant JAK2, however, it would be expected that most if not all 
patients would harbour a homozygous clone. As such, it remains unclear why some 
patients generate V617F-homozygous clones and others do not.  
 
The identification of V617F-homozygous progenitor colonies in 50% of female ET 
patients indicates that disease phenotype is more complex than the simple presence 
or absence of a homozygous clone (Chapter 6). ET patients with a homozygous 
clone had significantly higher haemoglobin levels than those without, consistent with 
an increased mutant to wild-type JAK2 ratio resulting in a bias towards erythroid 
differentiation. The lack of a PV phenotype in these patients suggests that 
erythropoiesis may be restrained, for example by reduced iron stores. Sub-clinical 
depletion of storage iron is observed not infrequently in normal females, including 
post-menopausal subjects, but is a rare phenomenon in males275,276. Alternatively a 
raised red cell mass may be masked by an increase in plasma volume. Although 
assessment of cardiovascular parameters suggested that aging in normal females 
(but not males) may be associated with an increase in plasma volume315, direct 
measurements were not made, and gender differences in the prevalence of masked 
PV have not been observed278-280. Other potential contributing factors include 
differences in genetic background73 or the presence of additional phenotype 
modulating lesions, for example secondary to 9p loss of heterozygosity. Whereas 
LOH in V617F-homozygous clones invariably extends from the JAK2 locus to the 
telomere, extension in the centromeric direction is highly variable, covering between 
2 and 40 megabases31,316. Given that polymorphisms within this region will become 
homozygous and expression of imprinted genes will be altered, it is theoretically 
possible that 9p LOH generates additional genetic alterations that act in concert with 
mutant JAK2. As such, the extent of 9p LOH may play a role in modulating disease 
phenotype.  
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Within the Cambridge MPD cohort, trisomy 9 was present in 6% of JAK2 V617F-
positive patients, usually associated with a PV phenotype (Table 7.4). Trisomy 9 
results in duplication of the chromosome bearing the JAK2 V617F mutation (Chapter 
4), and as such plays a similar role to mitotic recombination, giving rise to a subclone 
bearing two copies of the mutant JAK2 allele. Although cell line studies have 
suggested expression of wild-type JAK2 may inhibit the transforming effects of JAK2 
V617F28, PV patients with trisomy 9 retain the wild-type allele, and thus loss of wild-
type JAK2 is not essential for the development of PV. Of note, trisomy 9 was present 
in a female patient with ET, in whom diagnostic haemoglobin and haematocrit levels 
were within normal limits. Similar to patients with a V617F-homozygous clone, 
therefore, duplication of the mutant JAK2 allele in patients with trisomy 9 is not 
invariably associated with a PV phenotype. 
 
Table 7.4. Prevalence of trisomy 9 in Cambridge MPD patients with ET or PV 
 
 JAK2 V617F  JAK2-exon 12  JAK2-wild-type 
      
PV 6/68 (9%)  0/10 (0%)  - 
      
ET 1/44 (2%)  -  0/48 (0%) 
      
Total 7/112 (6%)  0/10 (0%)  0/48 (0%) 
      
 
 
In summary, studies presented herein indicate that female ET patients may harbour a 
clone that is homozygous for the JAK2 V617F mutation. Similarly the presence of an 
additional copy of chromosome 9, leading to duplication of the JAK2 V617F allele, 
may be associated with either PV or ET. Although biochemical and murine studies 
have indicated a role for mutant allele gene dosage in the determination of disease 
phenotype, other factors are likely to be of importance, including erythropoietin and 
iron homeostasis, patient genetic background, changes in plasma volume and 
possibly the presence of additional acquired genetic lesions (Figure 7.3).  
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  Figure 7.3. Interplay of genetic lesions and modulating factors in the
determination of a polycythaemic versus thrombocythaemic phenotype. LOH:
loss of heterozygosity.   156
7.2.2 MPL exon 10 mutations in essential thrombocythaemia  
 
At the time of these studies, little was known about the prevalence and clinical 
significance of MPL mutations in patients with ET. Three different mutations in MPL 
exon 10 were seen in patients with ET or IMF (S505N, W515L and W515K) whereas 
mutations outside MPL exon 10, restricted to the megakaryocyte lineage or in 
patients with PV were not identified (Chapter 3). A previous study had found MPL 
mutations rarely in patients with ET, leading to the suggestion that these alleles may 
be specifically associated with IMF175. Using sensitive assays, however, MPL 
mutations were identified in 8.5% of JAK2 V617F-negative ET patients. Moreover 
MPL mutant patients showed typical laboratory and histological features of ET 
without an increased risk of progression to IMF, indicating that MPL mutations are 
associated with genuine ET. Although MPL mutations do not appear to define a 
specific clinical or histopathological sub-type of ET, their detection provides a useful 
new tool in the diagnostic armamentarium. 
 
An MPL S505N mutation, previously reported as an inherited allele in familial 
thrombocytosis172, was identified as an acquired mutation in MPD patients (Chapter 
3). Mutations in KIT or KRAS are also associated with both inherited and acquired 
forms of myeloid disease, occurring in mast cell disease202-211 and juvenile 
myelomonocytic leukaemia317-319 respectively. In contrast to the MPL S505N allele, 
however, inherited and acquired mutations in KIT or KRAS are mutually exclusive, 
with inherited mutations not found in acquired disease and vice versa (Figure 7.4). 
Although inherited and acquired KRAS alleles are associated with similar biological 
sequelae such as increased cellular proliferation and cytokine hypersensitivity, 
inherited alleles are consistently weaker in their transforming effects . It may be 
that more strongly activating acquired alleles would not be tolerated in the germline, 
or conversely that weaker inherited alleles may not be of sufficient strength to initiate 
malignancy if acquired in a single cell. As such there are at least two potential 
explanations for the occurrence of the MPL S505N mutation in both acquired and 
inherited forms of disease. Firstly, the S505N allele may be weak enough to be 
tolerated in the germline but require additional genetic events in order to drive an 
acquired clonal expansion. Secondly, the restriction of MPL expression to the 
haematopoietic compartment (in contrast to both KIT and KRAS) may allow a 
232,317
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mutation of sufficient strength to drive an acquired clonal expansion to be tolerated 
as a germline mutation.  
 
7.2.3  MPD patients without an identified mutation 
 
The JAK2 V617F mutation is found in the vast majority of patients with PV, and many 
of the remainder harbour mutations in JAK2 exon 1229,105. Analysis of the Cambridge 
MPD cohort identified JAK2 mutations in all 114 patients who met PVSG criteria for 
PV, with 97% harbouring a JAK2 V617F mutation and 3% a JAK2 exon 12 
mutation176. Therefore most, if not all, PV patients harbour mutations in JAK2. 
 
The prevalence of both JAK2 V617F and MPL exon 10 mutations is similar in ET 
compared to IMF, with known mutations accounting for around 60% of such patients 
(Chapter 3). Despite their association with an MPD-phenotype in mouse models, 
MPL T487A, JAK2 T875N and JAK2 R683 mutations were not identified in MPD 
patients (Chapter 6). Analysis of clinical and laboratory features of mutation negative 
ET patients in the PT-1 cohort revealed similar laboratory features to the MPL-mutant 
patients (Chapter 3). Specifically, mutation negative ET patients manifest a 
megakaryocyte restricted MPD, in contrast to the trilineage myeloid proliferation 
associated with the JAK2 V617F mutation68. Mutation negative ET may therefore be 
considered a phenocopy of MPL-mutant ET, with the initiating genetic events likely 
affecting components of the MPL signalling pathway. 
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 Figure 7.4. Acquired and inherited mutations in KIT, KRAS and MPL.   
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 7.2.4  Molecular lesions associated with accelerated phase disease 
 
Little is known about the precise genetic events associated with the development of 
accelerated and blastic phase disease. Expression of either JAK2 V617F or MPL 
W515L in mouse models leads to an IMF-like syndrome including bone marrow 
fibrosis, splenomegaly and falling haemoglobin levels50,53,174. The relatively short 
latency between disease initiation and development of bone marrow fibrosis in these 
models is consistent with a direct role for JAK2 signalling in disease progression, 
although it should be noted that retroviral models are generally associated with 
oncogene over-expression. A role for increased JAK2 activity in human MPD is 
suggested by studies demonstrating methylation of SOCS family gene 
promoters320,321. SOCS proteins (suppressors of cytokine signalling) function as 
negative regulators of JAK2, such that decreased SOCS expression may be 
expected to result in increased JAK2 activity322,323. Data are conflicting, however, as 
to whether SOCS proteins are able to suppress the activity of mutant JAK241,320. 
Although it is possible that increased activity of mutant JAK2 is associated with 
progression to IMF, this is yet to be demonstrated in human disease.  
 
Both RAS and STAT5 signalling pathways are activated by mutant JAK2, with 
studies suggesting a central role for STAT5 activation in the phenotype of chronic 
phase disease42,71. Oncogenic RAS mutations were identified in 4% of patients with 
IMF but not in those with ET (Chapter 6). In murine models, expression of oncogenic 
RAS results in suppression of erythroid differentiation, augmentation of granulocyte 
proliferation and increased megakaryocyte proliferation with abnormalities of nuclear 
ploidy292-295, features also associated with human IMF. Taken together, these 
findings suggest a potential role for increased signalling via the RAS pathway in 
progression to accelerated phase disease (Figure 7.5).  
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Figure 7.5. Increased signalling via the RAS pathway may play a role in
progression to accelerated phase disease.   
 
 
In MPL W515L-positive disease, a higher mutant allele burden was seen in IMF 
compared to ET patients (0.59 ± 0.27 versus 0.17 ± 0.11 respectively; p=<0.0001). 
Specifically, 4 of 6 IMF patients had a mutant allele burden of greater than 50%, 
indicating the presence of subclones with reduced or absent wild-type allele. Studies 
identified mitotic recombination leading to duplication of the mutant allele as the 
mechanism responsible in one of these patients. Homozygous clones, however, were 
rare in MPL W515L-positive ET patients (Chapter 3), suggesting that homozygosity 
for the MPL W515L mutation may be associated with the development of 
myelofibrosis. 
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7.2.5  Molecular lesions associated with blastic phase disease 
 
Patients with de novo AML often harbour genetic lesions of two distinct types. Type 1 
lesions, resulting in signalling pathway hyperactivity, lead to increased cellular 
proliferation. Type 2 lesions, often due to altered activity of DNA transcription factors, 
lead to a block in cellular differentiation231. In this model, JAK2 V617F could function 
as a type 1 lesion driving the proliferation of the leukaemic clone, and indeed a small 
proportion of de novo leukaemias are JAK2 V617F-positive60,61,65,66. Of 16 JAK2 
V617F-positive patients who developed blastic phase disease, 7 (44%) were positive 
for the JAK2 V617F mutation (Chapter 5). In 6 of these 7, leukaemic blasts were 
homozygous for the JAK2 V617F mutation, suggesting that either loss of wild-type or 
increased mutant JAK2 may be important for the development of blastic phase 
disease. Type 2 lesions were identified in 5 of 7 patients with a JAK2 mutant 
leukaemia, comprising 4 with RUNX1 point mutations and 1 with over-expression of 
EVI1. Of note, genetic lesions leading to disruption of the RUNX1 DNA-binding 
complex have also been associated with JAK2 V617F in de novo AML61,65,66, 
suggesting that mutant JAK2 and RUNX1 may cooperate in the development of 
blastic phase disease. 
 
6 of 7 patients with V617F-positive AML had a phenotypically defined preceding 
MPD, with all cases showing evidence of accelerated phase disease. This finding 
lends support to a triphasic model of JAK2 V617F associated disease, where 
accumulation of genetic events is associated with phenotypic progression from 
chronic phase via an accelerated phase to blastic phase disease. In a patient with de 
novo AML, bone marrow histological appearances and established JAK2 V617F-
positive erythropoiesis suggested the presence of a prior MPD. Thus patients with a 
JAK2 V617F-positive MPD may present with blastic phase disease, a situation also 
observed in patients with CML. 2 of 7 patients with JAK2 V617F-positive leukaemia 
had received no prior cytoreductive therapy, indicating that progression to blastic 
phase is part of the natural history of JAK2 V617F-positive disease, and not 
necessarily the consequence of previous therapy97. Mirroring the situation with JAK2 
V617F, the MPL W515L mutation may also be present in chronic, accelerated and 
blastic phase disease (Chapter 3).  
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 7.2.6  Towards a triphasic model of MPD pathogenesis: summary 
 
In conventional models of MPD pathogenesis, ET, PV and IMF were considered as 
distinct but related disorders. In the revised, triphasic model of disease the three 
different phenotypes, along with progression to acute leukaemia, are considered as 
different manifestations of a single disease process. Consistent with this notion, both 
the JAK2 V617F and MPL W515L mutations may be present in chronic, accelerated 
and blastic phase disease (Figure 7.6). It is currently unclear how the JAK2 V617F 
mutation is associated with either an ET or PV phenotype, although the explanation 
appears more complex than the presence or absence of a homozygous clone. 
Potential events associated with the development of accelerated phase disease 
include increased dosage of the MPL W515L allele or increased signalling via the 
RAS pathway. Mutations in RUNX1 occur as recurrent lesions in blastic phase 
disease, and may cooperate with mutant JAK2 in the development of acute 
leukaemia. JAK2 V617F-positive patients who develop blastic phase disease 
generally progress via a phenotypically apparent accelerated phase, consistent with 
a step-wise acquisition of genetic events driving disease progression.  
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 Figure 7.6. JAK2 V617F and MPL W515L mutations may be associated with
chronic, accelerated or blastic phase disease, with the accumulation of
further genetic events associated with disease progression. 
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7.3  Clonal diversity in the myeloproliferative disorders 
 
Neoplastic proliferations are thought to be initiated in a single cell, with step-wise 
accumulation of additional genetic events leading to a fully malignant phenotype215. 
CML and the MPD are premalignant haematopoietic disorders often associated with 
constitutive activation of intracellular signalling pathways. In CML, the BCR-ABL1 
fusion results in activation of the ABL1 cytoplasmic tyrosine kinase223, and the 
majority of MPD patients harbour activating mutations in JAK2 or MPL29,176 (Chapter 
3). The clonal nature of both CML and the MPD has been established by studies of 
X-chromosome inactivation patterns in female patients21,22,324, and expression of 
BCR-ABL1, mutant JAK2 or mutant MPL in murine bone marrow recapitulates many 
features of the counterpart human disease50,105,174,325. Taken together, these studies 
imply a single cell of origin for CML and the MPD, and support a central role for 
alterations of ABL1, JAK2 or MPL in disease pathogenesis.  
 
Although a triphasic model of disease progression explains many of the biological 
and phenotypic features of CML and the MPD, studies have suggested that a higher 
degree of complexity exists in human disease. A familial tendency to develop an 
MPD has been identified by registry data and kindred studies, with affected family 
members showing clonal haematopoiesis and acquired mutations such as JAK2 
V617F, indicative of a genuine MPD15-19. These findings have led to the suggestion 
that mutations in JAK2 are insufficient alone to produce an MPD phenotype, with 
additional genetic alterations being inherited in familial cases and acquired in 
sporadic disease. In a proportion of patients with CML or an MPD, studies of X-
chromosome inactivation pattern (XCIP) in immortalised B-cells (CML)186,187 or 
granulocytes (MPD)177,178 have suggested clonal haematopoiesis in excess of that 
accounted for by the mutation bearing clone (BCR-ABL1 or JAK2 V617F 
respectively). CML patients treated with imatinib (a tyrosine kinase inhibitor) may 
develop BCR-ABL1 negative clones which harbour acquired chromosomal 
abnormalities188-190, and along with the XCIP studies may be interpreted as evidence 
for clonal haematopoiesis prior to the acquisition of BCR-ABL1 or a JAK2 mutation. 
In the MPD, growth of JAK2 wild-type endogenous erythroid colonies (EEC) has 
been reported in patients with a JAK2 V617F-positive MPD184,185. As EEC growth is 
not a feature of normal haematopoiesis, such findings suggest the presence of 
additional genetic alterations in these patients. Similarly patients with a JAK2 V617F-
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positive MPD may progress to acute leukaemia that is negative for the JAK2 
mutation102,103. Finally, a proportion of patients may harbour more than one disease 
associated genetic lesion, including JAK2 V617F in combination with BCR-ABL1, 
MPL or JAK2 exon 12 mutations60,175,185,227.  
 
There are two main explanations for the observations outlined above: (1) MPD 
associated genetic lesions are not the disease initiating events, and/or (2) a 
proportion of patients harbour more than one clonal expansion. In order to examine 
the role of clonal heterogeneity in MPD pathogenesis, studies were undertaken in 
two groups of patients: those with more than one acquired genetic alteration (Chapter 
4) and those with progression to acute leukaemia following a JAK2 V617F-positive 
MPD (Chapter 5).  
 
In patients with more than one acquired genetic alteration, cytogenetic abnormalities 
were usually found in the same clone as a signalling pathway mutation (BCR-ABL1 
or mutations in JAK2 or MPL). In one case, a deletion of chromosome 20q preceded 
the acquisition of BCR-ABL1. As such, BCR-ABL1 was acquired as a secondary 
event in an abnormal haematopoietic clone. Deletions of 20q are the most common 
chromosomal alteration in the MPD229, and have also been reported in CML228. The 
functional consequences of this abnormality, however, are currently unknown. Of 
note, in a second patient a JAK2 V617F mutation and a 20q deletion were present in 
separate clones. It is possible, therefore, that 20q deletions may serve as clone-
initiating events, with subsequent mutations such as BCR-ABL1 giving rise to the 
specific disease phenotype. However acquisition of a 20q deletion after a JAK2 
mutation was also observed in these studies. There are at least three potential 
explanations for this inconsistency: (i) both the 20q deletion and JAK2 mutation are 
able to initiate clonal haematopoiesis, (ii) both lesions are acquired as secondary 
events within a pre-existing clonal expansion, or (iii) deletions of 20q are markers of a 
genetically unstable clone with little or no functional consequence. 
 
In contrast to patients with cytogenetic aberrations, the presence of two signalling 
pathway mutations (mutations in JAK2 or MPL) indicated the presence of a second 
clonal expansion in all cases studied. Moreover in 2 patients, studies of XCIP 
demonstrated that the two mutations had arisen in unrelated stem cells. In the 
 166
remaining 4 patients, it is not known whether the two clones arose independently or 
from a shared founder clone.  
 
In studies of patients progressing to acute leukaemia following a JAK2 V617F-
positive MPD, over half were negative for the JAK2 mutation in leukaemic blasts 
(Chapter 5). Reversion to wild-type by mitotic recombination, gene conversion or 
gene deletion was excluded in all cases. Differences in the clinical features of V617F-
negative versus V617F-positive transformations may provide clues to the biological 
differences between the groups. Firstly, patients progressing to V617F-negative AML 
were significantly older at the time of disease progression. Secondly, whereas 
patients with V617F-positive AML displayed features of accelerated phase disease 
prior to transformation, this was not necessarily the case with V617F-negative AML, 
with the majority of patients progressing directly from chronic to blastic phase 
disease. The lack of accelerated phase disease suggests that the MPD and AML 
clones developed as parallel and separate entities; whilst evolution within the AML 
clone leads to the development of a fully malignant leukaemia phenotype, the MPD 
clone may remain genetically stable without evidence of disease progression. As 
such, there are two possible explanations for the development of V617F-negative 
AML following a V617F-positive MPD: either (i) the two phases of disease are 
genetically related, representing the progeny of shared founder clone, or (ii) the 
diseases are unrelated, having arisen in independent stem cells. 
 
The coexistence of separate MPD clones and progression to JAK2 V617F-negative 
AML may both be conceived as manifestations of a biclonal disease process (Figure 
7.7). In this model the two clones, which may be phylogenetically related or 
unrelated, harbour phenotypic mutations resulting in either an MPD or AML 
phenotype. Genetically related clones represent the progeny of a shared founder 
clone. This founder clone harbours a ‘clone-initiating mutation’: a hypothetical genetic 
event leading to the onset of clonal haematopoiesis, but not necessarily associated 
with the phenotypic manifestations of the disease. Different phenotypic mutations are 
subsequently acquired in progeny of the founder clone, giving rise to genetically 
diverse but related daughter clones. The phenotypic mutations, whilst directly 
implicated in the biological and clinical features of the resulting disease, may not be 
directly involved in the proliferation of the abnormal stem cell clone. Indirect evidence 
cited in support of clone-initiating mutations includes discrepant XCIP patterns in 
 167
CML and MPD patients, cytogenetically abnormal BCR-ABL1 negative clones in CML 
and the growth of JAK2 V617F-negative EEC from patients with a JAK2 V617F-
positive MPD. Each of these observations, however, is equally well explained by the 
presence of a second clonal expansion which is not necessarily genetically related to 
the original clone. Recent work presented in abstract form identified mutations in the 
TET2 gene in a proportion of patients with an MPD326. Of note, TET2 mutations 
preceded the acquisition of a phenotypic mutation (in this case JAK2 V617F). Little is 
known about the TET2 protein, although the identification of nonsense and biallelic 
mutations suggests tumour suppressor activity. These preliminary data suggest that 
alterations in TET2 may serve as clone-initiating mutations in a proportion of patients, 
and work is underway to identify TET2 mutations in patients with biclonal disease 
and JAK2 V617F-negative leukaemia following a JAK2 V617F-positive MPD. 
 
In the alternative model, phenotypic mutations are acquired in genetically unrelated 
stem cells (Figure 7.7). Given that the prevalence of biclonal disease (either two MPD 
clones or progression to V617F-negative AML) appears higher than expected by 
chance alone, this model would predict a predisposition to the acquisition or survival 
of such clones. It is possible that exposure to an environmental clastogen leads to 
the acquisition of both phenotypic mutations. Alternatively patients may harbour an 
inherited stem cell defect that leads to an increased rate of acquisition and/or survival 
of abnormal clones. Data presented in this thesis provides direct evidence for the 
presence of genetically unrelated clones in patients with two phenotypic mutations 
(Chapter 4). 
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7.4  Conclusions 
 
Our understanding of MPD pathogenesis has advanced considerably since the 
identification of the JAK2 V617F mutation. As well as leading to improvements in 
patient diagnosis and raising the hope of targeted molecular therapy, the association 
of specific mutations such as JAK2 V617F with apparently distinct MPD phenotypes 
has stimulated discussion as to how these disorders are best classified. A triphasic 
model of disease progression explains many of the phenotypic features of the MPD, 
with JAK2 V617F and MPL W515L mutations present in chronic, accelerated and 
blastic phase disease. The mechanisms by which the JAK2 V617F mutation is 
associated with two distinct manifestations of chronic phase (ET or PV) remain to be 
fully elucidated, but appear more complex than the presence or absence of a 
homozygous clone. Progression to accelerated phase disease may be associated 
with increased signalling via the RAS pathway or an increase in mutant to wild-type 
ratio in patients with an MPL W515L mutation. In blastic phase disease, genetic 
lesions involving transcription factors such as RUNX1 or EVI1 likely cooperate with 
mutant JAK2 to produce a fully malignant acute leukaemia phenotype. 
 
The presence of clonal diversity, however, suggests that a triphasic model represents 
an oversimplification of disease pathogenesis in a proportion of patients. In some 
cases, the presence of two genetically unrelated clones implicates either 
environmental exposure or an inherited stem cell defect in the genesis of disease. In 
other cases, the phenotypic mutation appears not to be the clone-initiating event. 
These observations are particularly prescient in the era of targeted molecular 
therapy, as the use of JAK2 inhibitors may permit continued proliferation of either a 
founder clone or a second clonal proliferation. The identification and study of 
potential clone-initiating mutations and inherited predisposition alleles will not only 
improve our understanding of disease biology, but also help to guide the 
development of effective molecular therapies. 
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Appendix 1 
 
PCR primers 
 
 
Chapter 3 
 
Primer name Primer sequence Product size 
Annealing 
temp 
PCR 
conditions 
 
Mutation detection (direct sequencing)    
Mpl_FL_cDNA_Fa ACACAGTGGCGGAGAAGATG    
Mpl_FL_cDNA_Ra AGACTGGTCCAGAGCAGAGG 644 62 Standard 
Mpl_FL_cDNA_Fb GAGCCAGCTCCAGAAATCAG    
Mpl_FL_cDNA_Rb GAGCCCAGGTAGCTGTGAA 677 62 Standard 
Mpl_FL_cDNA_Fc TACCCCATCTGGGAGAACTG    
Mpl_FL_cDNA_Rc GAAACTGCCACCTCAGCAG 571 62 Standard 
Mpl_FL_cDNA_Fd GCGATCTCGCTACCGTTTAC    
Mpl_FL_cDNA_Rd AGGGAACTGGGAGTGAGGAG 577 62 Standard 
MPL_e10_DNA_F AGTAGGGGCTGGCTGGAT    
MPL_e10_DNA_R GCGGTATAGTGGGCGTGTTA 364 58 Standard 
MPL_e10_cDNA_F     GCCCCACCTACCAAGGTC    
MPL_e10_cDNA_R    GGCTGCAGTGTCCCTAAGGT 245 58 Standard 
 
SNP Genotyping     
MPL_SNP_1_F GCTGGCAAAAACGTCTCCT    
MPL_SNP_1_R TCATTGATGGACATTTAGGGTTT 623 58 Standard 
MPL_SNP_2_F GACGTAGGCTCCTCAACACC    
MPL_SNP_2_R TTAAGTCAAGGCGAGTGCAG 482 58 Standard 
 
Allele-specific PCR     
MPL_e10_control_F AGTAGGGGCTGGCTGGAT 
MPL_e10_control_R GCGGTATAGTGGGCGTGTTA    
MPL_W515L CCTGCTGCTGCTGAGGTT 364+234 58 Standard 
MPL_W515K CCTGCTGCTGCTGAGGAA 364+234 58 Standard 
MPL_S505N TCTAGTGCTGGGCATCAA 364+263 58 Standard 
JAK2_e14_F ATCTATAGTCATGCTGAAAGTAGGAGAAAG    
JAK2_e14_R CTGAATAGTCCTACAGTGTTTTCAGTTTCA    
JAK2_e14_V617F AGCATTTGGTTTTAAATTATGGAGTATATT 364+206 58 Standard 
 
Pyrosequencing     
W515_PY_F1 TTGGTGACCGCTCTGCATCT    
W515_PY_R3 7GCGGTGGACGGAGATCTG 193 60 Standard 
W515_PY_S CCTGCTGCTGCTGAG    
S505N_PY_F GTCTGACCCTTTTTGTCTCCTAGC     
S505N_PY_R 7GGGGCGGTACCTGTAGTGT  130 60 Standard 
S505N_PY_S TAGTGCTGGGCCTCA     
MPLV114M_PY_F TGCACCTCTGGGTGAAGAA    
MPLV114M_PY_R 7TGACAGGAGGATGGCTCTTA 93 58 2mM Mg++
MPLV114M_PY_S CCTCTGGGTGAAGAAT    
 
Real-time PCR     
C13_copy_F              CCATGGACGACGGGTTTCT    
C13_copy_R         TGTACAGGACGTAGGAGGGTGA 51 60 100nM primer 
MPL_copy_F1         CCAGCTCCAGCCCTACATAA    
MPL_copy_R1         TCTCACTGCCTGGGATAGGT 51 60 100nM primer 
 
Cloning     
M13F GTAAAACGACGGCCAGT    
M13R CAGGAAACAGCTATGAC variable 56  
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Chapter 4 
 
 
 
Primer name Primer sequence Product size  
Annealing 
temp 
PCR 
conditions 
 
BCR-ABL1 detection    
BCR_b2_F CAGATGCTGACCAACTCGTGT    
ABL_a3_R TTCCCCATTGTGATTATAGCCTA    
ABL_cDNA_F TGCGTGAGAGTGAGAGCAGT 119 + 65 2.5mM Mg++
ABL_cDNA_R GCTCTCGGAGGAGACGTAGA 200-400  1’ ext/ann 
 
Mutation detection (direct sequencing)    
JAK2_e14_F ATCTATAGTCATGCTGAAAGTAGGAGAAAG    
JAK2_e14_R CTGAATAGTCCTACAGTGTTTTCAGTTTCA 364 58 Standard 
JAK2_e12_F               CTCCTCTTTGGAGCAATTCA        
JAK2_e12_R            GAGAACTTGGGAGTTGCGATA 496 58 Standard 
MPL_e10_F AGTAGGGGCTGGCTGGAT    
MPL_e10_R GCGGTATAGTGGGCGTGTTA 364 58 Standard 
 
Pyrosequencing     
JAK2_PRYO_F            7GAAGCAGCAAGTATGATGAGCA     
JAK2_PRYO_R           TGCTCTGAGAAAGGCATTAGAA 120 58 Standard 
JAK2_PRYO_S TCTCGTCTCCACAGA     
8p6_PY_F 7CTTTTCGGTTCGTGCATGT    
8p6_PY_R1 GGCAGAGTATTACGCTTTTGTTAA 174 59 Standard 
8p6_PY_S GATTTTCAAATTTTCTCCTA    
8p7_PY4_F1 TCATTCGGGCTGGAGCAG    
8p7_PY4_R1 7GTTCCCCACTGTGGCCTAGAC 108 58 Standard 
8p7_PY4_S GCCCGGCCCTCCGCT    
9q12.5_PY_F 7GTCTCTGCATCAACCAGTCATT    
9q12.5_PY_R ATTCCTTCATTTGGCAAGAGTC 131 58 2mM Mg++
9q12.5_PY_S TTTGCCTAGCTGAAAGT    
20q4_PY_F CAAATGCATGTAAGGGGCTTAG    
20q4_PY_R 7CAGCCTAGGAATCCCACAAG 163 60 Standard 
20q4_PY_S1 CCCAGGGTCTGAACT    
 
SNP genotyping     
C20orf111_cDNA_F1 GAGCACCAGTCAGAACAGCA    
C20orf111_cDNA_R1 TGGCTTTTGTGCTTGAGTTG 214 60 Standard 
20qF4Sx CATGTAAGGGGCTTAGCACA    
20qR4Sx   ATGCATGTCCGAGGCTATTC 135 58 Standard 
20qF14Sx   CCCCACTGTCGTGTTTCTTT    
20qR14Sx   TGCCCAGGGAAATACAACCT 112 58 Standard 
NUP214_cDNA_F       GCTGCTTCATTCTCCTTTGG    
NUP214_cDNA_R      GCGCTCTGGGAGCTACTAAC 191 58 Standard 
9pF2Sx AAAAACAATTCTCTTTAACATTTCTCA    
9pR2Sx TCAAACACATGCATTTCAGC 123 58 Standard 
IDS_e4_F TGGAAACTTCTCCACCATCC    
IDS_e4_R AACATCCAGCACATCCACAG 235 58 Standard 
LANCL3_F            GCTCACGGCTTGTCGTCTAT    
LANCL3_R            CAGTGCACCAGCTCATTCTC 176 58 Standard 
MAGED2_e4_F        CCAAGGTCAAAGCCAAGAAA    
MAGED2_e4_R        AGCCAACCGAGTCCTTGAT 197 58 Standard 
     
 
 172
 
Chapter 5 (i) 
Primer name Primer sequence Product size 
Annealing 
temp 
PCR 
conditions 
 
Real-time PCR     
C13_copy_F              CCATGGACGACGGGTTTCT    
C13_copy_R         TGTACAGGACGTAGGAGGGTGA 51 60 100nM primer 
MPL_copy_F1         CCAGCTCCAGCCCTACATAA    
MPL_copy_R1         TCTCACTGCCTGGGATAGGT 51 60 100nM primer 
JAK2_copy_F TCCTCAGAACGTTGATGGCA    
JAK2_copy_R GTGCTTTGGTCCCTTTATATGGA 51 60 100nM primer 
ABL_cDNA_F TGCGTGAGAGTGAGAGCAGT    
ABL_cDNA_R GCTCTCGGAGGAGACGTAGA 119 60 300nM primer 
JAK2_cDNA_F1 GCAGGCAACAGGAACAAGAT    
JAK2_cDNA_R1 CCATTCCCATGCAGAGTCTT 109 60 300nM primer 
EVI1_cDNA_RTF        TGGAAGCTGGCTCAAGTACA     
EVI1_cDNA_RTR       GCGCAATGTCTGCAACTACT 110 60 300nM primer 
 
Mutation detection (direct sequencing)    
JAK2_e14_F ATCTATAGTCATGCTGAAAGTAGGAGAAAG    
JAK2_e14_R CTGAATAGTCCTACAGTGTTTTCAGTTTCA 364 58 Standard 
NRAS1213_F AGAACCAAATGGAAGGTCACA    
NRAS1213_R TGCATAACTGAATGTATACCCAAAA 370 58 Standard 
NRAS61_F GGCAGAAATGGGCTTGAATA    
NRAS61_R AAAGCTCTATCTTCCCTAGTGTGG 397 58 Standard 
KRAS1213_F CGTCTGCAGTCAACTGGAAT    
KRAS1213_R CCCTGACATACTCCCAAGGA 492 58 Standard 
KRAS61_F  CCAGACTGTGTTTCTCCCTTC    
KRAS61_R  CACTGCTCTAATCCCCCAAG 377 58 Standard 
CFMS969_F            GTGTTAATGGCCCCTGGAC    
CFMS969_R    ATGACCGAAGGCAGAGTTTG 524 58 Standard 
WT1_e7_F            GCCACCCCTTCTTTGGATA    
WT1_e7_R            CTGGAAATAACCTGGGTCCT 348 58 Standard 
WT1_e9_F            AGGAAATGCTGGGCTCCT    
WT1_e9_R           GCCACGCACTATTCCTTCTC 333 64 Standard 
CEBPA_DNA_F1 GCCGGGAGAACTCTAACTCC    
CEBPA_DNA_R1 AGCCTGCCGTCCAGGTAG 451 58 10% DMSO 
CEBPA_DNA_F2      TGGACAAGAACAGCAACGAG    
CEBPA_DNA_R2      GTTGCCCATGGCCTTGAC 236 58 Standard 
RUNX1_e3_F GAGCTGCTTGCTGAAGATCC    
RUNX1_e3_R          CATCCCAAGCTAGGAAGACC 496 58 10% DMSO 
RUNX1_e4_F          CATTGCTATTCCTCTGCAACC    
RUNX1_e4_R          GGGATTCCATCACAGAAATCA 387 58 Standard 
RUNX1_e5_F          GAAGGGCTGGACAGCATAAA    
RUNX1_e5_R          TCTGAGACATGGTCCCTGAG 283 58 Standard 
GATA2_e4_F  TTAGCCCTCCTTGACTGAGC    
GATA2_e4_R          AGCCAAGCTGGATATTGTGG 334 58 Standard 
TP53_e4_F         CTGGTAAGGACAAGGGTTGG    
TP53_e4_R         GCCAAAGGGTGAAGAGGAAT 495 58  
TP53_e5-6_F       GTTTCTTTGCTGCCGTCTTC   Standard 
TP53_e5-6_R         TTGCACATCTCATGGGGTTA 590 58 1’ ext/ann 
TP53_e7_F               
TP53_e7_R               
TP53_e8_F           TGTGGCTTCTCCTCCACCTA    
TP53_e8_R           AGGAAAGAGGCAAGGAAAGG 378 58 Standard 
 
FLT3-ITD detection     
FLT3_ITD_F GCAAATTAGGTATGAAAGCCAGC    
FLT3_ITD_R CTTTCAGCATTTTGACGGCAACC 329 56 1' ext/ann 
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Chapter 5 (ii) 
 
Primer name Primer sequence Product size  
Annealing 
temp 
PCR 
conditions 
 
Pyrosequencing     
9p1_pyro_F ATCAGCGCAACTCCTAACACA    
9p1_pyro_R 7GAGCAGCAGGGGTTTGTTAC 82 58 Standard 
9p1_pyro_S ACACACTCCTTGGCA     
9p2_pyro_F 7CATGTTACCAAATATGAGGATAGG    
9p2_pyro_R AACTGTGTAGGATCCCGGTCT 72 58 Standard 
9p2_pyro_S AAAGGCACCAGAAAAC     
9p3_pyro_F 7GGCAGCACTCAGAACTAAAAGAGG    
9p3_pyro_R CTAGGGTCTTTCCACTCCAACAAA 129 58 Standard 
9p3_pyro_S TTTGTCTTATTTTCATGTCA     
9p5_pyro_F 7CTTCTCACTTCACTTGGCAGGTAT    
9p5_pyro_R GAAAAGGGGTGTTTGATATTGGG 108 58 Standard 
9p5_pyro_S TATGGCTGGGGGCTT     
 
SNP Genotyping     
9pF1 TCCCCAGTCAGGTCATCAAT    
9pR1  GCCAGTGGCCGAGTCTATAA 668 63 Standard 
9pF2 CTCCCAGCCAAAAAGACCT    
9pR2 CCTTGCCAAGTTGCTGTAGA 677 58 Standard 
9pF4 GACAGCCCTTTCAAATCTGG    
9pR4  CAACTATCTGAAAAAGGAGAAAAGG 579 58 Standard 
9pF5 CAGGATCCTTTGTGGGTCTT    
9pR5 TGATGTTACCACCACGCAGT 579 58 Standard 
9pF12 GTTCCATCCATGTTGCTGTG    
9pR12 CGGCCCAAGCTAAAAATCT 667 58 Standard 
9pF24 GCAATGCATGAAGGTTCTCA    
9pR24 GACGCAGCACTGCTCTTCTT 219 58 Stabdrad 
J2_5_F          TCATCGTCCTCAATTAGGTTGT    
J2_5_R         GGCACCCTTCATACACAAAGA 178 58 Standard 
J2_10_F          TCCCAAAGTGCTGGGATTAC    
J2_10_R         TTTGGGACCCATAATATTGACTTT 220 58 Standard 
IDS_cDNA_e4_F TGGAAACTTCTCCACCATCC    
IDS_cDNA_e4_R AACATCCAGCACATCCACAG 235 58 Standard 
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Chapter 6 
 
Primer name Primer sequence Product size 
Annealing 
temp 
PCR 
conditions 
 
Pyrosequencing     
JAK2_PRYO_F            7GAAGCAGCAAGTATGATGAGCA     
JAK2_PRYO_R           TGCTCTGAGAAAGGCATTAGAA 120 58 Standard 
JAK2_PRYO_S TCTCGTCTCCACAGA     
 
Mutation detection (direct sequencing)    
JAK2_col_seq_F1       GTCTTTCTTTGAAGCAGCAAG    
JAK2_col_seq_R1 GGCATTAGAAAGCCTGTAGTTTT 118 57 Standard 
JAK2_R683_F         CAATGCATGCCTCCAAATTA    
JAK2_R683_R         CAAATTAAATGGAATTCAAGGAAAA 369 56 2mM Mg++
JAK2_T875_F         AATTTGCCTTGAAAACTTGGT    
JAK2_T875_R         CTCTGGGCATTGGCATAAGT 349 58 2mM Mg++
MPL_e9_F2           CAAACAGACGCTGGGCTATC   
MPL_e9_R1           AGCCAGCCCCTACTCTGG 422 62 
2.5% 
formamide 
NRAS1213_F AGAACCAAATGGAAGGTCACA    
NRAS1213_R TGCATAACTGAATGTATACCCAAAA 370 58 Standard 
NRAS61_F GGCAGAAATGGGCTTGAATA    
NRAS61_R AAAGCTCTATCTTCCCTAGTGTGG 397 58 Standard 
KRAS1213_F CGTCTGCAGTCAACTGGAAT    
KRAS1213_R CCCTGACATACTCCCAAGGA 492 58 Standard 
KRAS61_F  CCAGACTGTGTTTCTCCCTTC    
KRAS61_R  CACTGCTCTAATCCCCCAAG 377 58 Standard 
     
Note: primer prefix 7 denoted biotinylated primer 
 
 
 
 
 175
Appendix 2 
 
Single nucleotide polymorphisms 
 
 
Patient ID SNPs PCR primers 
 
Chapter 3 
  
   
PT-1 cohort rs12731981  MPLV114M_PY 
   
W515L-hom IMF rs7537577 & rs1870509 1p6 
 rs10737413 & rs1762830 1p7 
   
Chapter 4   
   
Patient 4 rs1329624 9q12.5_PY 
   
Patients 2 & 5 rs1729178 8p6_PY 
 rs867858 8p7_PY 
   
Patient 6 rs9346 C20orf111 
 rs103612 NUP214 
   
Patient 7 rs6031491 20q_PY 
   
Patient 8 rs6130271 20qF4Sx 
 rs7875908 9p2Sx 
   
Patient 9 rs12009345 LANCL3 
   
Patient 10 rs11549009 IDS_e4 
   
Patient 14 rs2071932 MAGED2_e4 
   
Chapter 5   
   
Pts 4, 5, 7, 10 - 12, 14 & 15 rs465514, rs456374, rs465793, rs17761666, rs16921966 9p1 
   
Pts 8, 11, 12 & 13 rs7875908, rs7034539, rs2230724 9p2 
   
Patient 2 rs9886808, rs10974623, rs9886720, rs9886723 9p4 
   
Pts 2, 15 & 16 rs7847141, rs7847294, rs3780372 9p5 
   
Patient 12 rs11794708, rs7043489, rs11794778 9p12 
   
Pts 8, 9 & 13 rs7031315, rs7046183, rs7034721 9p24 
   
Pts 9, 11, 15 & 16 rs7034753 J2_5 
   
Pts 4, 8, 13 & 14 rs7030260 J2_10 
   
Pt 8 rs6030071 & rs2299976 20q1 & 20q8 
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